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Abstract 
 
STRUCTURE ACTIVITY RELATIONSHIP STUDIES OF SYNTHETIC CATHINONES 
 AND RELATED AGENTS 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in Medicinal Chemistry at Virginia Commonwealth University. 
 
By 
 
RACHEL A. DAVIES 
Bachelor of Science, Middle Tennessee State University, United States, 2013 
 
Director: DR. GLENNON 
PROFESSOR 
DEPARTMENT OF MEDICINAL CHEMISTRY 
 
 
 
Synthetic cathinones and related agents represent an international drug abuse problem, 
and at the same time an important class of clinically useful compounds. Structure-activity 
relationship studies are needed to elucidate molecular features underlying the pharmacology of 
these agents. Illicit methcathinone (i.e., MCAT), the prototype of the synthetic cathinone class, 
exists as a racemic mixture. Though the differences in potency and target selectivity between the 
positional and optical isomers of synthetic cathinones and related agents have been demonstrated 
to have important implications for abuse and therapeutic potential, the two MCAT isomers have 
never been directly compared at their molecular targets: the monoamine transporters (MATs). 
Additionally, previous studies have found that the carbonyl oxygen atom can be replaced with a 
 xv 
methoxy group, but this results in two chiral centers (i.e., four possible optical isomers for 
synthesis and evaluation). Here, the individual isomers of MCAT, their racemate, and achiral 
MCAT analogs were prepared where necessary, and examined in vitro and in silico at the MATs. 
All agents were active as substrates, with a rank order of potency suggesting that α-position 
chirality, in either configuration, is favored but not required, with the S(-) configuration slightly 
preferred. Either chiral center removal approach resulted in a reduction in potency, suggesting 
both favorable interactions with the α-methyl, and limited bulk tolerance. To further investigate 
this possibility, docking studies were conducted using homology models of the MATs. Common 
binding modes were identified that were similar to the binding mode of S(+)amphetamine co-
crystallized at drosophila DAT. Taken together, these studies supported our conclusions, as steric 
hindrance was observed in the α-methyl region of the proposed binding site for the R(+)MCAT 
isomer. 
Inclusion of the original synthetic cathinones among Schedule I controlled substances 
has driven the clandestine development of a second generation of agents, resulting in an array of 
new synthetic cathinones diverse in structure and effect. Pyrrolidinophenones are a major 
constituent of second-generation bath salts. Little is known about their structure-activity 
relationships. Here, we have synthesized and examined a series of aryl-substituted 
pyrrolidinophenone analogs, as well as an achiral pyrrolidinophenone analog, utilizing novel 
synthetic chemistry and an innovative cell-based epifluorescence Ca2+ imaging technique. Herein, 
we evaluated the neurochemical properties of these novel compounds at the dopamine 
transporter (DAT), considered to exert a major role in actions of drugs of abuse. 
For future structure-activity relationship studies, additional analogs of synthetic 
cathinone-related agents were produced using novel synthetic approaches, including analogs and 
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isomers of known amphetamine drugs of abuse.  
Finally, though much has been learned about the role of the dopamine and serotonin 
transporters in the mechanisms of action of synthetic cathinones, the role of the norepinephrine 
transporter is poorly understood. Homology models of the human norephinephrine transporter 
were built and docking studies conducted to inform the study of MAT ligand selectivity, activity, 
and binding.  
In conclusion, these studies represent progress towards the establishment of 
comprehensive structure-activity relationships for synthetic cathinones and related agents. 
Particular emphasis was placed on the SAR of the phenylalkylamine α-carbon in the synthetic 
cathinone context, and the role of the norepinephrine transporter in their activity. 
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I. Introduction 
The drug abuse problem has received increasing attention in recent years as overdose 
deaths have risen to surpass automobile accidents as the leading cause of accidental death in the 
United States.1 Yearly economic costs of illicit drug use in the United States were estimated at 
$193 billion overall for 2007, the last year comprehensive data were available.2 However, that 
number is expected to have risen substantially in the intervening years; the White House Council 
of Economic Advisers estimated a cost of $504 billion dollars for 2015, or 2.8 percent of GDP, 
due to changes in drug misuse and their associated social and healthcare costs.3 This problem 
includes the current “opioid crisis,” and it has been associated with increased potency, purity, 
availability, and marketing of both illicit and prescription opioids.4  
In the study of the opioid crisis thus far, three distinct phases can be identified. First, 
high-potency prescription opioids (i.e., OxyContin®) became widely available and clinically 
accessible. Although they were marketed as abuse-deterrent based on an extended-release 
formulation, abuse became a major problem. Recognizing this, new regulations were put in place 
to stop prescription opioid misuse, but these policies drove users towards illicit heroin, which 
was increasingly available in a high-purity formulation (i.e., “black tar”).5 Heroin overdose 
defined the second phase. Most recently, new psychoactive substances (NPS) in the form of 
highly potent fentanyl analogs have emerged, followed by a rapid acceleration in already rising 
overdose rates to define the third phase.6 However, and unfortunately, the story of the drug abuse 
crisis does not end with opioids.  
Global supply-driven increases in markets for non-opioid drugs of abuse, including 
cocaine, benzodiazepines, and amphetamine-type stimulants,6 have coincided with increased 
contributions of non-opioids to overdose deaths in the US.1 Meanwhile, molecular and 
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pharmacological diversity of abused drugs has expanded, with 803 distinct NPS reported 
between 2009 and 2017. Stimulants are the primary psychoactive effect group amongst NPS 
(36%), and prominent among these are synthetic cathinones, a chemical group defined by their 
phenylisopropylamine scaffold and β-keto moiety.6 
 Beginning in 2008, synthetic cathinones started to garner significant attention, as they 
were detected in emerging mixtures of NPS known as “bath salts,” which became known for the 
bizarre behavior with which their intoxication was associated; many synthetic cathinones are β-
keto analogs of abused amphetamines. Synthetic cathinones were often sold legally in these 
mixtures under the protection of facetious labeling such as “not for human consumption” or 
“bath salts,” earning them their colloquial name. Use of bath salts often led to unpredictable, 
severe adverse effects,7,8 leading to the scheduling of many synthetic cathinones in the United 
States and Europe.9,10 Despite the ban, however, new synthetic cathinones and related agents 
continued to emerge in the NPS marketplace; these largely consisted of analogs of the newly 
scheduled compounds and were termed “second-generation” bath salts.10–15 These compounds  
produced adverse behavioral and physiological effects that were sometimes life-threatening.16,17 
Today, bath salts have gone “generic” and the name is employed for many different agents that 
contain at least one synthetic cathinone. The term “bath salts” no longer represents a specific 
combination of agents.18 
 Much like the opioid crisis, with one phase leading directly into the next, for stimulants, 
many of the same trends and problems have emerged. Diverted extended-release stimulants 
prescribed for neuropsychiatric conditions are a considerable drug abuse problem, especially 
among youth.5 Deaths attributable to high-purity imported illicit methamphetamine are on the 
rise, especially in rural communities, where their rise outpaces the rise in opioid overdose. 
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Synthetic cathinones and related agents likely have a fentanyl-like role to play in the developing 
global drug abuse problem with respect to stimulants.  
 The parallels between the opioid and stimulant abuse trends don’t end with classes of 
substances. A clear trend emerges from the observation of both classes of drugs: despite decades 
of attempts to deter abuse through scheduling and otherwise banning these substances, the drug 
abuse problem has only become more widespread and deadly. The increasing variable in both 
classes is potency. NPS synthetic opioids range from 15- to 10,000-fold the potency of 
morphine.19 Some NPS synthetic cathinones are 50- to 100-fold more potent than cocaine.15 
Prohibition incentivizes the invention and manufacture of agents with increased potency, as first 
described and termed the “iron law of prohibition” by economist Richard Cowan in 1986.20 Like 
many current strategies to prevent and deter drug abuse, this strategy is increasingly 
demonstrated to be counterproductive.  
 Moving forward, new strategies will be necessary to reduce drug-related harm, treat 
individuals with substance use disorders, and effectively regulate psychoactive drugs. 
Fundamental to effective clinical treatment and public policy will be a strong foundation in 
science of drug action and effects. In the case of synthetic cathinones, our group pioneered the 
study of their structure-activity relationships beginning in the 1987 with the prototype 
methcathinone.21 Since then, we have learned a great deal about their mechanisms of action and 
abuse-related effects. However, much remains to be elucidated, including additional structural 
features of the synthetic cathinones, and the details of the complex interplay between 
neurochemistry and abuse-related pharmacological effects in animals and humans. 
Structure-activity relationship studies of cathinones might be useful in developing both 
antidotes to their poisoning and pharmacotherapy to treat addiction. Additionally, some synthetic 
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cathinones might have clinical utility in the treatment of various psychiatric and neurological 
disorders. For example, bupropion (Wellbutrin®) is currently approved for the treatment of 
major depressive disorder, and is unmistakably, from a structural perspective, a cathinone. N,N-
Diethylpropion (Tenuate®), another synthetic cathinone, is used clinically as an appetite 
suppressant. Furthermore, cathinones share molecular scaffolds and molecular targets with drugs 
used in the management of attention-deficit hyperactivity disorder, sleep-related disorders, mood 
disorders, Parkinson’s disease, and substance-use disorders. Many of these conditions lack 
adequate options for treatment. Studies of synthetic cathinones may inform future drug 
development in this area, resulting in improved patient health. 
In these studies, progress was made towards the establishment of comprehensive 
structure activity relationship data for synthetic cathinones and related agents. This included the 
utilization of design concepts, novel synthetic approaches, innovative pharmacological 
evaluation, and molecular modeling for several series of compounds, each aimed at elucidating a 
particular feature of a specific cathinone or related amphetamine structure. Together, the insight 
gleaned from these studies will strengthen and inform the science of drug abuse, an essential 
starting point for an effective global response, and might lead to novel therapeutic agents for the 
treatment of various neuropsychiatric disorders. 
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II. Background 
A. The Phenylalkylaminome 
1. Overview 
Synthetic cathinones, the subject of this dissertation, belong to the greater 
phenylalkylamine chemical class of centrally-acting agents, that belong to an even greater 
arylalkylamine class. The phenylalkylamine moiety is common amongst centrally-acting 
agents,18 from endogenous neurotransmitters to psychoactive drugs (Figure 1), including those of 
clinical, recreational, and illicit use. A prominent group of molecular targets for 
phenylalkylamines are those proteins involved, both directly and indirectly, with monoaminergic 
neurotransmission. Modifications to the general phenylalkylamine scaffold can confer selectivity, 
and even specificity, for individual targets in the monoamine signaling pathways, exerting 
corresponding quantitative changes in the pharmacological effects of a compound.18 Selectivity 
for specific targets has been linked to distinct psychoactive effects, that are associated with 
names of the classes of drugs producing them, such as psychostimulants, empathogens, 
hallucinogens, or antidepressants, all of which feature phenylalkylamines as prominent 
members.18 Some effects of phenylalkylamines are clinically useful in treating psychiatric 
disorders and neurological diseases, whereas others confer potential for abuse, though 
considerable overlap exists between these two outcomes. Thus, structure-activity relationship 
(SAR) studies of phenylalkylamines are critical for distinguishing between: 1) feasible pathways 
for pharmaceutical development, and 2) scaffolds, pharmacophores, and lead compounds of 
likely high abuse potential. 
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Figure 1. Chemical structures of selected phenylalkylamines, with their common scaffold 
emphasized in purple. 
 The phenylalkylamine scaffold is defined as a phenyl ring connected to a basic amine, 
most commonly by a two-carbon linker, but sometimes by a three-carbon linker. Because of the 
typical two-carbon distance in phenylalkylamines, they are also commonly referred to as 
phenylethylamines or phenethylamines.18,22 However, the alkyl chain is frequently extended at 
the alpha (α) position; commonly, it is extended by one carbon atom, and compounds meeting 
the latter description are also referred to as phenylisopropylamines.23 This extension by one 
carbon atom at the α position is ideal for stimulant effects of amphetamine.24 However, as is the 
case for the pyrrolidinophenones investigated herein, the alkyl chain can sometimes be extended 
further than one carbon with activity retained; sometimes, this extension results in an increase in 
potency.25 Additional subcategorization is possible (Figure 2): ephedrine and related compounds 
are grouped into the subcategory of phenylpropanolamines. Cathinones contain a keto group at 
the beta (β) position. Recognizing the disparate pharmacological effects scattered throughout the 
phenylalkylamine subgroups, it is useful to discuss psychoactive effects, mechanisms of action, 
and SAR of synthetic cathinones in the context of the greater “phenylalkylaminome.” The latter 
term was coined by Glennon to refer to the entire known set of compounds fitting the 
phenylalkylamine chemical description,18 a survey of which will be henceforth presented.  
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Figure 2. Selected subgroups of the phenylalkylamines displayed as concentric circles. 
 
2. Psychoactive Classes of Phenylalkylamines 
Endogenous phenylalkylamines include two of the monoamine neurotransmitters:  
dopamine (DA, 1) and R(-)norepinephrine (NE, R(-)6),26–28 and the related hormone epinephrine 
(R(-)7, Figure 3).29,30 These compounds, while phenylalkylamines, are commonly called 
catecholamines in acknowledgement of their catechol moiety. The third monoaminergic 
neurotransmitter, serotonin (5-HT, 8), belongs to the structurally related but distinct tryptamine 
chemical class, and is not strictly a phenylalkylamine.31 5-HT is an indolealkylamine. 
Collectively, phenylalkylamines and indolealkylamines belong to a larger class of agents referred 
to as arylalkylamines.18 
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Figure 3. Monoamines that share an arylalkylamine chemical scaffold. A common 
phenylalkylamine structure is highlighted in purple where it exists. 
 
Exogenous centrally-active phenylalkylamines include those used for medicinal purposes 
and those used recreationally.18 Psychoactive effects that confer these applications may be 
distinct or overlapping. Included among the top 100 pharmaceutical products by prescription are 
many phenylalkylamines acting at monoaminergic targets,18,32 including venlafaxine, an 
antidepressant with no known abuse potential, bupropion, an antidepressant with moderate abuse 
potential,33,34 and amphetamine, a stimulant with high abuse potential,35 but which is used 
commonly in the treatment of attention-deficit hyperactivity disorder (ADHD) and 
narcolepsy.36,37 In the study of phenylalkylamines that are commonly abused, three predominant 
psychoactive effect groups emerge: psychostimulants, classical hallucinogens, and 
empathogens.18  
Psychostimulants of prevalent use in the phenylalkylamine class include amphetamine (9), 
methamphetamine (10), and the synthetic cathinones (e.g., 5).6 As psychostimulant 
phenylalkylamines (also known as amphetamine-type stimulants, or ATS) are a major focus of 
this dissertation, they will be reviewed in detail in the following section.  
NH2
OH
HO
Dopamine 
(1)
NH2
OH
HO
R(-)Norepinephrine
(R(-)6)
HO
HN
OH
HO
HO
R(-)Epinephrine
(R(-)7)
CH3 NH2
Serotonin
(8)
NH
HO
 
 
9 
Another principal psychoactive effect class of phenylalkylamines is the “classical 
hallucinogens,” so called for their ability to produce visual, tactile, and auditory hallucinations. 
They are defined by this quality, and their corresponding agonist activity at 5-HT2 receptors.38 
Also referred to as “psychedelics,” meaning “mind-manifesting,” for the psychological and 
spiritual utilities for which they are sometimes employed, they are capable of producing 
transcendent states otherwise associated with dreams or spiritual experiences.39,40 The use of 
these agents is prehistoric, playing important roles in ancient cultures of Asia, North and South 
America, and Europe.40 Phenylalkylamines are well represented among the hallucinogens, 
including plant-derived agents such as mescaline, and synthetic substances such as 2,5-
dimethoxy-4-bromoamphetamine (DOB; 2). 
The term “empathogen” was coined to describe 3,4-methylenedioxyamphetamine (MDA, 
23), 3,4-methylenedioxymethamphetamine (MDMA, 3), and related agents, which were distinct 
from other phenylalkylamines based on their purported ability to produce empathy-related states 
such as “emotional oneness and connectedness,” as described by Ralph Metzner, in human 
users.41 MDMA (3), which is often considered the prototypical empathogen, is a 
phenylisopropylamine structurally derived from methamphetamine by the addition of a 3,4-
methylenedioxy moiety. MDMA (3) has been found to exert its empathogenic class-defining 
psychoactive effects by 5-HT- and oxytocin-mediated processes.42 Advancements in 
neuropsychological understanding of empathy combined with decades of sophisticated 
pharmacological analysis of MDMA (3) have confirmed that it does promote emotional empathy, 
but not cognitive empathy, with which it may interfere. The empathogens have alternatively been 
called sympathogens, or entactogens, for their ability to enhance introspection in MDMA-
assisted psychotherapy.41 The effective labeling and definition of this psychoactive class of 
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compounds has been the subject of some controversy,41 and complicated by the mixed activity 
and subjective effects of its constituents.18  
 
B. Amphetamine-Type Stimulants 
1. The State of ATS Use and Misuse 
Overdose deaths for ATS are on the rise. In the year 2017 (the last year data were 
available), 10,333 overdose deaths in the United States were attributed to ATS. 1 This represents 
an 8-fold rise in rate of death since 2007, the second-greatest increase in any drug class after 
fentanyl-type opioids.1 In rural areas, the rate increased by 10-fold, the highest for any drug class 
in those areas.1 In the state of Virginia, 88 deaths were reported for methamphetamine alone in 
2017, representing a 69.8% increase from the previous year. An additional increase, for a total of 
106, is estimated for 2018.43 
Despite the increase in overdose deaths, use of ATS has remained relatively stable in the 
United States among young people (Table 1).44 Worldwide, ATS are considered a major concern, 
with 34.2 million estimated users in 2016, and increases in use reported in West Asia, Western 
and Central Europe, and Latin America.45 In many East Asian countries, ATS are considered the 
highest priority illicit drug concern,45 as countries including Japan, Korea, and the Philippines 
have reported rates of ATS use 5- to 7-fold higher than rates of cocaine and heroin use 
combined.46 
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Table 1. Prevalence of use of various ATS among United States 12th graders, in percent. 
Brackets indicate significant change from previous year. Adapted from NIDA’s Monitoring the 
Future Study.44 
Drug 2015 2016 2017 2018 
Methylphenidate (16)  2        [1.20] 1.3 0.9 
Amphetamine (9) 10.8 10 9.2 8.6 
Adderall® (Salts of 9)   7.5     6.2 5.5   [4.60] 
Methamphetamine (10)  1     1.2 1.1  0.7 
MDMA (3)        [5.90]       [4.90] 4.9  4.1 
“Bath salts” (Synthetic cathinones)  1     0.8 0.6  0.6 
  
The cause of the ATS burden on public health is likely multi-faceted. Sharp increases in 
ATS-related overdose deaths might be related to the widespread emergence of imported, high-
purity illicit formulations, as was the case for a significant portion of opioid-related deaths (i.e., 
high-purity heroin).47,48 Also implicated in high rates of ATS misuse is the diversion of those 
agents prescribed for clinical treatment of ADHD, narcolepsy, and binge eating disorder (e.g., 
Adderall®, see Table 1).37 Finally, the emergence of high-potency new/novel psychoactive 
substances (NPS) with diverse structural modifications contribute to the overall health burden of 
NPS.44  
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2. Definitions of ATS 
It is necessary, before discussing the history, pharmacology, and SAR of ATS, to 
describe the scope of their amorphous, sometimes controversial, label. Multiple definitions exist 
for ATS. Some prominent definitions include the following: 
“[A] group of substances composed of synthetic stimulants controlled under the 
Convention on Psychotropic Substances of 1971 and from the group of substances called 
amphetamines, which includes amphetamine, methamphetamine, methcathinone and the 
“ecstasy”-group substances (3,4-methylenedioxymethamphetamine (MDMA) and its 
analogues).” – United Nations Office on Drugs and Crime6 
“[A] group of drugs whose principal members include amphetamine and 
methamphetamine. However, a range of other substances also fall into this group, such as 
methcathinone, fenetylline, ephedrine, pseudoephedrine, methylphenidate and MDMA or 
‘Ecstasy’ – an amphetamine-type derivative with hallucinogenic properties.” – World Health 
Organization46 
These definitions are not strictly in alignment, with the former specifying that ATS are 
controlled under a specific act, while the latter includes ephedrine and pseudoephedrine, which 
are not federally scheduled, and are unscheduled in many states.49,50 Additionally, ephedrine and 
pseudoephedrine are natural products, whereas the former definition specifies a synthetic origin 
for ATS. 
In general, it can be said that all ATS share three main points in common: 1) an 
amphetamine (9) core structure; 2) psychostimulant pharmacological effects; and 3) indirect 
augmentation of catecholamine signaling. While the reinforcing effects of ATS are thought to be 
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mediated by DA, most ATS increase NE signaling to a degree greater than or equal to that of DA, 
and ATS active doses more closely correlate with noradrenergic potency.51 Therefore, adrenergic 
signaling is thought to be more important for ATS subjective effects than dopamine signaling. 
However, an agent that selectively increases either catecholamine might still be considered a 
psychostimulant. Additionally, a compound falling under the ATS umbrella could interact with 
other neurotransmitter signaling pathways, including the serotonergic system, although, as in 
such a case, this can result in additional subjective effects (e.g. S(+)MDA, MDMA).18 
The structure of the eponymous amphetamine (9) was defined as “(1) an unsubstituted 
phenyl ring, (2) a two-carbon side chain between the phenyl ring and nitrogen atom, (3) an α-
methyl group, and (4) a primary amino group” by Biel and Bopp,52 and Sulzer and colleagues.53  
ATS may diverge from this definition, containing substituted phenyl rings, and/or secondary or 
tertiary amines.18 Contained within their structures, however, the amphetamine (9) scaffold is 
almost universally present (Figure 4). The α-carbon substituent distinguishes this scaffold from 
that of the general phenylalkylamines, and is the reason for the name amphetamine (9), a 
contracted form of α-methyl-phenethyl-amine. 
 
Figure 4. Selected ATS, with their similarity to amphetamine (9) highlighted in blue. 
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3. History of ATS 
The first known synthesis of amphetamine (9) itself was reported by Romanian chemist 
Lazar Edeleano, who had been working on methodology of liquid-liquid extraction,54 in 1887, 55 
but it was not pharmacologically evaluated at that time. It was not until 1927, in the course of 
early investigations of sympathomimetic pharmacology, that its stimulant properties were first 
explored. These studies arose, like much early pharmacology, from the discovery of 
pharmaceutically-active natural products. 
 
a. ATS Natural Products: Pharmacognosy of Khat and 
Ephedrine 
 The story of ATS begins with two plants: ephedra (i.e., 
ma-huang; ephedra sinica), and khat (i.e., “qat;” catha edulis).  
Estimates of the early history of these plants date back at least 
5,000 years when ephedra was described in a catalog of herbs by 
Chinese emperor Shen Nung.56 Ephedra was used in traditional 
Chinese medicine for millennia, with written records of its 
clinical applications emerging in the sixteenth century. These 
applications included use as a circulatory stimulant, diaphoretic, 
antipyretic, and antitussive.56  
In the Arabian peninsula, the khat plant has been 
cultivated for clinical use, specifically depression treatment, Figure 5. Illustration from 
Vaughan's report on khat use 
in Aden.56 
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dating back to the 11th century.57  Cultivation for other purposes in Yemen and Ethiopia is 
thought to date back further, preceding that of coffee.56 The plant was introduced to Western 
literature by Swedish botanist P. Forskal, who characterized it on a trip to northern Africa in 
1762.56,58 He did not survive the return home to witness publication of his findings, but a 
colleague edited and submitted Forskal’s manuscript, calling the plant in Forskal’s honor “catha 
edulis Forskal,” a name still used today.57,58  
Western interest in the pharmacology of khat began with the writings of Vaughan, a 
physician in Yemen’s port city, Aden, who published on the plant in 1852 (Figure 5). He 
described the cultural value of the plant, and how its stimulant properties interacted with local 
Islamic tradition forbidding intoxication.56,59 Khat use was common in that time, as it still is 
today, throughout much of the Arabian peninsula and East Africa, most notably Yemen, where 
its leaves were often chewed for their stimulant effects and as part of social activities.54,60 
Thirty years later, in the 1890s, back in East Asia, but following the birth of modern 
pharmacology,61 ephedra became the project of interest for Japanese chemist Nagayoshi Nagai.62 
Nagai had recently completed 12 years of post-doctoral training in Berlin, and would eventually 
found the Pharmaceutical Society of Japan.54,62 In collaboration with the pharmacologist Miura, 
he isolated, identified, and profiled the active constituents of ephedra. They identified two active 
compounds: diastereomers, which would be called l-ephedrine (i.e. (-)ephedrine, 1R,2S(-)12)  
and d-pseudoephedrine (i.e., (+)pseudoephedrine, 1S,2S(-)13).62 Miura evaluated “ephedrinum 
muriaticum” (the hydrochloride salt of the ephedra alkaloid base), a slightly yellow salt that 
crystallized in needles, and considered the results of such high interest as to justify a rapid 
communication of his findings.63 He had evaluated the compound in frogs, dogs, and mice, 
finding it fatal via cardiac and respiratory effects. However, in all species, he noticed dilation of 
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the pupil, and this effect was recapitulated upon application directly to the conjunctival sac. He 
moved into clinical experiments with the assistance of Drs. Scriba and Kono at the Surgical 
Ophthalmalogical University Hospital in Tokyo, in which ephedrinum muriaticum appeared to 
be a potent, well-tolerated mydriatic of significant advantage to homatropine, an anti-cholinergic 
in common use at the time.63 
Despite Miura’s enthusiasm, interest in ephedra and its active constituents waned until 
the early 1900s,62 when interest was growing in adrenergic pharmacology.30 The pressor effect of 
a suprarenal extract had been discovered, and epinephrine (i.e., “adrenalin”) identified as its 
active constituent.29,30,64 Japanese pharmacologists Kubota and Amatsu revisited 1R,2S(-)12 in 
1913, in the wake of these new discoveries. Testing its sympathetic modulatory properties, they 
found it similar to adrenaline and tyramine, both of which had recently been described as 
sympathomimetics.62 They found that 1R,2S(-)12 raised blood pressure, accelerated heart rate, 
and relaxed smooth bronchial muscle. As a result of the latter property, an anti-asthmatic 
formulation of 12 was prepared and introduced into clinical usage in Manchuria, but this 
pharmaceutical product was not particularly successful. Ephedra was forgotten for another 
decade.62 
In 1923, Chen and Schmidt, who were stationed at Peking Union Medical College, but 
trained in physiology in the United States, began an investigation of the indigenous 
pharmacopoeia in the area. Ignorant of the previous work of Nagai and Miura, as those papers 
were written in German, Chen and Schmidt conducted dose-response studies in dogs and cats, 
describing many aspects of the sympathomimetic response in more detail than was possible with 
the resources of the earlier Japanese investigations. Their results aligned with those of Kubota 
and Amatsu: 12 was similar to epinephrine and tyramine in pharmacological effect, and therefore 
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belonged in the sympathomimetic amine category defined by Barger and Dale.30,65 They 
concluded that 12 was similar to 7 in structure (Figure 6), but importantly, its actions were more 
prolonged. Publication of these findings in English received much attention, as pharmacologists 
were searching for a superior anti-asthmatic to the recently developed pharmaceutical 
preparation of 7 itself, which was effective, but had many drawbacks, including poor oral 
bioavailability and stability/shelf life.30 Clinical testing showed that 12 was superior across many 
therapeutic dimensions, and it became first-line therapy for asthma by the 1930s, with its use 
peaking in the 1940s and 1950s.62  
 
Figure 6. The hormone epinephrine, displayed alongside ephedrine isomers and similar 
compounds extracted from ma-huang and khat, and the structurally related compound 
(+)norephedrine. 
 
Pharmacologic investigations of khat had also begun by the early 1900s. 56  After decades 
of attempts to identify the active constituents of khat, in the 1930’s, (+)norpseudoephedrine 
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incipient designation as such.60,66 However, these extraction studies had been performed on old 
dry plant material,67 in which the later-extracted β-keto counterpart of 1S,2S(+)15 (i.e., cathinone, 
16, Figure 6) was likely degraded, therefore going undetected at the time. Rothman and 
coworkers67 would later investigate all four stereoisomers each of ephedrine and norephedrine 
alongside S(-)16, finding that S(-)16 and 1S,2S(+)15 were similar in noradrenergic potency, but 
S(-)16 was >3-fold higher in dopaminergic potency as compared to 1S,2S(+)15. Later behavioral 
studies found correlations between dopaminergic potency and reward-related effects for 
synthetic cathinones,68,69 supporting the assertion that cathinone is the constituent of khat more 
responsible for its widespread abuse. However, the impact of noradrenergic potency on abuse-
related effects was yet to be determined. To date, 1S,2R(+)12 and 1S,2R(+)14 are the most 
selective known noradrenergic releasing agents in this series (9.7- and 10-fold selectivity, 
respectively, as compared to DA; Table 2). 
 
Table 2. Potencies of ephedrine isomers and related compounds as synaptosomal releasing 
agents. Modified from Rothman et al., 2003.67 
 EC50, nM 
Compound NE DA 
(-)Ephedrine (1R,2S(-)12)       43.1     236 
(+)Pseudoephedrine (1S,2S(+)13)   223 1988 
(+)Ephedrine (1S,2R(+)12)   218 2104 
(-)Pseudoephedrine (1R,2R(+)13) 4092 9125 
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(-)Cathinone (S(-)16)        12.4       18.5 
(-)Norephedrine (1R,2S(-)14)        42.1  302 
(+)Norpseudoephedrine (1S,2S(+)15)         15.0       68.3 
(+)Norephedrine (1S,2R(+)14)   137 1371 
(-)Norpseudoephedrine (1R,2R(-)15)       30.1   294 
 
 
Pseudoephedrine (13) was later found to be effective as a decongestant.70 Being orally 
active, its use became widespread in over-the-counter pharmaceutical products for colds and 
other sinus conditions. In the early 2000’s, it became the most common precursor for illicit 
methamphetamine synthesis in home labs, which led many states to regulate it more 
carefully.49,54 Various formulations of 12 have been popular as appetite suppressant and 
performance-enhancing drugs.54 For the latter reason, 12 was banned by the FDA for use in 
unregulated supplements in 2004.54  
 
b. Amphetamine and Early Synthetic ATS: Clinical Use and Misuse 
Just as they were inspired by the endogenous phenylalkylamine epinephrine (7), 
medicinal chemists were intrigued by the pharmacognosy of khat and ma huang. Analogs and 
homologs of the natural products discussed above were produced and evaluated using new 
physiological techniques.71–73 Various ATS, and amphetamine (9) itself, were produced in the 
course of these investigations. Methcathinone (MCAT, 5), the term being coined by Glennon and 
coworkers,21 which would later be described as a psychostimulant, was first produced during this 
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time. Its clinical utilization was limited, and it eventually became a controlled substance due to 
reports of its abuse, which was particularly widespread in the former Soviet Union.60  
Of particular interest in the late 1920s was an improved bronchodilator.37,74 Ephedrine 
(12) was prized for its oral bioavailability, but its supplies were limited,62 and it was difficult and 
expensive to make with the synthetic tools available at the time. Medicinal chemistry studies in 
search of a new bronchodilator, originally focused on phenylethanolamine, which was 
disappointing, led to the discovery of amphetamine (9) by Gordon Alles. Observing positive 
results in animals, he tested the compound on himself. He noted its stimulatory, euphoriant 
properties, but considered these side effects unwanted in an anti-asthmatic.75,76  In the mid-1930s, 
he offered samples of 9 to clinicians for testing in various applications, having struggled to 
optimize a bronchodilator. Coincident to these studies, Smith, Kline and French (SKF) 
Pharmaceuticals introduced to the market their product “Benzedrine” – the free base form of 9. 
Alles had only patented the salts, as the free base was volatile, and he had likely lost some 
initiative following a research presentation in 1929.37 SKF capitalized on the volatility of the free 
base, delivering the drug via an inhaler for decongestant purposes.37 
In 1934, Alles resolved his dispute and partnered with SKF to further develop and market 
9. Together, they sought to reposition their drug in the developing field of neuropsychiatry. 
Results of early trials were intriguing for the treatment of Parkinson’s disease,76  alcoholism,77 
narcolepsy,78 and most prominently: mood-related conditions that were likely synonymous with 
depressive disorders of today.76 Amphetamine (9), in tablet formulation, was adopted for the 
treatment of “neurotic depressions,” and its use expanded dramatically during the 1940s. Annual 
sales of amphetamine (9) tablets were $500,000 in 1941, or 4% of SKF revenue, and $2,000,000 
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in 1945.37 Reports of amphetamine (9) abuse had begun to emerge by this time, with some 
patients taking the drug ad libitum rather than as prescribed.  
 
 
Over the next several decades, use of prescription amphetamine and similar ATS 
continued to rise as new formulations, derivatives, and indications (e.g., weight loss) were 
introduced.37 Methamphetamine (10), first synthesized by Ogata in Japan in 1919, was marketed 
as an anorectic under the brand name “Methedrine.”79 By 1971, reviewers had estimated, based 
on manufacturing data, approximately 5% of Americans had used amphetamine or 
methamphetamine within the past year. Widespread diversion, along with misuse of legitimately 
obtained prescriptions, led to public scrutiny.37 For years, some psychiatrists had raised the alarm 
that the abuse potential of ATS were not worth the benefits. In response, the United States 
Bureau of Narcotics and Dangerous Drugs (BNDD) moved amphetamine and its ATS 
derivatives methylphenidate (17) and phenmetrazine (18) to Schedule II, increasing regulatory 
control, in 1971. In coordination, the United States Food and Drug Administration (FDA) revised 
the approved indications for these agents, limiting them for the treatment of narcolepsy and 
“hyperkinetic disorder of childhood,” while removing depression and obesity on the basis of 
poor evidence of effectiveness.37 This same year, President Richard Nixon declared the “War on 
HN
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Figure 7. Amphetamine and selected synthetic ATS developed for clinical use in the mid-1900s. 
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Drugs,” dissolved the BNDD, and established the modern Drug Enforcement Administration 
(DEA). These combined actions precipitated an estimated 60% decline in amphetamine 
prescription sales.37 However, in the intervening years, the numbers of prescription ATS use has 
steadily climbed such that in 2005 they surpassed their 1969 peak. This increase might be related 
to expanded scope and increased diagnosis of the modern clinical conception of “hyperkinetic 
disorder of childhood:” ADHD, which now includes adults.80 
 
c. Illicit ATS and Designer Drugs: Methamphetamine, MDA, MDMA, and Methcathinone 
 Following increased regulations on clinical amphetamine prescriptions, demand-driven 
illicit methamphetamine supply increased. As measured by rates of treatment-seeking patients, 
methamphetamine use and abuse specifically increased alongside trends in supply.37 Various 
“designer drugs,” or uncontrolled analogs, based on amphetamine, were observed on the market 
in the coming decades.81 Designer drugs are now more commonly referred to as new 
psychoactive substances (NPS), and are generally intended to recapitulate the subjective effects 
of a controlled substance while subverting regulation, both of which are often achieved by slight 
structural modifications to a known drug of abuse. 
Illicit MDA (23) and MDMA (3), empathogens, emerged in the 1960s and 1970s, 
respectively, following diversion from research settings, where they were considered promising 
agents for use in assisted psychotherapy. They became prominent fixtures in electronic music 
“rave” culture.82 Concerns about abuse and neurotoxicity, although this has since been 
challenged,83 led to their controlled substance designations (Schedule I). At the time of this 
writing, following renewed interest, 3 is again under investigation in clinical trials for the 
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treatment of post-traumatic stress disorder, social anxiety, and anxiety associated with life-
threatening illness.84 
MCAT (5a), which had not previously been scheduled despite the discovery of its 
stimulant properties decades earlier, emerged as a “designer drug” (i.e., NPS) in the 1990s. It 
was named “methcathinone” by Glennon and coworkers in acknowledgement of its structural 
similarity to cathinone (16). Users had called it “cat” or “jeff.” It saw some abuse at this time and 
was included in an emergency scheduling action that also included other ATS designer drugs, 
such as 4-methylaminorex. MCAT is currently prohibited in Europe, the US, and at the level of 
the United Nations since its addition to Schedule I in the 1990s.85 
 
d. ATS NPS: Synthetic Cathinones (2010-Present) 
i. Bath Salts 
In the late 2000s to early 2010s, a group of ATS NPS emerged consisting primarily of 
mephedrone (5f), MDPV (21), and methylone. These substances, and related cathinone 
derivatives, together became known as a distinct class, collectively referred to as synthetic 
cathinones, although they are closely related to other ATS in pharmacology and SAR.86  As a 
group, they received special attention following recognition of an upsurge in related poisonings 
and emergency room admissions.87 These compounds were colloquially referred to as “bath 
salts,” as being NPS, they were available for purchase legally, and were sold at many retail 
locations in the United States in packages facetiously labeled “not for human consumption,” 
“plant food,” or “bath salts,” among others; hence, their name. Other synthetic cathinones were 
available for purchase through online retailers, and were known as “legal highs.” This was quite 
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common in the United Kingdom.11 Accessibility of purchase, and perceptions of superior purity 
to street drugs led some drug users to choose bath salts.88  
Bath salts mixtures contained compounds that our lab, and later others, found to act via 
two distinct mechanisms of action, resulting in synergistic effects when mixed.89 Being sold in 
inconsistent ratios, and often consumed alongside other substances, bath salts often led to 
unpredictable effects for users and clinicians treating them. Adverse effects, both acute and 
chronic, were sometimes severe, including agitation, tachycardia, psychosis, addiction, and 
multi-organ failure.7,8 In response, the cathinones found in “bath salts” were rapidly banned in 
the United States and many European countries.9,10 
 
ii. α-Pyrrolidinophenones and Second-Generation “Bath Salts” 
Following the prohibition of the original bath salts compounds in the United States and 
much of Europe, a second generation of synthetic cathinones emerged,90,91 populating the 
psychoactive drug space with an array of synthetic cathinones diverse in structure and 
effect.10,14,91,92 Like their progenitors, second-generation bath salts acted differentially at the 
monoamine transporters in terms of potency, selectivity, and mechanisms of action.10,93 They 
also produced adverse behavioral and physiological effects that were sometimes life-
threatening.16,17 
The “second-generation” moniker was first employed in reference to NPS by Brandt and 
coworkers in 2010.11 This publication followed the 2010 general ban on synthetic cathinones in 
the United Kingdom, which precipitated a shift in marketing of NPS towards purportedly legal 
alternatives to mephedrone (5f), MDPV (21), and butylone.11 Using gas chromatography ion-trap 
mass spectrometry in combination with nuclear magnetic resonance (NMR) spectrometry, 
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Brandt and coworkers analyzed 24 samples of NPS obtained via internet drug retailers, 22 of 
which were labeled “NRG-1” or “NRG-2,” a code for 1-(naphthalen-2-yl)-2-(pyrrolidin-1-
yl)propan-1-one, also known as naphyrone or naphthylpyrovalerone.11 Only one of these samples 
contained the expected compound; instead detected in the other samples were caffeine, local 
anesthetics procaine and benzocaine, then recently scheduled mephedrone and butylone, and 
other synthetic cathinones, including flephedrone (i.e., 4-fluoromethcathinone), and the entirely 
novel compound 4-methyl-N-ethylcathinone.11,18 The ban on cathinones seemed ineffective at 
promoting public safety, as the diversity of NPS was increasing, and banned products were 
consistently mislabeled, both seemingly to subvert said ban.88 This occurred despite the fact that 
users of NPS reported harm reduction-related reasons, such as perceived increased purity, among 
their primary motivation for their choice of substance.88 
Pyrrolidinophenones were prominent amongst second-generation bath salts in the United 
States (i.e., α-PVP, α-PHP). Like most ATS and synthetic cathinones, their pharmacological 
effects have been linked to activity at the monoamine transporters (MATs).18,89  
 
C. Monoamines and their Transporters 
1. Monoaminergic Neurotransmission  
a. Overview 
Monoamines, including DA (1), NE (6), and 5-HT (8), are important neurotransmitters 
responsible for chemical signaling between their respective neurons. They are each synthesized 
in their presynaptic neurons, where they are stored in vesicles, and upon upstream electrical 
stimulation in the form of an action potential, they are released into the synapse via fusion of the 
vesicle with the plasma membrane of the presynaptic neuron. Following release, the monoamine 
 
 
26 
meets with its receptors (i.e., transmembrane proteins found both pre- and post-synaptically), to 
propagate its signal. 
 
b. Biosynthesis 
The major biosynthetic pathway of DA is via hydroxylation of dietary L-tyrosine by 
tyrosine hydroxylase, followed by decarboxylation of L-DOPA by DOPA decarboxylase 
(DDC).94 These processes occur in the cytosol of dopaminergic neurons.94 Analogously, 5-HT 
(8) is produced following decarboxylation of L-5-hydroxytryptophan, which is synthesized by 
hydroxylation of dietary tryptophan by tryptophan hydroxylase.95 NE (6) is made from DA (1) 
by dopamine β-hydroxylase.96 The latter process takes place primarily within storage vesicles.97 
 
c. Monoamine Receptors 
 Multiple subtypes of receptor exist for each individual neurotransmitter. Five types of 
DA receptor are known (D1-D5), each G-protein coupled. D1 and D5 are considered D1-like, and 
coupled to Gs, stimulating cyclic AMP (cAMP) production. The remaining DA receptors (D2-D4), 
called D2-like, are Gi-coupled, inhibiting cAMP in contrast to their D1-like counterparts. For 5-
HT (8), there are seven populations of receptors (5-HT1-5-HT7), some of which are subdivided 
into subpopulations for a total of at least 14 distinct 5-HT receptors in humans.98 All are G-
protein coupled with the exception of 5-HT3, a ligand-gated ion channel. Like the DA receptor 
family, they include Gi-coupled (5-HT1 and 5-HT5) and Gs-coupled 5-HT4, 5-HT6, and 5-HT7) 
receptors, as well as Gq-coupled 5-HT2, which stimulates protein kinase C. NE (6) binds to 
adrenergic receptors, which are divided into two types: α and β, which are each subdivided into 
multiple subtypes, and all of which are G-protein coupled, including Gs, Gi, and Gq among them. 
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ATS are indirect agonists, and as such activate these receptors indiscriminately, with selectivity 
between dopaminergic, noradrenergic, and serotonergic (where applicable) potency. There are 
some exceptions to this rule, as in the case of MDA, which acts directly at 5-HT2 receptors.99 
 
d. Monoamine Degradation and Signal Termination 
 Early understanding of monoaminergic signal termination focused exclusively on 
enzymatic degradation.100 Their metabolism has been reviewed in detail elsewhere,95 but can be 
summarized as follows. The catecholamines (1, 6) are degraded primarily by      ccatechol-O-
methyltransferase (COMT), which abstracts a methyl group from S-adenosylmethionine and 
places it at the 3-O position of its substrate.95 The methylated metabolites are then oxidized to 
aldehydes by monoamine oxidase (MAO), followed by dehydrogenation or reduction before 
excretion.95 Alternatively, they may be oxidized by MAO first, and methylated by COMT later.95 
While methylation of 5-HT (8) is possible by hydroxyindole-O-methyltransferase, this pathway 
is of little metabolic importance in vivo.95 The primary metabolic degradation of 5-HT (8) is 
analogous to that of the catecholamines, via oxidation by MAO.95 While metabolism is an 
important component of monoaminergic signal termination, there is another critically important 
contributor (i.e., reuptake), but this remained unknown for decades after the discovery of 
monoaminergic degradative enzymes.101 The transporters responsible for monoamine reuptake 
(i.e., MATs) are also the primary molecular target for ATS, and their discovery be discussed in 
greater detail in a following section. 
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e. Discovery of DA Pathways  
Monoaminergic circuits differ in their projections, localization, and the neuropsychiatric 
processes under their control. Their mapping has been extensively reviewed,102 but its genesis 
can be summarized briefly as follows. Carlsson and coworkers first identified the catecholamines 
(1, 6) in the brain, followed by the description of 12 distinct groups of catecholamine cells (A1-
A12) by Dahlestrom and Fuxe in 1964. DA projections were mapped in the 1970s by 
immunohistochemistry and tyrosine hydroxylase staining.102 The accumulation of decades of 
mapping has revealed multiple pathways in which DA is involved.103 The mesolimbic DA 
pathway, one of these pathways, is central to current theories of drug addiction, as will be 
discussed in the final subsection herein (C.6). 
 
2. Monoamine Transporters: Discovery 
The existence of MATs was a surprise. As reviewed by Iversen,101 and described above, 
termination of monoamine signaling was thought to be exclusively mediated by enzymatic 
degradation. The enzymatic model was revised following experiments with tritium-labelled 
catecholamines, which became available in the late 1950s.100 Hertting and Axelrod observed that 
[3H]NE, in vivo, was not all degraded; 30-40% of it was absorbed and stored in tissue.100 
Furthermore, they found that denervation of sympathetic nerves prevented the observed uptake 
of [3H]NE.100 Therefore, they proposed the mechanism of re-uptake into the presynaptic 
neuron.100 Similar mechanisms were eventually discovered for the other monoamines, as well as 
for other neurotransmitters, including γ-aminobutyric acid (GABA), glycine, and L-glutamate, 
among others.100 Additionally, vesicular transporters, including those specifically for 
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monoamines (i.e., VMAT) were discovered in the membranes of synaptic vesicles, and included 
two subtypes (VMAT-1 and VMAT-2).100 
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3. Structure of MATs – from Cloning to Crystals and Beyond 
In 1991, Tadeus Pocholczyk and coworkers at Yale reported the first cloning of a human 
monoamine transporter: the human NE transporter (hNET).104 Using an expression cloning 
strategy, they elucidated the DNA sequence, amino acid sequence, and topology of hNET.104 
Their findings suggested a 69 kilodalton (KDa) protein of 617 amino acid redidues, with 12-13 
hydrophobic regions  of 18-23 amino acid residues each that were proposed to form 
transmembrane domains (Figure 8).104 Similarly to the  γ-aminobutyric acid transporter (GAT), 
which had been cloned just a year earlier,105 the hNET cloning suggested that the hNET N and C 
termini were located intracellularly, with an extracellular loop containing three glycosylation 
sites.104  
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The cloning of a DA transporter (DAT), in this case the rat DAT, was first reported in 
Science in 1991 by John Kilty and colleagues.106 They used PCR, degenerate oligonucleotides, 
and stringent screening to identify a full-length clone containing 12 hydrophobic regions 
corresponding to 12 transmembrane helices, similarly again to GAT, as well as to the just 
reported hNET. In situ hybridization and pharmacological inhibition by cocaine, mazindol, and 
desipramine supported the identification of DAT.106 In the same issue of Science, Beth Hoffman 
reported the cloning of rat SERT, and its homology to GAT, NET, and DAT.107 Ramamoorthy 
cloned the first human SERT (hSERT) several years later.108 
Figure 8. Pacholczyk's proposed structure of hNET based on cloning. Conserved residues with 
GAT are indicated by darkened circles. Reproduced from Pacholczyk et al., 1991.104 
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The first crystal structure of a solute carrier 6 (SLC6) transporter was published in 2005 
by Yamashita and coworkers.109 This would become the basis for many homology modeling 
studies of MATs.109  
In 2013, the first MAT was 
crystallized by Penmatsa, Wang, and 
Gouaux, working at the Vollum Institute 
of Oregon Health and Science 
University.110 The DA transporter of 
drosophila melanogaster (i.e., the fruit 
fly; dDAT) was cocrystallized with 
nortriptyline. The same team published 
a series of new dDAT crystal structures 
in 2015, which were cocrystallized with a range of other ligands, including amphetamine (9; 
Figure 9).111 Coleman and Green, also working with Gouaux, released the first and, at the time of 
writing, only human MAT crystal structure: that of hSERT, cocrystallized with antidepressants 
(S)-citalopram and paroxetine.112  
In each of the crystal structures, cocrystallized ligands were found in a common binding 
site defined by conserved residues, including an aspartate residue that likely forms hydrogen 
bond interactions with the basic amine of ATS.110–112 This site is commonly referred to as the S1 
site. An additional S2 site has been proposed on the basis of previous crystallography studies 
with the related protein LeuT, the leucine transporter.113 In hSERT, an additional molecule of 
(S)-citalopram was cocrystallized in what was proposed as a potential allosteric site just above 
the common MAT binding site.112  
Figure 9. S(+)Amphetamine (green) co-crystallized 
with dDAT (blue), PDB ID: 4XP9. Generated in 
PyMOL Version 2.1.1. 
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No crystal structure has been produced for NET, and no crystal structure has been 
produced for the human form of DAT (hDAT). However, homology modeling studies have been 
used to simulate the structures of all three human MATs. Koldsø and colleagues created 
homology models of hDAT, hNET, and hSERT even before the release of the first dDAT crystal 
structure, basing their models LeuT.114 They conducted induced-fit docking studies of the 
endogenous substrates using the leucine binding site of LeuT as the pre-defined binding site.114 
This site was the same as that later identified for ligands in the crystal structures of dDAT and 
hSERT.111,112,114 Koldsø and colleagues found at least two common binding modes for each 
substrate.114 In our studies described in later chapters, we were able to identify similar common 
binding modes for the endogenous substrates of hNET using a different template for hNET 
models. 
Models of the human MATs have also been used to dock synthetic cathinones. Sakloth 
and coworkers docked a series of previously synthesized and biologically evaluated para-
substituted MCAT analogs at models of hDAT and hSERT.69 Through qSAR analysis, they 
described a correlation between the volume and maximum width of the para-substituent and 
selectivity for hSERT activity over hDAT activity.69 Modeling revealed a non-conserved residue 
in the direct vicinity of the para substituent.69 The same residue by alignment was a serine in 
hDAT and an alanine in hSERT, potentially explaining why larger substituents were favored by 
hSERT. 69  This residue was proposed to control the selectivity of MCAT (5a) analogs between 
hSERT and hNET.69 The studies described herein describe developments in this explanation. 
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4. Evolution of MATs 
Systems of monoaminergic neurotransmission are widespread in the animal kingdom. 
Evidence suggests that 5-HT and DA neurons emerged at least 600,000,000 years ago, based on 
their presence in an ancient flatworm (i.e., the stem metazoan) thought to be the shared common 
ancestor of all animals, including bilateria (i.e., bilaterally symmetrical animals) and cnidaria 
(i.e., radially symmetrical animals).115 Following this flatworm, the bilaterian common ancestor 
possessed genes for the full suite of monoaminergic neurotransmission, including reuptake.115 
The genes for  these MATs were derived from the greater solute carrier 6 (SLC6) transporter 
family, which also includes amino acid and GABA transporters.116 
The basal bilaterian is thought to be a common ancestor for all protostomes and 
deuterostomes, which are two clades distinguished predominantly by embryonic developmental 
factors.115 The MATs, however, did not descend from the basal bilaterian unmodified.115 Its gene 
for SERT persisted into protostomes and deuterostomes, and its gene for DAT, termed 
invertebrate DAT (iDAT), persisted in many protostomes.115 Among the deuterostomes, iDAT 
was lost in the common ancestor of chordata.115 Instead, the genes for both DAT and NET in 
chordata evolved from a general catecholamine transporter (Figure 10).115 Therefore, hNET and 
hDAT are both derived from this common catecholamine transporter, and are evolutionarily 
divorced from dDAT, which descended from iDAT.115 Therefore, similarity in structure and 
function of hDAT and dDAT are a consequence of convergent evolution. In protostomes, the 
catecholamine transporter became the octopamine transporter in those cases where it 
remained.115 
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Figure 10. Evolutionary origin of the MATs. Highlights the evolutionary distance between 
dDAT and hDAT. Generated in ChemDraw Professional 17.1. 
 
5. Mechanism of Neurotransmitter Transport 
Transport of monoamines against their concentration gradient, from the extracellular 
space to the cytosol, is entropically unfavorable when considering the transport of substrate itself. 
Therefore, substrate transport is dependent on another source of energy.117 This energy comes 
from coupling substrate transport to that of Na+ ions along their concentration gradient. The 
extracellular monoamine substrate is thought to bind to the MAT along with Na+ and Cl- ions, 
and they are all transported together into the cytosol.109 
Physically, the MATs are thought to cycle through discrete conformations to facilitate 
substrate transport, as described by the alternating access model. As reviewed by Kristensen,116 
this model originated from the work of Mitchell and Wilbrandt in the late 1950s, who proposed 
that transporters are allosteric proteins, and that they alternate conformation between cytosolic 
and extracellular accessibility.116 Jardetzky refined this model in the 1960s. The model states that 
transporters undergo conformational changes that allow sequestration of the substrate and its 
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binding site from the extracellular or cytosolic medium.116 These discrete conformations are 
known as outward-facing open, occluded, and inward-facing open states.109 
Though the alternating access model can be supported by observations of each of the 
proposed states in crystal structures of LeuT and detailed kinetic analyses, there are observations 
that it cannot totally explain.109 For example, the stoichiometry of ion transport is out of step 
with what would be predicted based on the cotransport of substrate, Na+, and Cl- ions alone.109 
Alternatives, such as a channel mode, in which the transporter is open to both cytosol and the 
extracellular medium, have also been proposed.118–120 
 
6. Monoamines and ATS in Substance Use Disorders 
There are various models in biology, psychology, and sociology that attempt to explain 
how drugs of abuse exert complex behavioral effects in humans, and how this behavior can 
sometimes lead to consistent symptoms of behavioral dysfunction that define a distinctive 
psychiatric disorder.121 At the time of writing, a widely accepted definition and labeling of this 
disorder is that of the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition 
(DSM-5), which calls it substance use disorder (SUD).122 SUD is diagnosed on the basis of 
symptoms of impaired control over substance use, social impairment, risky use, and/or 
pharmacological criteria (Table 3). SUD involving ATS are defined more specifically as 
stimulant use disorders (StUD), which are subdivided into StUD involving amphetamine-type 
substances or cocaine. Out of 11 possible symptoms, diagnosis of most SUD, regardless of 
substance, requires 2-3 symptoms for mild, 4-5 for moderate, and 6 or more for severe SUD, the 
latter severity which is associated with the pathological drug-taking pattern traditionally defined 
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as addiction.123 The common symptoms, regardless of substance, are reflective of the unified 
theories of addiction neurobiology that are prevalent in current literature. 
 
Table 3. Diagnostic Criteria of Substance Use Disorders. Adapted from DSM-5.122 
Category Criterion 
Impaired control 
over substance 
use 
1. Substance taken in greater amount/time than originally intended 
2. Unsuccessful efforts to decrease/discontinue use 
3. Great deal of time using, recovering from substance 
4. Craving 
5. Failure to fulfill major role obligations at work, school, or home 
Social 
Impairment 
6. Continue use despite persistent interpersonal problems 
7. Activities given up or reduced because of use 
Risky Use 8. Recurrent physically hazardous use 
9. Continued substance use despite persistent health problem  
Pharmacological 
Criteria 
10. Tolerance 
11. Withdrawal 
 
Unified theories of addiction emphasize the similarities in SUD across drug classes.121,124 
Major current theories include hedonic allostasis, incentive sensitization, aberrant learning, and 
frontostriatal dysfunction.124 The role of DA-mediated activation of reward circuitry, particularly 
via the mesolimbic system, at least in the initial phases of drug taking, is a common theme in 
many of these theories.124,125 The mesolimbic DA system extends through several brain regions 
implicated in rewarding and reinforcing effects of drugs, and those mediating incentive salience, 
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including the basal ganglia, which includes the nucleus accumbens, and the ventral tegmental 
area (VTA).126,127 An important role for DA has also been implicated in the withdrawal/negative 
affect stage of addiction central to the allostasis model.126 Unified theories are not without 
controversy, as differences have been identified between individual substances and their 
associated behavioral and molecular pharmacological profiles.121 Additionally, while many 
people will use drugs of abuse, including ATS, most will never develop SUD;128 this and 
additional behavioral evidence clearly suggest that the individual is a variable in the 
developmental process of SUD.129 The environment can also play an important role, and its 
effects vary on the basis of substance.124  
For StUD as opposed to other SUD, the evidence for DA as a central mediator of 
addiction may be strongest, as psychostimulants directly increase DA by their molecular 
interaction with the DAT.111,126 Intracranial injection studies in the 1990s led to the identification 
of DA neurons in the nucleus accumbens and VTA as those primarily responsible for 
psychostimulant reward-related properties.130 Animal study evidence of ATS neurotoxicity via 
dopaminergic mechanisms had also accumulated by this time.131–136 Imaging of human brains by 
N. Volkow and coworkers in the early 2000s revealed severe disruptions in dopaminergic 
systems of methamphetamine (10) users, even after detoxification.137 These disruptions were 
associated with motor and cognitive impairment, and specifically indicated DA transporters as 
the site of the dysfunction. This work produced famous images (Figure 8) that served as 
supporting evidence for the brain disease model of addiction, which in development at the 
time,125 and has since been strongly promoted by the National Institutes of Drug Abuse 
(NIDA).137,138  
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Though SUD is often a chronic, progressive, and potentially fatal disorder, sustained 
remission and recovery are possible.139 However, StUD patients face particular barriers to 
recovery and treatment. These can include, based on direct activation of DA by ATS, psychosis, 
and neurotoxicity-based cognitive and behavioral impairment, which preclude engagement with 
treatment and recovery processes.140 Sociodemographic trends of users may pose additional 
barriers.140 Though many have been evaluated at the pre-clinical and clinical level, no 
pharmacotherapies are currently FDA-approved for use in treating StUD. Considering the rising 
contribution of ATS to the overdose crisis and global drug abuse problem,6 and unique features 
of StUD,141 it may be in need of targeted intervention. 
 
Figure 11. PET scan of DAT radioligand  [11C]d-threo-methylphenidate bound to 33-year-old 
male human brains. The methamphetamine user was imaged 80 days after detoxification. 
[Reproduced from Volkow et al. 2001. 
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D. Pharmacology 
1. Overview  
As discussed in a prior section, some important features of ATS are their ability to 
augment catecholamine signaling indirectly and produce psychostimulant effects. As argued 
convincingly by Sitte and Freissmuth in their thorough review,109 evidence suggests that this 
augmentation is dependent first and foremost on interaction as ligands at MATs. Besides ATS, 
other phenylalkylamines also act at MATs, include monoaminergic neurotransmitters, the 
endogenous substrates. MATs serve as important drug targets for a broader molecular scope as 
well; notably, most antidepressants are MAT ligands, though most antidepressants are neither 
ATS nor traditional phenylalkylamines. In addition to differences in selectivity between DAT, 
SERT, and NET, ligands for these transporters differ in mechanism of action. In general, they act 
via one of two general mechanisms of action: as blockers (i.e., reuptake inhibitors) or substrates 
(i.e., releasing agents). Additionally, some evidence suggests the existence of intermediate 
mechanisms of action between the two prior categories (i.e., partial releasers),142 and additional 
molecular targets that modulate substrate activity.109 Subtle differences in target selectivity and 
mechanism of action at MATs have important implications for pharmacology, giving rise to 
behavioral effects, psychoactivity, and therapeutic class where applicable. 
 
2. ATS as MAT Blockers 
The most seemingly straightforward mechanism by which ATS may augment 
catecholamine signaling is by reuptake inhibition. Many therapeutic drugs and drugs of abuse act 
at the MATs in this way. They bind to the S1 site of the outward-facing open conformation of 
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DAT, NET, and/or SERT, competing with the substrate and stabilizing the outward-facing open 
conformation.116  
The primary pharmacological class utilizing reuptake inhibition is that of antidepressant 
drugs. Antidepressants may inhibit all three MATs, though modern antidepressants are more 
selective for SERT, and sometimes NET (SSRIs and SNRIs), over DAT. Bupropion (20), Figure 
12) is an exception. An ATS synthetic cathinone, 20 is an approved antidepressant and is more 
selective for DAT and NET (an NDRI) than for SERT. 
The prototypical psychostimulant drug of abuse acting as a reuptake inhibitor is cocaine 
(19, Figure 12). Cocaine is relatively nonselective between the three MATs, and not particularly 
potent. It is not an ATS, as it has a distinct molecular structure from that of phenylalkylamines. 
However, it has been cocrystallized in the same S1 binding site as ATS and antidepressants alike 
at dDAT.111  
Comparing potency and selectivity of psychostimulant MAT reuptake inhibitors yields 
surprising results (Table 4). Though cocaine is considered a drug of high abuse potential in 
humans, it is not considerably more potent at DAT than the antidepressant bupropion, which is 
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Figure 12. Known psychostimulant MAT blockers, with ATS structural features highlighted in 
blue where applicable, including known drugs of abuse (all) and drugs approved for medical use 
(17, 20, under rare circumstances 19). 
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considered to have lower abuse potential. This, despite the fact that dopaminergic activity is 
thought to be determinative of abuse potential.109 Cocaine is also nonselective between DAT and 
SERT, and much less selective than bupropion or methylphenidate, which are both approved 
psychiatric medications. Therefore, neither can DAT/SERT selectivity explain its history of 
abuse in humans, despite observed correlations between these pharmacological properties for 
other compounds (vide infra).68,143 
Table 4. Inhibition of [3H]neurotransmitter reuptake at MATs for cocaine (19), methylphenidate 
(17), bupropion (20), MDPV (21), and α-PVP (11). While not all rat brain synaptosome assay 
results were gathered from the same paper, they were all performed in the same laboratory. 
Compound 
IC50 (µM) 
Assay Reference DAT NET SERT 
Cocaine (19) 0.211 
 
0.292             0.313 Rat brain 
synaptosome 
aBaumann 
et al. 
2013144 
0.90 0.48            1.5 HEK 293 cells Luethi et al. 
2017145 
Methylphenidate (17) 0.13 0.12       274 HEK 293 cells Luethi et al. 
2017145 
Bupropion (20) 0.305  3.715 >10000 Rat brain 
synaptosome 
aShalabi et 
al. 2017146 
MDPV (21) 0.004 0.026            3.305 Rat brain 
synaptosome 
aBaumann 
et al. 
2013144 
α-PVP (11) 0.01 0.01        >10 Rat brain 
synaptosome 
aMarusich 
et al. 201415 
a Experiments performed in the same laboratory under the same or similar conditions. 
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 MDPV (21) and α-PVP (11) are the prototypical synthetic cathinones in the MAT 
blocker mechanistic class. Both emerged as NPS as part of the synthetic cathinone “bath salts” 
phenomenon (see section B.3.d. above), though they had both been investigated and patented in 
the mid-1900s (see Glennon and Young for a thorough review).91 
Pyrovalerone (22; Figure 13), the 4-methyl counterpart of α-PVP, was also 
investigated in the mid-1900s, and used clinically as an anti-obesity and 
wakefulness agent in France, alongside amphetamine and its analogs as 
described in section B.3.b. However, it was withdrawn from the market in 
France in 1979 due to problems with its abuse.147 In general, the α-
pyrrolidinophenones act as MAT blockers, most often as NDRIs, based on 
their inactivity or negligible activity as blockers of SERT.  
 
 
3. ATS as MAT Substrates 
 
a. Mechanism of Substrates as Releasing Agents 
Though ATS MAT blocker activity is the more straightforward mechanism, ATS 
substrate activity is by far more common. Amphetamine (9), methamphetamine (10), cathinone 
(16), MCAT (5a), ephedrine (13), MDMA (3), and mephedrone together represent many of the 
most well-known ATS. Though they differ in pharmacological effects, they all act as substrates 
for the MATs, eventually triggering augmentation of monoaminergic signaling through various 
processes. The details of how this augmentation takes place in the case of substrates remains to 
be fully elucidated, but several components of the mechanism have garnered significant evidence 
in their support. These hypotheses were reviewed by Sitte in 2015 with application specifically 
to ATS NPS.109  
N
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Pyrovalerone, an 
NDRI. 
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In the “weak base hypothesis,” described first by Sulzer in 1993,148 the concerted actions 
of ATS on multiple targets give rise to their substrate-releasing properties.109 As substrates for 
MATs, ATS enter presynaptic neurons.109 As substrates for VMATs, they enter the vesicle.109 As 
weak bases, they bring protons with them, dissipating the physiological baseline proton gradient, 
and precluding the transport of endogenous substrate into the vesicle.109 This, in concert with 
ATS inhibition of degradative enzyme COMT, elevates cytosolic monoamine concentration to 
unnatural levels; under normal circumstances, little endogenous substrate remains in the cytosol 
thanks to spatial proximity of vesicles and high turnover number of VMATs.109 The 
concentration of neurotransmitter in the cytosol near the MATs it thought to be high enough for 
neurotransmitter to occupy the inward-facing binding site of the MAT and drive transport in 
reverse.109 
Alternative targets, including trace amine associated receptor 1 (TAR1), ligand gated 
channel-55 (LGC-55), and the glutamate receptor (EAAT3), have also been proposed as 
responsible for ATS substrate releasing effects.109 These additional targets have been linked to 
ATS activity, and even the weak base hypothesis implicates multiple targets (MATs, VMATs, 
and COMT).109 This plethora of targets for substrate ATS raises a question as to which target is 
most directly responsible for substrate release. Considerable evidence calls into question the 
possibility of targets other than MATs as the primary mediators of release. VMAT blockade fails 
to induce DA release in DAT-deficient neurons, not all substrates are active at TAR1, 
amphetamine is weakly potent at LGC-55, and EAAT3 internalization may explain long-term 
effects of ATS, but would fail to explain their rapid psychoactivity.109 On the other hand, 
substrate potency at MATs expressed in HEK 293 cells has been correlated with releasing 
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activity at rat brain synaptosomes, supporting the primacy of MAT activity in determining 
substrate release.149 
 
b. Potency and Selectivity of ATS Substrates 
Crystal structures in concert with mutagenesis studies have suggested that substrates (e.g. 
amphetamine, 9) and blockers (e.g. cocaine, 19) bind at the same S1 site in DAT.111 By 
definition, substrates have low affinities for the MATs. Higher affinities would be predicted to 
convert these substances into blockers, as remaining bound to the transporter would increase 
competition for the substrate binding site. Instead, substrates have low affinities, as they 
ostensibly must detach easily from the binding site to be transported. Therefore, functional data 
is more reliable for evaluating molecular pharmacology of substrate ATS. 
Potency of substrate ATS can be evaluated using various assays. One can evaluate the 
degree of transport into the cell, or the degree of substrate release. The studies described in these 
works utilize calcium imaging as a biosensor process to detect substrate activity. In this assay, 
voltage-gated calcium channels are co-expressed with DAT, NET, or SERT in HEK-293 cells. 
The cells are pre-loaded with Fura2 dye, which fluoresces when exposed to Ca2+. The substrate 
of interest (e.g. 9) is perfused on the cell, and substrate transport increases the permeability of the 
cell membrane to Na+ ions. This results in a substrate-induced but uncoupled Na+ current that 
depolarizes the membrane, opening the co-expressed voltage-gated Ca2+ channels. This allows 
the influx of Ca2+ ions along their concentration gradient, which corresponds to a fluorescence 
that can be visualized and quantified using epifluorescence microscopy.150 This assay has been 
validated as a measure of substrate-induced release by correlating measured substrate potency 
with release potency in rat brain synaptosome assays.149,150 
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4. Behavioral Pharmacology of Synthetic Cathinones 
 Synthetic cathinones produce reliable results in various behavioral animal models. 
Psychostimulants, including cocaine and ATS, typically produce locomotor stimulation, which 
can be measured using rodents in an open field chamber. Synthetic cathinones including MCAT, 
mephedrone, MDPV, and bupropion, among others, produce locomotor stimulation, as reviewed 
in detail by Glennon.86 ATS are readily self-administered in an operant paradigm, and produce 
conditioned place preference. Cocaine (19), amphetamine (9), and MCAT (5a) readily substitute 
for one another in drug discrimination trials.86  
Of particular interest in measuring abuse-related effects of ATS, considering their 
mechanism of action at the MATs, is the intracranial self-stimulation (ICSS) paradigm. This 
assay allows differentiation of DA- and 5-HT- mediated effects by measuring facilitation and 
depression of baseline responding rates,151 which have been connected to distinctive 
dopaminergic and serotonergic effects in synthetic cathinones.68,152 In the ICSS protocol used in 
these studies, rats are implanted with an electrode in their left medial forebrain bundle, an area of 
the brain directly connected to rewarding effects of drugs of abuse.151 They are able to press a 
lever to receive an electrical stimulation of a variable frequency; the amplitude of this 
stimulation is tuned to stimulate the proper neurons.151 At a high frequency, the rats will reliably 
press the lever to receive the stimulation. When the frequency is reduced, however, the rats will 
no longer press the lever. Lever-pressing at a low frequency is facilitated, however, when a 
rewarding substance is administered before the trial.151 This phenomenon is clearly observed in a 
dose-dependent manner for DAT blockers and substrates, including MDPV (21), 
methamphetamine (10), and MCAT (5a). SERT releasers, on the other hand, produce depression 
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of ICSS (e.g. fenfluramine).151 For ATS with serotonergic activity, ICSS allows for the 
observation of facilitation and depression, teasing out DAT-mediated and SERT-mediated 
effects.151 
 
E. SAR of ATS 
Simple variations to the amphetamine (9) structure confer drastic changes in 
pharmacology in terms of molecular target and pharmacological effect, with various 
psychoactive states on offer from the shared phenylalkylamine scaffold (hallucinogens, 
empathogens, stimulants, etc., vide supra). Alterations to the structure can be divided into five 
categories: 1) to the amine nitrogen, 2) to the α-carbon atom, 3) to the β-carbon atom, 4) to the 
two-carbon side-chain connecting the phenyl ring to the nitrogen atom, and 5) to the phenyl ring. 
 Though Biel and Bopp defined amphetamines as primary amines, the N-methyl 
counterparts of amphetamine (9; i.e., methamphetamine, 10) and MDA (23; i.e., MDMA, 3) are 
well-known drugs of abuse whose reputations precede even those of their primary amine 
counterparts (Figure 14). The degree to which N-methylation of amphetamine (9) to 
methamphetamine (10) produces changes in pharmacology has been a subject of some debate in 
the literature for many years. Methamphetamine (10) is often reported to be more potent and 
dangerous, but this observation may be biased in light of its status as the more widely abused 
substance obtained via illicit production.153 Often cited as a possible explanation for its decrease 
in polarity as giving rise to greater blood-brain barrier penetrability.154 An alternative 
explanation for the widespread illicit production of methamphetamine, as opposed to 
amphetamine, has been its facile synthesis via reduction of pseudoephedrine (13),79 which until 
recently was widely available over the counter (i.e., purchase limits or prescriptions are now 
required in many states). Pharmacological investigations have yielded mixed results. 
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In studies of tritiated neurotransmitter release from rat brain synaptosomes,  (+)-
amphetamine and (+)-methamphetamine were similar in potency (Table 5).67 The two were 
virtually identical in terms of dopaminergic releasing potency,67 and counterintuitively, (+)-
amphetamine was both more potent as a NE releaser, and less potent as a serotonergic releaser.67 
If methamphetamine was the more potent drug of abuse, one might expect it to be the more 
potent NET releaser and less potent SERT releaser, as noradrenergic potency has been associated 
with the active dose of psychostimulants,51 and 5-HT release has abuse-limiting effects.155  
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Figure 14. Primary amine amphetamines with their secondary amine counterparts. 
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Table 5. Effect of S(+)amphetamine or S(+)methamphetamine on [3H]neurotransmitter release 
from rat brain synaptosomes. Adapted from Rothman et al. 2003.67 
Compound 
EC50, nM 
DA  NE  5-HT  
S(+)Amphetamine S(+)(9)  24.8   7.07 1765 
S(+)Methamphetamine S(+)(10) 24.5 12.3   736 
  
 
In vivo, differences in molecular pharmacology between the (+)-isomers of amphetamine 
and methamphetamine have been observed across various dimensions of activity. In 
microdialysis studies, methamphetamine was less effective at raising DA levels in the prefrontal 
cortex, and amphetamine, but not methamphetamine, raised glutamate levels in the nucleus 
accumbens.156 However, methamphetamine but not amphetamine raised glutamate levels in the 
prefrontal cortex.156 More recent electrophysiological studies found that methamphetamine 
generated greater whole-cell DAT-mediated currents than amphetamine in vitro, released five 
times the levels of DA in vitro, and was more effective to inhibit clearance of DA in the nucleus 
accumbens in vivo.157 
Behavioral studies have also yielded mixed results in the comparison of amphetamine (9) 
and methamphetamine (10). Depending on the study and the behavioral assay employed, 10 may 
appear similar,156,158–161 less potent,162–164 or more potent than 9.165–168 Some of the mixed results 
may be due to differential pharmacological behavior of individual optical isomers. Some earlier 
behavioral studies directly compared (+)9 to (±)10. In one study directly comparing the (+)9 to 
(+)10 and (-)9 to (-)10 in rat self-administration studies, there was no difference between (+)9 
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and (+)10, but rats self-administered 1.75 times greater quantities of (-)10 than (-)9 at the same 
dose.162 Though 10 is thought to be primarily abused as a racemic mixture, various formulations 
at a range of optical purities are available clinically for 9; as such, stereochemistry may be of 
nuanced importance to abuse in humans. A potential criticism of previous experiments has been 
the high doses used, which may not be etiologically relevant.169 In a low-dose study argued to be 
more constructively valid, which compared the effects of methamphetamine (10) and 
amphetamine (9) on locomotor activity in rats, methamphetamine (10) was more potent than 
amphetamine (9) at low doses of 0.5 mg/kg or 1.0 mg/kg in the presence of cues, but not in the 
absence of cues.169 This subtle difference was proposed to partially explain the fact that 
methamphetamine (10) is more likely to be abused via smoking and injection routes of 
administration, which offer the opportunity for cue association with drug-taking, even in a real-
world setting.169  This is in contrast to amphetamine, which is more likely to be taken orally, a 
route of administration without cues.169 However, an alternative explanation for the discrepancy 
is that amphetamine is much more widely available via prescription in oral formulation, and it is 
this diverted supply that constitutes the bulk of amphetamine-specific abuse.37 
For the 3,4-methylenedioxy counterparts of amphetamine (9) and methamphetamine (10; 
MDA, 23, and MDMA, 3, respectively), the transition from primary amine to secondary amine 
confers changes not only in potency, but in subjective effects and mechanism of action. MDA 
(23) is both a stimulant and hallucinogen, based on its actions at 5-HT2 receptors, whereas 
MDMA (3) is a mixed stimulant and empathogen, based on activity at SERT.18 
Further extension of the N-alkyl substituent of methamphetamine to N-ethyl, N-propyl, or 
N-butyl causes a progressive loss of activity for amphetamine in behavioral assays.170 These N-
alkylations in the presence of a 4-methyl substituent at the phenyl ring (the impact of which is 
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described later in this section) were examined in greater detail at the individual MATs using 
uptake and release assays in rat brain synaptosomes, voltage-clamp measurements, and the 
calcium flux assay descrived above, as well as ICSS in vivo.149 All analogs were active as 
inhibitors of substrate transport at all MATs, and as substrates at SERT. N-ethyl- and N-methyl-
4-methylamphetamine were also substrates at NET, and N-methyl-4-methylamphetamine was 
also a substrate at DAT. The extension of the N-alkyl substituent caused a decrease in reuptake 
inhibition potency, and appeared to cause a progressive loss of substrate activity, with DAT, 
followed by NET, most sensitive to these effects. This activity was also associated with a 
decrease in abuse-related effects in ICSS.149 
The α-carbon atom is a chiral center in most ATS. For the strict psychostimulants 
amphetamine (9), cathinone (15), and MCAT (5a), the S isomer (S(+) in amphetamines, but S(-) 
in cathinones) is typically more potent by 2- to 5-fold in behavioral studies including drug 
discrimination and locomotor activity.60,171 An important caveat is the α-pyrrolidinophenones, in 
which the R isomer is dramatically less active or inactive.172 For MDA (23), the two isomers are 
not only different in potency, but also different in mechanism of action and pharmacological 
effect. Glennon and Young determined, utilizing an innovative 3-lever drug discrimination 
paradigm in which rats were trained to discriminate between the isomers and vehicle, that the S-
isomer was largely responsible for MDA stimulant effects, whereas the R-isomer was 
responsible for hallucinogenic effects.99 
Extension of the alkyl substituent at the α-carbon atom for the pyrrolidinophenones 
results, rather than in a loss of reuptake inhibition potency as observed for 4-methylamphetamine 
N-alkyl extension, in an increase in potency up to at least a five-carbon substituent length (i.e., 
PV-8, Table 6).25 Several studies have confirmed the same trends, with α-carbon alkyl chain 
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length increasing potency at DAT, NET, and even SERT, where the pyrrolidinophenones are 
relatively much less potent (Table 5).15,25,173 In these studies, we progress in our investigation of 
whether the α-substituent extension will increase potency for other ATS scaffolds, such as 4-
methylmethamphetamine (4-MMA). For pyrrolidinophenones with extended α-carbon alkyl 
chains, stereochemical effects are also much more dramatic. Rather than the 2- to 5-fold decrease 
in potency observed for cathinone and amphetamine, the difference is closer to two orders of 
magnitude for reuptake inhibition potency at DAT and NET.172 These studies also seek to 
investigate the nature of that selectivity.  
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Table 6. Potency of α-alkyl chain-extended α-pyrrolidinophenones as inhibitors of 
[3H]neurotransmitter uptake at MATs. 
 
 
 
R 
IC50, nM 
Reference Compound  DAT NET SERT 
α-PPP (70) -CH3 196.7 444.7 >10000 aMarusich et al. 201415 
540 305 188000 bEshleman et al. 2017173 
α-PBP (71) -CH2CH3   63.3   91.5 >10000 aMarusich et al. 201415 
  78 143   67000 bEshleman et al. 2017173 
α-PVP (11) -(CH2)2CH3  12.8   14.2 >10000 aMarusich et al. 201415 
 17.5 ND >10000 aKolanos et al. 201525 
 19.7   46   57000 bEshleman et al. 2017173 
α-PHP (29) -(CH2)3CH3  11.6 ND >10000 aKolanos et al. 201525 
 21.6   36.3   40000 bEshleman et al. 2017173 
PV-8 (72) -(CH2)4CH3 14.5   55.2   26800 bEshleman et al. 2017173 
aData were obtained in the same laboratory under the same or similar conditions in rat brain 
synaptosomes; bData were obtained using HEK-293 cells.  
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The carbonyl oxygen atom of the cathinones appears to be of more importance for the 
pyrrolidinophenones as DAT reuptake inhibitors than for the smaller releasing agents (i.e., 
MCAT) Though MCAT is similar in potency to its des-keto counterpart methamphetamine, the 
des-keto analog of MDPV generated in deconstruction studies was 10-fold less potent as a 
reuptake inhibitor at DAT.174 
Introductions of oxygen atoms via other sp3-hybridized carbon-oxygen bonds may result 
in active compounds that are clinically useful (i.e., aminorex). In ephedrine (12), its isomers, and 
norephedrine (14) and its isomers, the β-carbon substituent is an alcohol, conferring a 10-fold 
degree of selectivity for noradrenergic releasing potency, as described above (Table 2). but little 
is known about their SAR.  The addition of the sp3-hybridized atom also creates a second 
stereocenter, which complicates the SAR. 
Aryl substitution confers a range of new mechanisms of action and subjective effects to 
ATS, as in the example of MDA (23) and MDMA (3) above. Patterns of aryl substitution on 
amphetamine (9) have been established to confer hallucinogenic activity via 5-HT2A receptor 
agonism. Specifically, 2,5-dimethoxy, 4-substitution, or 3,5-dimethoxy, 4-substitution, often 
gives rise to these effects. 3,4-dimethoxy substitution produces hallucinogenic or empathogenic 
effects, as in MDA (23) and MDMA (3). 4-substituted amphetamines and cathinones may 
remain strictly psychostimulants, or gain other activity via other targets, depending on context.  
In the late 1960s, some early SAR studies investigated the effects of aryl substitution on 
amphetamine. Observing that amphetamine use sometimes triggered psychotic states, and that 
ATS with methoxy substitutions to the aryl ring caused hallucinations,175 they sought to elucidate 
the connection between the two. Today, the psychosis sometimes elicited by ATS use is called 
stimulant-induced psychotic disorder (ICD-11),176 and is thought to arise via a distinct 
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mechanism (i.e., DA, glutamate, and GABA) from that of classical hallucinogens (i.e., 5-HT2A 
receptor agonism).38,177 These mechanisms were unknown in 1967, when Smythies and 
coworkers developed their aryl-substituted amphetamine SAR using a novel behavioral test in 
rats that was predictive of psychotomimetic activity in humans.178 In a series of mono, di, and tri-
methoxy substituted amphetamine analogs, the para-methoxy analog was the most potent in the 
behavioral assay for hallucinogenic effects.179 Following up on this work, Smythies joined 
Beaton and coworkers to test additional groups at the 4-position, including methyl, fluoro, and 
chloro. The assay allowed for the observation of a hallucinogenic profile for 4-methoxy-
amphetamine,  and a high- and low-dose stimulant profile for the other three compounds. 4-
methyl-amphetamine was the least potent as a stimulant, and showed no signs of hallucinogenic 
activity. This led the team to conclude that, though they had previously observed the 
hallucinogenic effects of 2,5-dimethoxy-4-methylamphetamine (i.e. DOM), the 4-methyl group 
alone could not confer hallucinogenic activity as a 4-methoxy group could.180 
Decades later, in 1990, following reports of abuse of ring-methylated amphetamines, 
Higgs and Glennon undertook an SAR study of 2-, 3-, and 4-methylamphetamine.81 
Discriminative stimulus effects in rats with respect to (+)-amphetamine were assessed at various 
doses. Only 2-methylamphetamine substituted fully for (+)-amphetamine, and it was less potent 
by an order of magnitude (ED50 = 4.1 mg/kg, ED50 = 0.42 mg/kg, respectively).81 3-and 4-
methylamphetamine only partially substituted for (+)-amphetamine, and produced disruption of 
behavior in the subjects.81 Higgs and Glennon concluded that the aryl-methylated amphetamines 
were less potent as stimulants, and that drug discrimination with amphetamine was not the best 
way to assess their pharmacology.81 Thus, SAR studies led to the differentiation between 
structural features of ATS giving rise to psychostimulant effects and those giving rise to 
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hallucinogenic effects, facilitating efficient development of ATS agents to treat neuropsychiatric 
disorders (i.e., bupropion, 20).  
Bupropion is an aryl-substituted (3-chloro) clinically available cathinone analog, and 
provides a basis for investigation of aryl substitution effects of the cathinone scaffold, 
particularly in the context of N-substitution with a tert-butyl group (Figure 15). In a 
deconstruction study by Shalabi et al.,146  the N-methyl (i.e., 22) and primary amine (i.e., 23) 
counterparts to bupropion were synthesized and evaluated. They retained potency at DAT, but 
lost selectivity, gaining reuptake inhibition and releasing activity at all three transporters (Table 
7). Comparing the N-methyl bupropion analog (22) to its des-chloro counterpart MCAT suggests 
that 3-chloro substitution may slightly reduce potency at DAT and NET (approximately 2-fold), 
but substantially increase SERT potency (10 to 20-fold). Together, these observations suggest 
that aryl modification is highly context-dependent, varying on the basis of other structural 
modifications present in the molecule. Systematic SAR studies are needed to draw conclusive 
assessments of aryl-substitution effects.  
 
Figure 15. Bupropion, its analogs, and MCAT for comparison. 
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Table 7. Potency to release or inhibit uptake of [3H]neurotransmitter in rat brain synaptosomes.  
Compound Uptake Inhibition 
 IC50, nM 
Release  
EC50, nM 
Reference 
 DAT NET SERT DAT NET SERT  
Bupropion (20) 305 3715 >10000 Inactive Inactive Inactive aShalabi 2017146 
22 342 290 1104 29 40 212 aShalabi 2017146 
23 399 551 2779 64 105 567 aShalabi 2017146 
MCAT (5a)    12.5 22 3860 a,bBonano 201568 
a,cShalabi 2019181 
aThese data were obtained in the same laboratory under the same or similar conditions; bOriginal 
publication of DAT and SERT data for MCAT (5a); cOriginal publication of NET data for 5 
 
Systematic studies of 2-,3-, and 4-substituted MCAT analogs have since been conducted 
by our laboratory.181 A wide range of substituents are tolerated, but variation in substituent 
identity shifts potency and selectivity between MATs. For the 4-substituted compounds, 
DAT/SERT selectivity was found to correlate strongly with abuse-related effects.68 Selectivity 
and abuse-related effects correlated additionally with steric bulk of the substituent.68 This 
structural feature was further dissected via quantitative structure activity relationship studies to 
show that maximum width and volume of the substituent were the controlling features of the 
relationship between pharmacology and steric bulk.69  
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Table 8. Potency of para-substituted MCAT analogs to release [3H]Neurotransmitter from rat 
brain synaptosomes. Reproduced from Bonano et al. 2015,68 and Shalabi et al. 2019.181 
 
 
R EC50 
 
DAT             NET SERT 
H (5a)      13   22 ± 4 3860 
MeO (5b)    506 111 ± 24   120 
F (5c)      83   62 ± 10 1290 
Cl (5d)      42   44 ± 9   144 
Br (5e)      59 100 ± 16    60 
CH3 (5f)      49   63 ± 17  118 
CF3 (5g) 2700 900 ± 300  190 
 
 Parallel series of 2- and 3-substituted MCATs were similarly evaluated. These 
investigations revealed a robust correlation between DAT and NET potency. The 2-substituted 
compounds were the least potent, whereas the 3-substituted analogs were found to be similar in 
potency to their 4-substituted counterparts.181 
For α-pyrrolidinophenones, little is known about aryl substitution. The 3,4-
methylenedioxy group of MDPV appears to confer the small degree of SERT activity present is 
NH
CH3
H3C
O
R
 
 
59 
that compound. The 4-methyl substituted pyrovalerone remains active as a psychostimulant, as 
described above (pyrovalerone, 22). 
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III. Specific Aims 
The goal of these works is to progress the establishment of comprehensive SAR for 
synthetic cathinones and related agents (i.e., certain ATS), a distinct aspect of the drug abuse 
problem which will require further scientific understanding in order to most effectively respond. 
Currently, these compounds represent a unique threat within the drug problem landscape. Mixed, 
synergistic mechanisms,89 in concert with substance novelty, give rise to unpredicted adverse 
effects including agitation, tachycardia, psychosis, addiction, and multi-organ failure.7 The 
original “bath salts” components were added to Schedule I in the United States and many other 
countries, but this only drove the clandestine development of a second generation of agents,9,10,90 
resulting in an array of new synthetic cathinones diverse in structure and effect.10,14,91,92  
Despite their toxicity, no antidote for synthetic cathinone poisoning exists. Additionally, 
no pharmacotherapy for addiction to cathinones or any central stimulant is currently FDA-
approved. SAR studies of cathinones might be useful in developing such treatments. Some 
synthetic cathinones also have clinical utility in the treatment of various psychiatric disorders. 
For example, bupropion (Wellbutrin®, Figure 2), which might be considered as a synthetic 
cathinone, is an FDA-approved antidepressant. Our laboratory has previously investigated its 
mechanism of action,146,181 prepared bupropion metabolites182 and analogs,146 and investigated 
their mechanism of action.146,182 In summary, some effects of phenylalkylamines are clinically 
useful or promising for the treatment of psychiatric and neurological disorders, whereas others 
confer potential for abuse, though considerable overlap exists between these two outcomes. Thus, 
SAR studies of synthetic cathinones are critical for distinguishing between: 1) feasible pathways 
for pharmaceutical development, and 2) scaffolds, pharmacophores, and lead compounds of 
likely high abuse potential. 
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In these investigations, our goal is to progress towards the establishment of 
comprehensive SAR for synthetic cathinones and related agents, utilizing design, synthesis, 
pharmacological evaluation, and molecular modeling, aimed at elucidating particular structural 
features. Particular emphasis in the present studies will be placed on the role of the α-carbon 
atom, its substituents, and other structural modifications in the context of α-carbon atom changes. 
Thus, the specific aims of the following work are as follows. 
 
Aim 1: To elucidate the role of stereochemistry of the MCAT α-carbon atom.  
The α-carbon atom is a chiral center for most synthetic cathinones, as is the case for 
MCAT (5; Figure 16). In these studies, we will attempt to further elucidate MCAT 
stereochemistry in terms of pharmacology at the monoamine transporters, and eventually abuse-
related effects as measured by ICSS. The latter goal, however, is not a specific aim of this 
dissertation. Though racemic MCAT ((±)5a) is the prototypical synthetic cathinone, its two 
isomers (S(-)5a, R(+)5a) have never been directly compared in terms of activity at MATs or 
behavioral reward magnitude. Therefore, we seek in the first component of this aim to 
pharmacologically evaluate the optical isomers of 5a. We aim to evaluate efficacy and potency 
of these isomers at hDAT and hSERT using a calcium flux assay described above. In the second 
portion of this aim, we seek to determine the feasibility of removing the MCAT chiral center. It 
is known that the β-carbonyl oxygen atom can be replaced with an alcohol, but this results in two 
stereocenters (i.e., ephedrine, norephedrine, and their isomers 12-15). We have also found that 
the carbonyl oxygen atom of MCAT can be replaced with a methoxy group (unpublished data). 
But, this results in a diastereoisomeric mixture of four isomers. That is, both the α- and β-carbon 
atom are now optically active. In order to progress further in synthetic cathinone SAR at the β-
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position, it would be preferable to remove the α-carbon chiral center in a manner that results in 
only a single chiral center if the β-keto group becomes a chiral center. This can be accomplished 
a) by adding a second methyl group (i.e., 26), or b) by eliminating the α-methyl group (i.e., 27). 
We will synthesize 26 and 27 and evaluate them along with the MCAT optical isomers (+)5 and 
(-)5, and the MCAT racemate (±)5.  
 
The hypothesis here is that because there is little difference in the potency of 
methcathinone analogs in behavioral studies,60,183 there will be little difference in their potencies 
for DAT release. Consequently, S(+)5 and R(-)5 should not differ much in this regard. 
Removal of the α-methyl group of cathinone or amphetamine generally results in 
decreased potency in behavioral assays.24,171,184,185 This is likely the result of decreased blood-
brain barrier permeability (due to decreased lipophilicity) or to decreased potency at the 
dopamine transporter. Two α-des-methyl ATS have been investigated in vitro using rat brain 
synaptosome-based assasys to detect DA releasing activity: the N-des-methyl counterpart of 27 
(i.e., α-des-methylcathinone), and β-phenylethylamine (i.e., α-des-methylamphetamine, or PEA). 
Both were less potent than their respective α-methyl parent compounds by 3- and 4-fold, 
respectively.186,187 Those findings suggest that α-des-methylation decreases potency at MATs, 
rather than simply on the basis of decreased lipophilicity and corresponding blood-brain barrier 
permeability. These studies will further test that finding by applying the same concept to MCAT. 
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Figure 16. Methcathinone, its isomers, and proposed achiral analogs. 
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Aim 2: To establish the SAR of α-pyrrolidinophenones at DAT. 
2.1: To assess the nature of stereoselectivity observed for α-pyrrolidinophenones by 
synthesizing and evaluating an achiral α-pyrrolidinophenone analog.  
Our laboratory has shown a higher degree of stereoselectivity for MDPV than for most 
synthetic cathinone substrates.172 The nature of this stereoselectivity is not well understood. To 
determine the nature of α-pyrrolidinophenone stereoselectivity, we propose to synthesize and 
evaluate an achiral analog of α-PPP (28, Figure 17). As it is expected to 
be a blocker rather than a substrate, it will be evaluated using the calcium 
flux assay described previously,150 but with a modified protocol to 
evaluate blocker activity (vide infra, VI.D.2.). 
 The actions of MDPV (21) are nearly stereospecific.172 The S-
isomer is nearly 200-fold more potent than its enantiomer as an hDAT 
reuptake inhibitor.172 Hence, the α-gem-dimethyl counterpart of 
simplified α-pyrrolidinophenone α-PPP (70), that is, 28, might be 
expected to be substantially less potent than 70 at hDAT as a reuptake inhibitor. 
 
2.2: To establish QSAR for aryl-substituted α-pyrrolidinophenones, and determine 
similarity with MCAT activity via parallel SAR.  
Aryl substitution modulates activity of MCAT at DAT and SERT, and correlations with 
QSAR parameters have been established for MCAT analogs.68,69 Little is known about the 
effects of aryl substitution on α-pyrrolidinophenones. α-PHP is among the most potent of the α-
pyrrolidinophenones, and is a known drug of abuse of the second generation of synthetic 
N
CH3
28
O CH3
Figure 17. An 
achiral α-PPP 
analog. 
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cathinone “bath salts.”17,25 Its SAR has, hitherto, never been investigated. In these studies, we 
address the lack of α-pyrrolidinophenone SAR information, conducting as systematic 
investigation of aryl substitution to the α-pyrrolidinone 4-position, as performed for the MCAT 
series. 
We propose to synthesize a series of para-substituted α-PHP analogs (Figure 18) that are 
systematically designed to evaluate contributions of physicochemical QSAR parameters to 
activity upon evaluation. Each analog has a different substituent at the 4-position of the phenyl 
ring, and each substituent varies in size, shape, lipophilicity, and electron-withdrawing character. 
para-Substituted analogs were selected, as opposed to ortho- or meta-substituted analogs, to 
avoid problems with rotameric binding. To evaluate this series, we will utilize a cell-based 
epifluorescence assay that will test the ability of each compound to block uptake of the 
fluorescent DAT substrate APP+. Considering the established blocking mechanism of action of 
the pyrrolidinophenone class of synthetic cathinones, it is of interest to determine whether these 
compounds act in a similar manner to substrates. Though cocaine and its analog RTI-55 have 
been co-crystallized with dDAT (PDB ID 4XP4 and 4XP5, respectively),111 no synthetic 
cathinone or other ATS MAT blocker has been co-crystallized. Little is known about the 
mechanism of binding for α-pyrrolidinophenones. Having previously synthesized and 
functionally examined a parallel series of MCAT analogs,68,69 we might be able to compare the 
two series to ascertain similarity using Portoghese’s parallel SAR concept.188 In other words, do 
releasing agents and reuptake inhibitors bind at the same transporter site? 
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Aim 3: To synthesize analogs to progress the SAR of synthetic cathinone-related 
amphetamines at the α-carbon atom.  
 
3.1 To synthesize analogs for the investigation of the impact of α-carbon alkyl chain 
extension on 4-methylamphetamines.  
Synthetic cathinones are closely related to ATS, differing only in the presence or absence 
of a β-keto group, respectively. Ring-methylated amphetamines have seen some abuse as NPS in 
previous decades,81 and 4-methylmethamphetamine (4-MMA) in particular has emerged in 
recent years as part of the newest wave of ATS NPS with which synthetic cathinones are 
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Figure 18. α-PHP and para-substituted analogs proposed in Aim 2.2. 
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associated.189 Earlier SAR studies had not conclusively determined the basis for aryl-methylated 
amphetamine analog abuse potential.81,179 More recent studies in our laboratory have examined a 
series of amphetamine analogs, finding that extension of the 
N-alkyl substituent in the context of 4-methylation 
modulates selectivity between MATs, and can convert a 
MAT substrate to a blocker.190 Other recent studies on α-
pyrrolidinophenones have found that α-carbon atom alkyl 
chain extension increases MAT blocker potency.25 The 
effect of α-carbon atom alkyl chain extension on 4-
methylamphetamines (4-MAs) is unknown.  
The hypothesis for this study is that, for 4-methylamphetamines, alkyl chain extension at 
the α-carbon atom will reduce substrate activity, as it did for N-alkyl chain extension. Rather 
than reducing potency with further chain extension, however, it might increase blocker potency, 
as observed in the pyrrolidinophenone series.25 We propose to prepare two α-alkyl extended 
analogs of 4-MMA (Figure 19) for future comparison with 4-MMA in pharmacological effect.  
 
3.2 Stereoselective synthesis of N-ethylamphetamine for evaluation of ATS stereochemistry 
on DAT/NET/SERT selectivity. 
Currently, few substrates with high selectivity between transporters exist, and while we 
have learned a great deal about the relative importance of DAT and SERT to abuse potential, the 
contribution of NET is still unknown. The relative contribution of NET to abuse-related effects 
in ICSS has yet to be determined. Currently, the most selective noradrenergic releasing agents 
are no more than 10-fold selective for NE as opposed to DA release.67 SAR studies suggest the 
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Figure 19. Synthetic targets of 
Aim 3.1: 4-MMA analogs. 
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following: R-N-ethyl-4-methyl-amphetamine is a more 
potent releaser at NET than at DAT, but is also a releaser 
at SERT;190 removal of the 4-methyl in MCAT analogs 
decreases SERT activity.68,69 It is of interest to determine 
the relative MAT releasing activity of R-N-
ethylamphetamine, with the hypothesis that it might be a 
selective NET releaser. Such a compound would be of use 
for the investigation of NET effects in abuse-related 
behavioral effects. For this study, the R-isomer of N-ethylamphetamine will be synthesized 
stereoselectively, along with its S-isomer for comparison (Figure 20).  
 
Aim 4: To construct homology models of NET and use them to gain insight into MAT 
substrate selectivity.  
hNET is also the only one of the three MATs for which a crystal structure is currently 
unavailable. As such, this study aims to prepare a population of hNET models and conduct 
docking studies using the endogenous transporters, as well as novel synthetic cathinones. 
Previously in our laboratory, homology models of hDAT and hSERT were constructed using the 
crystal structure of dDAT co-crystallized with nortriptyline.25 
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Figure 20. Synthetic targets of Aim 
3.2: N-Ethylamphetamine optical 
isomers. 
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IV. Results and Discussion 
 
A. Aim 1: To elucidate the role of stereochemistry of the MCAT α-carbon atom.  
These studies involved the synthesis where necessary (MCAT isomers were already on 
hand as their HCl salts), pharmacological evaluation, and molecular modeling of (±)5a, S(-)5a, 
R(+)5a and achiral analogs 26 and 27 (Figure 16). The following section details the findings of 
this investigation.  
 
1. Synthesis 
Compounds (±)5a, S(-)5a, and R(+)5a were available as their HCl salts following 
previous investigations in the Glennon laboratory.60,183 Though 26 is a known compound in the 
literature, it was synthesized for the first time in our group in the course of these investigations. 
Compound 27 had been previously synthesized by F. Sakloth (unpublished data), a prior student 
in the Glennon laboratory, but was synthesized de novo for these investigations.  
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Retrosynthetic analysis of 26 resulted in a simple scheme in which the desired product 
would be synthesized from α-bromoisobutyrophenone (40), which would in turn be synthesized 
from isoutyrophenone (39), which was readily commercially available. Such methods had been 
used many times to success in our laboratory in the production of similar compounds. Indeed, α-
bromoisobutyrophenone (40) was synthesized in quantitative yield from 38 using liquid bromine 
(Scheme 1). The procedure for bromination was adapted from one published by Layer and 
MacGregor, using chloroform as the solvent rather than the markedly more carcinogenic carbon 
tetrachloride of the published synthesis.191 
 
NH
CH3
• HCl
CH3O
H3C
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CH3
CH3OCH3
CH3
O a b
c
CH3
N
O
H3C
O
HO
O
OH
•
39 40 26
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Scheme 1.a Synthesis of Compounds 26 and 41. 
aReagents and conditions: (a) Br2, CHCl3, 24 h, rt; (b) 1. K2CO3, MeOH, 3 h, rt; 2. MeNH2 
(g), 14 h, 70 °C; (c) HCl, EtOH/Et2O 
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 In an attempt to utilize the adapted procedure of Blough et al. that had been used with 
success by another student in the laboratory (A. Shalabi) for similar compound,192 the synthesis 
of 26 from 40 was attempted by the substitution of N-benzylmethylamine for the α-bromine atom. 
Had the reaction been successful, it was to be followed with debenzylation to afford 26, the 
target compound. However, analysis of the product (i.e., 41) revealed that N-benzylmethylamine 
had substituted for a hydrogen atom at what had been a terminal CH3 on the isobutyrophenone 
substrate. This was surprising, as the pattern of substitution was not observed for analogous 
syntheses using substrates lacking a gem-dimethyl moiety (e.g., propiophenone). Consideration 
of 41 and the unique structural features of substrate 40 led to the proposal of a mechanism for the 
observed transformation (Figure 21). It is possible that the phenyl ring of 40 allows for 
elimination via anchiomeric assistance, with the pi system donating into the antibonding orbital 
of the carbon-bromine bond. The tertiary carbocation would be more stable as compared to a 
secondary carbocation, explaining why this mechanism does not predominate in other analogous 
syntheses in our laboratory using non-geminal starting materials. The resulting α,β-unsaturated 
carbonyl intermediate 44 would serve as a Michael addition donor, allowing for the formation of 
observed product 41.  
 
 
71 
  
Figure 21. A potential mechanism via Michael addition for the transformation of 40 to 41. 
 A literature search was conducted for alternative methods, leading 
to a 2008 patent from Perboni and Giubellina193 on an “improved process 
of amide formation.” Within the patent was a specific route to α-
aminoisobutyrophenones from α-bromoisobutyrophenones (i.e., 26 and 40, 
respectively), which seemed perfectly suited to these investigations. In 
their method, the α-bromo intermediate was stirred with potassium 
carbonate and methanol for 3 hours, by which time it had formed a stable intermediate thought to 
be the epoxy compound by NMR analysis (i.e., 45, Figure 22). Only after this intermediate 
formed was the amine added, resulting in the final compound.193 The Perboni and Giubellina193 
procedure was used with success to afford the free base of target compound 26, which was 
converted to its HCl salt.  
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Compound 27 was prepared by the same method recorded by Sakloth (Scheme 2, 
unpublished data). In this approach, a protected amine acid chloride 48 was prepared for Friedel-
Crafts acylation of benzene by first protecting sarcosine (46) with TFAA, then converting it from 
the acid 47 to the acid chloride 48. The Friedel-Crafts reaction was performed neat in great 
excess of benzene, and the amine was deprotected by stirring in HCl and i-PrOH to afford the 
HCl salt directly. 
 
2. Pharmacology 
In the first known evaluation of MCAT isomers at the MATs, compounds were examined 
pharmacologically using a novel epifluorescence microscopy technique that utilized calcium as a 
biosensor for substrate activity.150 Each agent was examined at multiple concentrations, allowing 
for the construction of concentration-response curves (Figure 23A). The achiral analogs were 
examined using the same technique, in the same series of experiments. Their dose-response 
curves are shown in Figure 23B. 
aReagents and conditions: (a) CF3COOCOCF3, CH2Cl2, rt, 2 h; (b) ClCO2, benzene, 
pyridine, reflux, 1 h; (c) 1. Benzene, AlCl3, reflux, 4 h; 2. Conc. HCl, i-PrOH, 40 °C, 48 
h. 
NH
• HCl
O
H3C
N
CH3
Cl
O
O
F3CN
CH3
OH
O
O
F3C
HN
CH3
OH
O
cba
46 47 48 27
Scheme 2.a Synthesis of Compound 27.  
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Figure 23. Dose-response curves for: (A) MCAT racemate and optical isomers; (B) MCAT 
racemate and MCAT achiral analogs 26 and 27. 
 
All agents were active as substrates at hDAT (Table 9). The S(-) isomer of MCAT (S(-)5) 
was significantly more potent than its R(+) enantiomer R(+)5 at hDAT, but only by a small 
amount (i.e., approximately 1.3-fold). The racemate was not significantly less potent than the S(-
) isomer. 
 
Table 9. Potency of MCAT isomers and achiral analogs as substrates of hDAT in a calcium flux 
assay. 
Species hDAT EC50, nM (± SEM) 
S(-)MCAT (S(-)5a)   240 ± 11 nM 
R(+)MCAT (R(+)5a)   315 ± 14 nM 
(±)MCAT ((±)5a)   248 ± 15 nM 
α-gem-Dimethyl-MCAT (26)   590 ± 19 nM 
α-des-Methyl-MCAT (27) 1860 ± 90 nM 
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In the case of the achiral MCAT analogs compounds 26 and 27, removal of the chiral 
center resulted in a loss of potency, but both modifications were tolerated. The gem-dimethyl 
compound 26 was only approximately 2-fold less potent than the more potent isomer or the 
racemate, while the des-methyl analog 27 was approximately 8-fold less potent. 
 Similar experiments were conducted for the same set of compounds at hSERT by V. 
Nguyen, a student in the Eltit laboratory (Table 10). The S(-) isomer of MCAT S(-)5, but not 
R(+)5, was active as a substrate, with an EC50 value of 15300 ± 1439 nM. The difference in 
potency for S(-)5 between hSERT and hDAT was approximately 64-fold.  The racemate 
(±)MCAT ((±)5) had an even greater preference for hDAT over hSERT (100-fold), whereas 
R(+)5 was completely inactive at hSERT, making it selective as a substrate for hDAT over 
hSERT, without sacrificing much potency at hDAT as compared to its enantiomer (Table 9). For 
hSERT, removal of the chiral center was only tolerated by way of the gem-dimethyl modification 
(26), whereas the α-des-methyl analog (27) was inactive. With an hDAT/hSERT potency ratio of 
22, 26 is the least selective of this series between the two transporters.  
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Table 10. Potency of MCAT isomers and achiral analogs as substrates of hSERT, and their 
selectivity for  hDAT, in a calcium flux assay. 
Compound hSERT EC50, nM (± SEM) hDAT Selectivitya 
S(-)MCAT (S(-)5a) 15300 ± 1439 nMb 64 
R(+)MCAT (R(+)5a) Inactivec DAT Selective 
(±)MCAT ((±)5a)  24750 ± 5745 nM 100 
α-gem-Dimethyl-MCAT (26)  12860 ± 1270 nM 22 
α-des-Methyl-MCAT (27) Inactived DAT Selective 
aSelectivity was calculated as hDAT EC50 ÷ hSERT EC50; bHill slope for linear regression 
constrained to 2.0; ctested at concentrations up to 50000 nM; dtested at concentrations up to 
60000 nM 
 
The small difference between the isomers at hDAT, and the comparably considerable 
difference between the isomers at hSERT resulting in a corresponding difference in 
hDAT/hSERT selectivity, are of interest in light of previous behavioral studies. Previous 
investigations in our laboratory found that S(-)5a is more potent than R(+)5a in its ability to 
stimulate locomotor activity in mice (i.e. ED50 = 0.5 mg/kg, 3.0 mg/kg, respectively).60 
Additionally, S(-)5a was more potent than R(+)5a in its discriminative stimulus potency 
(approximately 4-fold). We hypothesized that these differences would correspond to differences 
in potency, and found a small difference in potency at hDAT between the individual MCAT 
isomers (1.3-fold for S(-)5a as compared to R(+)5a). While the behavioral effects of synthetic 
cathinones are traditionally associated with activity at hDAT, increasing evidence suggests that 
hDAT/hSERT selectivity is an important variable in abuse liability of such compounds,68 and 
that this selectivity emerges in the inspection of individual cathinone isomers.152 A greater 
difference between MCAT isomers was observed at hSERT, as R(+)5 was inactive at 
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concentrations over 3-fold higher than the EC50 for S(-)5. Thus, the differences between isomers 
of MCAT in behavioral studies are possibly due to differences in hSERT potency, or in 
hDAT/hSERT selectivity. Future studies will include the investigation of abuse-related effects in 
ICSS, in which the more hDAT selective compounds are expected to show a greater degree of 
ICSS facilitation. 
In the case of the achiral analogs 26 and 27, both being active, this validates the concept 
of chiral center removal for future SAR studies. Based on these results, either approach might be 
useful for further SAR studies at hDAT. For hSERT, only 26 could be used. Previous studies 
have found that α-des-methyl cathinones are generally less potent in behavioral assays, and one 
study in vitro found similar results.187 One goal of this aim was to further test whether actions at 
MATs contribute to the reduced potency of similar des-methyl cathinones. As 27 is 10-fold less 
potent at hDAT, and inactive at hSERT at concentrations of approximately 4-fold higher than the 
EC50 for S(-)5, direct action at the MATs seems to be important. These studies are particularly 
strong in their support of direct action at MATs, as they were conducted in HEK-293 cells 
expressing the MATs without any of the other known ATS targets (e.g. VMAT1) endogenously 
expressed by animals in behavioral studies or in synaptosome-based assays. 
 
3. Modeling  
The four agents were docked to homology models of MATs to inform our results. Models 
of hDAT and hSERT were previously available in our laboratory.69 The hNET models were 
generated in these investigations (vide infra). Common binding modes were identified for all 
compounds and were similar between transporters (Figure 24). For both hDAT and hNET, two 
similar binding modes were identified. In the first (hDAT-1 and hNET-1), the carbonyl oxygen 
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was oriented trans to the predicted basic nitrogen/aspartate interaction. An analogous binding 
mode for the compounds was found in hSERT (hSERT-1), which was likely strengthened by the  
addition of a hydrogen-bonding interaction with Tyr95, which is a phenylalanine residue in 
hDAT and hNET. In the second common binding mode observed at both hDAT and hNET (i.e., 
hDAT-2 and hNET-2), the carbonyl oxygen atoms of the compounds were oriented cis to the 
aspartate residues. This binding mode was not observed in hSERT, but an alternative binding 
mode was identified (hSERT-2), in which the compound is reversed and shifted out of the 
binding pocket. Previous X-ray crystallography studies have identified a second binding site in 
hSERT stacked just above and overlapping the common binding site used for docking in these 
studies.112 Binding mode hSERT-2 could be shifted towards that second binding site. In general, 
the α-gem-dimethyl MCAT analog 26 was slightly shifted out of alignment with the other 
compounds. This could be due to lack of steric bulk tolerance in the occluded inner portion of the 
binding site, and may explain the slight reduction in potency as compared to either S(-)5 or 
R(+)5a. 
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Figure 24. Common binding modes for Aim 1 compounds at hDAT (top), hNET (middle), and 
hSERT (bottom). 
S(-)MCAT docked similarly at hDAT (mode hDAT-1) to the binding of S(-)amphetamine 
in the template crystal structure of dDAT (Figure 25A). A similar mode was identified for S(-)5a 
at hNET as well (Figure 25B). The similar pose at hSERT varied more than the difference 
between the hDAT and hNET modes, in keeping with the high correlation between hNET and 
hDAT for MCAT-related compounds.67,181  These results support the hypothesis that 
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amphetamine and MCAT bind in a similar manner at the putative MAT binding site, at least 
when it comes to DAT. They provide incipient support for the general hypothesis that cathinones 
and other ATS bind in a similar manner during the transport process. Previous studies have 
shown that between MCAT and amphetamine, the difference in potency at MATs is negligible.67 
However, studies of other scaffolds (i.e., pyrrolidinophenones) have found 10-fold differences 
between keto and des-keto analogs.174 Further studies should include parallel SAR between 
series of cathinone and amphetamines, in concert with docking studies, to further test the 
generalizability of this concept. 
 
Figure 25. (A) S(+)Amphetamine (green) co-crystallized with dDAT (yellow, PDB ID:4XP9)69 
overlaid with S(-)5a (blue) docked at an hDAT homology model (yellow); (B) same as A, but 
overlaid with S(-)5a docked once to an hNET homology model (salmon). 
 
B. Aim 2: To further establish SAR of α-pyrrolidinophenones. 
1. Aim 2.1: To assess the nature of stereoselectivity observed for α-pyrrolidinophenones by 
synthesizing and evaluating an achiral α-pyrrolidinophenone analog.  
a. Synthesis Aim 2.1 
The achiral analog was designed by adding a second methyl group to the α-carbon atom 
(i.e., 28) of α-PPP (70; Table 6). The synthesis of the same compound was described in Perboni 
and Giubellina’s193 patent by the method described in the previous section: by employing 
(A) (B) 
 
 
80 
potassium carbonate and methanol to create an epoxy intermediate from α-
bromoisobutyrophenone (39) , to which the amine was added after stirring for several hours. As 
in the synthesis of gem-dimethyl-MCAT (26), the brominated intermediate 39 was synthesized 
from isobutyrophenone (38). 
 
b. Pharmacology Aim 2.1 
 Compound 28, the gem-dimethyl analog of α-PPP (70) was evaluated in a modified 
calcium flux assay to assess blocker activity by B. Ruiz, a student in J. Eltit’s laboratory. It was 
inactive at both MATs. 
c. Modeling Aim 2.1 
 Compound 28 was docked at models of the MATs as described in Aim 1, but no sensible 
binding modes were identified. It did not dock in a similar manner to MCAT (i.e., the typical 
interaction between the amine nitrogen and aspartate residue was not present).  This could 
explain the inactivity of the compound. 
 
2. Aim 2.2: To establish QSAR for aryl-substituted pyrrolidinophenones, and determine 
similarity with MCAT activity via parallel SAR.  
N
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Scheme 3.a Synthesis of Compound 28. 
aReagents and Conditions: (a) Br2, CHCl3, rt, 24 h; (b) 1. K2CO3, MeOH, rt, 24 h; 2. 
MeNH2, 70 °C, 14 h; 3. HCl/Et2O. 
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a. Synthesis Aim 2.2 
α-PHP (29) had been previously synthesized by 
Kolanos et al. in the Glennon laboratory,25 but was scaled 
up and resynthesized for the present investigations. The 
published procedure was followed exactly (Scheme 4), 
beginning with the commercially available 
hexanophenone (49), which was treated with bromine to undergo carbonyl α-carbon 
halogenation, followed by substitution of the newly introduced bromine by pyrrolidine (Scheme 
4). 
 
Scheme 4.a Synthesis of Compound 29. 
 
 
CH3O CH3O
CH3O
Br N
ba
2949 50
• (COOH)2
29: R = H 
30: R = CH3 
31: R = OCH3 
32: R = Et 
33: R = Cl 
34: R = Br 
35: R = CF3 
 
Figure 26. α-PHP analogs. 
N
O
CH3
R
aReagents and Conditions: (a) Br2, AlCl3 (cat.), 0 °C, 30 min; 2. rt, 1 h (b) 1. Pyrrolidine, 
0 °C, 10 min; 2.  rt, 30 min; 3. Oxalic acid, Et2O. 
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The synthesis of the α-PHP 4-substituted analog series (30-35, Figure 26) was achieved 
through two common synthetic routes. The first route was based on the approach to the 
unsubstituted α-PHP. However, in most cases, the 4-substituted hexanophenones were not 
commercially available, so these were synthesized from the appropriate substituted benzenes 
with hexanoyl chloride in a Friedel-Craft’s acylation (Scheme 5). This was followed by 
halogenation of the carbonyl α-carbon with bromine, and subsequent substitution of  the bromine 
with pyrrolidine. This process was effective for substrates with substituents that were electron-
donating and para-directing either inductively (e.g. ethyl) or via resonance (e.g. bromo). For the 
electron-withdrawing and aromatic substitution-deactivating substituent trifluoromethyl, 
however, the transformation was unsuccessful even after several attempts.  
R
CH3O
R
CH3O
R
CH3O
R
Br N • HCl
ba
c
aReagents and conditions: (a) 1. Hexanoyl chloride, AlCl3 DCM, N2, -10 °C, 30 min; 2. rt, 1-24 
h;  (b) 1. Br2, AlCl3 (cat.), 0 °C, 30 min; 2. rt, 1 h; (c) 1. Pyrrolidine, 0 °C, 10 min; 2.  rt, 30 min. 
 
30, R = CH3 
31, R = OCH3 
32, R = Et 
34, R = Br 
 
75, R = CH3 
59, R = OCH3 
60, R = Et 
61, R = Br 
 
76, R = CH3 
62, R = OCH3 
63, R = Et 
64, R = Br 
 
Scheme 5.a Synthesis of Compounds 30—32 and 34.  
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A new approach was considered to synthesize the necessary 4-hexanophenones by 
oxidation from their corresponding alcohols, which would be generated by Grignard reaction 
with 4-substituted benzaldehydes (Scheme 6). The 4-trifluoromethyl alcohol intermediate (67) 
was successfully synthesized, validating the Grignard approach. The Grignard reagent was 
synthesized in situ using magnesium turnings freshly ground in a mortar and pestle, with several 
drops of 1,2-dibromoethane as an activator. The Grignard procedure was adapted from a similar 
procedure in a 2001 patent from Sebti and 
coworkers.194
 
CH3O
R
CH3O
R
CH3O
R
Br N
dc
• HCl
CH3
R
b
HOO
R
a
77 78 
79 80 81 
Scheme 6.a Extended Grignard approach that was considered for making α-PHPs, as it had been 
used previously for related compounds. 
aReagents and Conditions: (a) n-Bromopentane, magnesium, 1,2-dibromoethane, THF, N2, 
rt, 5-24 h; (b) Jones’ Reagent; (c) 1. Br2, AlCl3 (cat.), 0 °C, 30 min; 2. rt, 1 h; (d) 1. 
Pyrrolidine, 0 °C, 10 min; 2. rt, 30 min. 
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The alcohols would then be oxidized with Jones’ Reagent, substituted with bromine, and 
then substituted with pyrrolidine, in a scheme that was similar to ones used previously in our 
laboratory. However, this scheme is long, and uses harsh reagents. An alternative was sought to 
simplify the procedure. 
A one-pot procedure utilizing milder, more environmentally friendly and safer reagents 
(NBS in place of both Jones’ Reagent and bromine), and which also simplified three steps into 
one (oxidation, bromination, and amine substitution) was discovered in the literature.195 Guha 
and coworkers had pioneered this method in the synthesis of the closely related compound 
pyrovalerone and several related analogs in 2015.195 In this procedure, the NBS is thought to 
oxidize the alcohol, then generate bromine in situ, which can be observed in a burst of brown gas 
that evolves from the reaction mixture. The method was employed successfully in the synthesis 
of several of the target compounds, including both electron-withdrawing and donating 
substituents (Scheme 7). Electron-withdrawing substituents, such as the 4-trifluoromethyl 
compound (35), required mild heating and longer times to initiate the evolution of bromine gas. 
The 4-methyl compound was prepared by both methods. The 4-ethyl compound was attempted, 
but the reaction resulted primarily in another product. 
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b. Pharmacology Aim 2.2 
The series was evaluated for its ability to inhibit transport of hDAT substrate APP+ 
through hDAT expressed in HEK 293 cells, as measured by epifluorescence microscopy. 
Nonlinear regression using the Hill equation was performed on dose-response curves for each 
compound (Figure 27) to generate IC50 potency values, which are shown in Table 11. The 
unsubstituted compound 29 was the most potent (IC50 = 99.3 nM), and the trifluoromethyl 
analog 35 was the least potent (IC50 = 5047 nM). The remainder of the series differed slightly but 
significantly from one another (less than 2-fold). Significance was determined using nonlinear 
regression in GraphPad Prism 6.0. 
30, R = CH3 
33, R = Cl 
35, R = CF3 
 
CH3O
R
N • HClCH3
R
b
HOO
R
a
65, R = CH3 
66, R = Cl 
67, R = CF3 
69, R = Et 
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Scheme 7.a Synthesis of Compound 30, 33, and 35. 
aReagents and Conditions: (a) n-Bromopentane, magnesium, 1,2-dibromoethane, THF, N2, 
rt, 5-24 h; (b) 1. NBS (1.3 equiv); 2. 1,4-dioxane, rt; 3. Pyrrolidine (24-48 h). 
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Figure 27. Concentration-response curves for inhibition of APP+ transport by 4-substituted α-
PHP analogs. 
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Table 11.  Inhibition of APP+ transport by α-PHP analogs in HEK cells, or release of [3H]MPP+ 
by MCAT analogs from rat brain synaptosomes. MCAT data reproduced from Bonano et al. 
2015.68 
Compound in α-PHP 
series 
                R 
α-PHP series  
IC50 (± SEM), nM* 
MCAT series EC50, nM 
α-PHP (29) -H    99.3 ± 7.9     12.5 
4-CH3-α-PHP (30) -CH3  182.7 ± 15.7      49.1 
4-OCH3-α-PHP (31) -OCH3  149.1 ± 13.4 506 
4-CH2CH3-α-PHP (32) -Et  246.6 ± 15.8              n/a 
4-Cl-α-PHP (33) -Cl  182.8 ± 25.3       42.2 
4-Br-α-PHP (34) -Br  127.0 ± 7.5       59.4 
4-CF3-α-PHP (35) -CF3 5047.0 ± 2310 2700 
 
*The APP+ assay can be summarized as follows. Plated cells, previously transfected with hDAT, 
were supplemented with doxycycline to induce expression of transporters. Test compounds or 
controls were exposed to the cells under constant perfusion. Fluorescence was observed at 460 
nm excitation, then recoded for off-line analysis. At least 3 wells were examined per experiment, 
and 2 experiments were conducted for each compound to calculate the IC50 values above. For 
reasons to be subsequently discussed, assays for 29, 31, and 35 were replicated. The new values 
were roughly consistent with the initial results (i.e., IC50 ≃ 29.4 nM, 93.6 nM, and 181100 nM, 
respectively; data points were not sufficient to calculate SEM in replicate experiment). The 
combined IC50 values were highly consistent with the initial results (IC50 ≃ 96.5 ± 3.7 nM, 111.4 
± 6.5 nM, and 7503 ± 3221 nM, respectively). However, the results shown in Figures 28-32 used 
the original data from this table. 
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c. Correlational Studies Aim 2.2  
 The α-PHP series was compared with a parallel series of MCAT analogs in which the 4-
position had the same substituents.68,69 The potencies of the MCAT series are shown for 
comparison in Table 11. Pearson correlational analysis and linear regression revealed a 
statistically significant correlation coefficient between the two series (r = 0.82, P = 0.046, n = 6, 
Figure 28). 
 
Figure 28. Correlation between potencies of α-PHP compounds and corresponding 
methcathinone analogs. 
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The most and least potent analogs of this α-PHP series were also the most and least 
potent analogs for a series of corresponding MCAT analogs previously synthesized in and 
published by the Glennon group.69 However, these points, and particularly the weakest 
compound, the 4-trifluoromethyl, define the correlation. The remainder of the data points cluster 
together, with only slight variations in the potencies of the remaining compounds in the α-PHP 
series. With the 4-trifluoromethyl compound removed from the data set, the correlation is 
completely lost (Figure 29, r = 0.36, P = 0.52, n = 5). Therefore, while the original correlation is 
statistically significant, its validity is still questionable. 
 
 
-7.1 -7.0 -6.9 -6.8 -6.7
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4-OCH3
4-Cl
4-Br
4-H
r = 0.38 
p = 0.52
Figure 29. Correlation between α-PHPs and methcathinone analogs when 4-trifluoromethyl is 
removed. 
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The most conspicuous discrepancy between the two series is between the 4-methoxy 
compounds. In the MCAT series, the 4-methoxy compound is the second-least potent, and 10-
fold less potent than the 4-methyl compound (EC50 = 506 nM and 49 nM, respectively). In the α-
PHPs, the 4-methoxy appears relatively potent, and nearly equivalent in potency to the 
corresponding 4-methyl compound (IC50 = 182.7 nM and 149.1 nM, respectively). The 
GraphPad Prism automatic outlier test, which utilizes their ROUT method of outlier detection, 
identified the 4-methoxy data point as an outlier when Q (the maximum false discovery rate) was 
set to 33%. Below Q = 33%, it was not identified as an outlier. No other points were identified as 
outliers at this Q value. The outlier test, and the placement of the 4-methoxy data point outside of 
the Gaussian distribution, are shown in Figure 30. 
 
Figure 30. Linear regression of α-PHPs and MCATs with outlier test applied. 
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Pearson correlation was performed again between the MCAT and α-PHP series with the 
4-methoxy compounds excluded, which resulted in a much more statistically significant 
correlation (r = 0.97, P = 0.0046, n = 5). The corresponding linear regression is shown in Figure 
31.  These results should be interpreted with a high degree of skepticism, considering the 
remaining importance of the trifluoromethyl compounds to the correlation, the high maximum 
false discovery rate applied in the outlier test, and the low number of XY pairs. Still, they 
suggest that it may be worth revisiting the methoxy compound for further testing.  
   
 
Figure 31. Linear regression analysis between α-PHP series and methcathinone series with 
4-methoxy compounds excluded. 
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QSAR analysis was performed, considering variety of physicochemical parameters 
including electronic and steric factors. A statistically significant correlation (r = -0.89, P = 0.013, 
n = 7) was found with only one: Taft’s steric E (ES), a measure of steric bulk. Linear correlation 
was used to produce Figure 32. Again, these results must be interpreted with skepticism, as the 
4-trifluoromethyl compound plays an important role in the significance of the correlation. 
Without the 4-trifluoromethyl compound, the correlation reduces to r = -0.77, and becomes 
insignificant (P = 0.07). 
 
Figure 32. Linear regression of potency to inhibit DAT and Taft's steric E for α-PHP series. 
  
In these studies, we were able to show that a wide range of aryl substituents are tolerated 
by hDAT at the 4-position of α-PHP. These substituents varied in size, electronic character, and 
lipophilicity, but there was less than a three-fold difference in the EC50 potency values for six out 
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of the seven analogs in the series. This suggests that aromatic substituents in the 4-position are 
not particularly important for activity at hDAT. The exception to this observation is the case of 
the 4-trifluoromethyl analog 35, which defines a correlation with the potency values of a parallel 
MCAT series, and with steric parameter Es. It might be that this compound helps to reveal these 
underlying, legitimate correlations, but the evidence for that claim is fairly weak. Another 
possibility is that 4-trifluoromethyl is universally bad for hDAT regardless of the agent under 
investigation, but for reasons that do not generalize to other substituents (i.e., they are not 
defined by a particular QSAR parameter in an operational manner). 
 
C. Aim 3: To synthesize analogs for progress in SAR of synthetic cathinone-related 
amphetamines at the α-carbon. 
1. Aim 3.1: To synthesize analogs for the investigation of the impact of α-carbon alkyl chain 
extension on 4-methylamphetamines. 
The α-ethyl 4-MMA analog 36 was synthesized from 53 in an analogous fashion to the 
common illicit synthesis route of methamphetamine from phenyl-2-propanone (i.e., P2P; Scheme 
8). Two methods were employed for the reductive amination with methylamine. In method A, 
following Jacob and coworkers’ procedure for a similar compound that had been successfully 
utilized by others in the Glennon laboratory,196 a traditional reductive amination reagent (sodium 
cyanoborohydride) was used. In method B (Scheme 8), Parr hydrogenation in the presence of a 
platinum oxide catalyst was used for the reduction in an attempt to improve the yield. This was a 
new approach to the target compound 36, but the general method of Heinzelman and 
Aspergrem197 was used as a guideline. The ketone intermediate 53 was made by reduction of 52 
with iron, following the Jacob et al.196  approach. The nitroalkene 52 was produced by a 
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modified Henry reaction from p-tolualdehyde (51) following generally the procedure of 
Koremura and coworkers198 for the same compound. Different quantities were used because they 
were working on a much larger scale, different times were used to allow the reaction to reach 
completion, and flash chromatography was used instead of distillation because previous 
attempted purification of 52 by Kugelrohr was unsuccessful. 
 
Scheme 8.a Synthesis of Compound 36. 
 
 
The α-propyl compound 37 (Scheme 9) was approached through an entirely different 
route, as the iron reduction was difficult to stir. The same starting material (i.e., 51) was 
converted to an alcohol (54) by Grignard reaction following a patent procedure.194 Compound 54 
was used in a modified form of Guha and coworkers’ one-pot reaction (vide supra).195 N-
Benzylmethylamine, rather than methylamine, was used in order to control the equivalents in the 
reaction. The benzyl group was removed from 55 with chloroethyl chloroformate using Blough’s 
procedure for similar compounds.199 Finally, the keto group was reduced by Parr hydrogenation 
aReagents and Conditions: (a) CH3(CH2)2NO2, CH3COO-NH4+, HOAc, reflux, 120°C, 
overnight (19.5 h); (b) Fe 90% aq. HOAc, 60°C, 20 min; (c) Method A: 40% aq. MeNH2, 
NaCNBH3, HOAc, MeOH, rt 40 min, HCl, Et2O; Method B: 33% MeNH2 (EtOH), H2, Pt2O, 
EtOH, rt 72 h, HCl, EtOAc. 
 
CH3
NHCH3
CH3
• HCl
CH3
O
CH3
CH3
NO2
CH3
CH3
O
a b
c
Method A
Method B
51 52 53 36
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with a palladium over carbon catalyst. The resulting product was impure, containing a large 
fraction of the ring-reduced cyclohexane counterpart to 37. 
 
Biological data on compounds 36 and 37 have not at the time of writing been collected. 
 
2. Aim 3.2: To stereoselectively synthesize N-ethylamphetamine isomers for future 
evaluation of ATS stereochemistry on DAT/NET/SERT selectivity 
The isomers of 38 were synthesized according to a scheme developed in the Glennon 
laboratory that was used for similar compounds.190 The R isomer R(38) was made in 
collaboration with U. Battisti, a former postdoctoral researcher in the Glennon group, who made 
the first two intermediates S(57) and S(58). Phenylmagnesium bromide was reacted with chiral 
O
NH
H3C
CH3
• HCl
CH3
O
NH3C
CH3
CH3
CH3
CH3
O
CH3
HO
51 54 55
68
a b c
d
NH
H3C
CH3
• HCl
CH3
37
Scheme 9.a Synthesis of Compound 37. 
aReagents and Conditions: (a) n-Butylmagnesium chloride, THF, N2, rt, 24 h; (b) NBS, N-
benzylmethylamine, 1,4-dioxane, rt, 40 h; (c) 1. 1-chloroethyl chloroformate, 2 h; 2. MeOH, 
reflux, 1 h; (d) H2, Pd/C (10%), TFAA. 
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propylene oxides to give S(57) or R(57). The alcohol was converted to a mesylate to make it a 
better leaving group in compounds S(58) and R(58). The substitution of ethylamine for the 
mesylate proceeded by SN2, resulting in inversion of the chiral center. 
 
 
 
At the time of writing, biological data for these compounds have not been collected. 
 
D. Aim 4: To construct homology models of NET to inform MAT substrate studies. 
1. Template 
 Previous modeling studies in our laboratory of hDAT and hSERT had used a 2013 dDAT 
crystal structure that was co-crystallized with reuptake inhibitor nortriptyline (PDB ID: 
4M48).110 The 2015 substrate-bound structures solved by Wang et al.111 had revealed shifted 
phenylalanine residues involved in substrate recognition, and as our hNET models were intended 
to inform substrate selectivity between MATs, a substrate-bound structure was thought to be 
preferable. Several structures of  MATs bound to different substrates dopamine (PDB ID: 4XP1), 
S(+)methamphetamine (PDB ID: 4XP6), S(+)amphetamine (PDB ID: 4XP9), and 3,4-
Reagents and conditions: (a) S(-)Propylene oxide or R(+)propylene oxide, CuI, THF, -
60 °C, 2 h, rt, 24 h; (b) MsCl, Et3N, CH2Cl2, 0 °C to rt, 12 h; (c) (i) Ethylamine (70% 
aq.), DMF, 50 °C, 72 h, (ii) HCl, EtOH/Et2O 
• HCl
CH3
MgBr
CH3
O
S
O O
CH3
CH3
HN
CH3
OH
56
57 58 38
a b c
Scheme 10. Synthesis of Compounds S(+)38 and R(-)38. 
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dichlorophenethylamine (PDB ID: 4XPA) were available and considered as templates. As many 
of the synthetic cathinones under investigation in the Glennon group are secondary or tertiary 
amines, and fewer are primary amines, 4XP6 (with methamphetamine, 10) was selected as a 
candidate template. 
A comparison between the selected template (i.e. 4XP6), and the previous template used 
to build hDAT and hSERT models (i.e. 4M48),69 was conducted in order to ascertain 
comparability of the resulting models for comparative modeling and docking studies between the 
MATs. Alignment and Root Mean Square Deviation (RMSD) analysis was performed in 
PyMOL, and showed that the difference between 4XP6 and 4M48 structure differed by only 
0.398 Å (Figure 33). Considering that a population of 100 models was generated, introducing 
some degree of variation, that distance should not be significant to the outcome of the studies. 
Wang and coworkers111 had identified a group of phenylalanine residues in the binding pocket 
that were shifted in substrate binding for the crystal structures. We observed this shift for Phe325 
between the nortriptyline-bound structure and the methamphetamine-bound structure, 
strengthening the justification for the choice of template as the methamphetamine-bound 
structure (Figure 33). 
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Figure 33. Alignment of dDAT/methamphetamine (beige/green, PDB ID: 4XP6) and 
dDAT/nortriptyline (red/pink, PDB ID: 4M48). Phe325 shift emphasized by grey arrow. 
Generated in PyMOL and Microsoft PowerPoint. 
The more recent crystal structures of hSERT, solved by Coleman et al.,111 were also 
considered as candidates for the hNET model template, as hSERT is of human origin, and dDAT 
is very much evolutionarily divorced from hNET (Figure 10, vide supra: C.4). Sequence identity 
was considered for four MATs transporters (dDAT, hDAT, hNET, and hSERT) by aligning their 
amino acid sequences. These were retrieved as FASTA from the National Center for 
Biotechnology Information (NCBI) using the Protein search function. The sequences were 
aligned using Clustal Omega (Figure 34).200 A percent identity matrix was generated directly 
from this alignment, which evaluated the identities between dDAT and hNET, and hSERT and 
hNET, as 56% and 50%, respectively (Figure 35). This supported the use of dDAT rather than 
hSERT for modeling of hNET, despite the species difference. Additionally, hSERT was co-
crystallized with inhibitors paroxetine and citalopram, which suggested it might be less suitable 
for substrate docking, just as in the case of the dDAT/nortriptyline structure. Nevertheless, we 
compared the candidate templates (dDAT/methamphetamine, PDB ID:4XP6;  hSERT/paroxetine, 
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PDB ID: 5I6X; hSERT/citalopram, Figure 36) to one another by alignment and RMSD analysis 
using PyMOL. The RMSD between dDAT/methamphetamine and hSERT/paroxetine or 
hSERT/citalopram were 1.024 Å and 0.998 Å, respectively. 
 
 
100  
hSERT      ME-----TTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNG----YSAVP 51 
dDAT       ----------MS------------------------------------PTG-HISKSKTP 13 
hDAT       MSKSKCSVGLMSSVV--APAKEPNA----------VGPKEVELILVKEQNGVQLTSSTLT 48 
hNET       -----MLLARMNPQV--QPENNGAD---TGPEQPLRARKTAELLVVKERNGVQCLLA--- 47 
                     :.                                     .*     :    
 
hSERT      SPGAGDDTRHSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQ 111 
dDAT       TPR--------------DNDNNSISDERETWSGKVDFLLSVIGFAVDLANVWRFPYLCYK 59 
hDAT       NPR--------------Q--SPVEAQDRETWGKKIDFLLSVIGFAVDLANVWRFPYLCYK 92 
hNET       -PR------------------DGDAQPRETWGKKIDFLLSVVGFAVDLANVWRFPYLCYK 88 
            *                         ****. *:******:*:****.*******:**: 
 
hSERT      NGGGAFLLPYTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFY 171 
dDAT       NGGGAFLVPYGIMLVVGGIPLFYMELALGQHNRKGAITCWGRLVPLFKGIGYAVVLIAFY 119 
hDAT       NGGGAFLVPYLLFMVIAGMPLFYMELALGQFNREGAAGVWK-ICPILKGVGFTVILISLY 151 
hNET       NGGGAFLIPYTLFLIIAGMPLFYMELALGQYNREGAATVWK-ICPFFKGVGYAVILIALY 147 
           *******:** :: :..*:***********.:*:*.   *  : *::**:*::: :*::* 
 
hSERT      IASYYNTIMAWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWT---------- 221 
dDAT       VDFYYNVIIAWSLRFFFASFTNSLPWTSCNNIWNTPNCRPFESQNASRVPVIGNYSDLYA 179 
hDAT       VGFFYNVIIAWALHYLFSSFTTELPWIHCNNSWNSPNCSDAHPGDSSG-DSSGL------ 204 
hNET       VGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTWNSPNCTDPKLLNGSVLGNHTK------ 201 
           :  :**.*:**:* ::::*** .***  * : **: **      :                
 
hSERT      --------------------------LHSTSPAEEFYTRHVLQIHRSKGLQDLGGISWQL 255 
dDAT       MGNQSLLYNETYMNGSSLDTSAVGHVEGFQSAASEYFNRYILELNRSEGIHDLGAIKWDM 239 
hDAT       -----------------------NDTFG-TTPAAEYFERGVLHLHQSHGIDDLGPPRWQL 240 
hNET       -----------------------YSKYK-FTPAAEFYERGVLHLHESSGIHDIGLPQWQL 237 
                                         : * *:: * :*.::.* *:.*:*   *:: 
 
hSERT      ALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGATLPGAWRGVLFYLKP 315 
dDAT       ALCLLIVYLICYFSLWKGISTSGKVVWFTALFPYAVLLILLIRGLTLPGSFLGIQYYLTP 299 
hDAT       TACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSV 300 
hNET       LLCLMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHI 297 
             *::::  : ***:***:.*******.** :** :*  **::* ****:  *:  **   
 
hSERT      NWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQDALVTSVVNCMTSFVS 375 
dDAT       NFSAIYKAEVWVDAATQVFFSLGPGFGVLLAYASYNKYHNNVYKDALLTSFINSATSFIA 359 
hDAT       DFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSS 360 
hNET       DFYRLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVS 357 
           ::  : :: **:***:*: **** *****:*::****: ** *:**::*: :*. *** : 
 
hSERT      GFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPASTFFAIIFFLMLITLG 435 
dDAT       GFVIFSVLGYMAHTLGVRIEDVAT-EGPGLVFVVYPAAIATMPASTFWALIFFMMLLTLG 418 
hDAT       GFVVFSFLGYMAQKHSVPIGDVAK-DGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLG 419 
hNET       GFAIFSILGYMAHEHKVNIEDVAT-EGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALG 416 
           **.:*:.*****.     : :**.  * .*:*: *  **:.:  *: :*::**:**::** 
 
hSERT      LDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVTLTFGGAYVVKLLEEY 495 
dDAT       LDSSFGGSEAIITALSDEFPKIK-RNRELFVAGLFSLYFVVGLASCTQGGFYFFHLLDRY 477 
hDAT       IDSAMGGMESVITGLIDEFQLLH-RHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHF 478 
hNET       LDSSMGGMEAVITGLADDFQVLK-RHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTF 475 
           :**::.* *.:**.: *:*  :  :.*: *.  :    *. .*   * ** *.. **: : 
 
hSERT      ATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRICWVAISPLFLLFIICS 555 
dDAT       AAGYSILVAVFFEAIAVSWIYGTNRFSEDIRDMIGFPPGRYWQVCWRFVAPIFLLFITVY 537 
hDAT       AAGTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVV 538 
hNET       AAGTSILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVV 535 
           *:* ::*  .::**:.*:*:**  :*. *:::* *  *. :*::**  ::* ****:    
 
hSERT      FLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIITPGTFKERIIKSITPE 615 
dDAT       GLIGYEPLTYADYVYPSWANALGWCIAGSSVVMIPAVAIFKLLSTPGSLRQRFTILTTPW 597 
hDAT       SIVTFRPPHYGAYIFPDWANALGWVIATXSMAMVPIYAAYKFCSLPGSFREKLAYAIAPE 598 
hNET       SIINFKPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPE 595 
            ::         * :* *:  :*: *.  *.  :*    :::    *:: :::    :*  
 
hSERT      TPTEIPCG----DIRLNAV--------------- 630 
dDAT       RDQQSMAMVLNGVTTEVTVVRLTDTETAKEPVDV 631 
hDAT       KDRELVDR---GEVRQFTLRHWLKV--------- 620 
hNET       NEHHLVAQ---RDIRQFQLQHWLAI--------- 617 
              .              :                
Figure 34. Sequence alignments of dDAT, hDAT, hNET, and hSERT for comparison. Asterisks 
(*) indicate fully conserved amino acid residues, colons (:) indicate moderately conserved 
residues, and periods (.) indicate weakly conserved residues. Generated using Clustal Omega. 
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Figure 36. Alignment of dDAT/methamphetamine crystal structures (beige/green, PDB 
ID:4XP6), with hSERT/paroxetine (blue/dark salmon, PDB ID:5I6X) and hSERT/citalopram 
(blue/salmon, PDB ID:5I71). Generated in PyMOL. Shows a different angle than Figure 33.  
 
# 
# 
#  Percent Identity  Matrix - created by Clustal2.1  
# 
# 
 
     1: hSERT       100.00   50.79   48.07   50.08 
     2: dDAT         50.79  100.00   52.65   56.03 
     3: hDAT         48.07   52.65  100.00   67.32 
     4: hNET         50.08   56.03   67.32  100.00 
 
Figure 35. Percent identity matrix (PIN) for MATs of interest. Percent identity between hNET 
and hSERT or hNET and dDAT highlighted in blue or red, respectively. Generated based on 
alignment shown in Figure 34 using Clustal Omega. 
hSERT dDAT hDAT hNET 
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2. Model Generation and Evaluation 
For the purposes of model building, the FASTA amino acid sequence for the dDAT 
template (PDB ID: 4XP6) was retrieved from the Protein Databank. The sequence of hNET was 
retrieved from the Universal Protein Resource database (UniProt accession code: P23975). These 
sequences were aligned using Clustal X and adjusted manually to account for sequence 
modifications to the crystal structure of 4XP6.  Modeller v9.14 was used to build a population of 
100 models based on this alignment.201 The models were assessed on the basis of molpdf, DOPE 
score, and GA341 score (Table 12). GA341 scores, which assess the quality of models using the 
percentage sequence identity between model and template as a parameter, can range from zero to 
one, with a score of one being ideal.202,203 All the hNET models had a GA341 score of one, 
supporting their validity. Higher scores for the modeller objective function (molpdf) are 
considered ideal,201 whereas lower DOPE (discrete optimized protein energy) scores are 
considered ideal. The DOPE score was used to select the best model, as DOPE is an optimized 
statistical method for assessing models.204 There is no benchmark for DOPE scores; all scores 
are relative and arbitrary. The lowest scoring model in the DOPE column was selected for further 
evaluation (homology model #66).  
 
Table 12. Model evaluation using molpdf, DOPE, and GA341 scores, generated using Modeller 
v9.14. Conditional formatting was added using Microsoft Excel, using green to indicate 
relatively superior models on the basis of the scoring function for that column. 
Model ID molpdf DOPE GA341 
1 2421.04932 -80946.734 1 
2 2416.73022 -80840.398 1 
3 2258.40137 -80466.148 1 
4 2607.85181 -80457.203 1 
5 2271.44482 -80720.109 1 
6 2404.61133 -80343.016 1 
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7 2455.85986 -80334.164 1 
8 2112.20264 -81030.297 1 
9 2424.18335 -80679.773 1 
10 2670.10693 -79913.219 1 
11 2351.76392 -80887.664 1 
12 2098.3147 -80702.273 1 
13 2529.13599 -80404.414 1 
14 2278.57056 -80643.984 1 
15 2353.59277 -81009.648 1 
16 2533.14722 -80913.695 1 
17 2131.19824 -80772.617 1 
18 2281.23096 -80600.289 1 
19 2359.65161 -81225.242 1 
20 2424.08374 -81164.797 1 
21 2371.58667 -80596.969 1 
22 2081.18506 -80982.039 1 
23 2419.19873 -80890.75 1 
24 2237.89258 -80521.883 1 
25 2118.3186 -80697.211 1 
26 2341.26807 -81039.297 1 
27 2085.75781 -80442.164 1 
28 2270.28296 -80887.891 1 
29 2113.53442 -80824.617 1 
30 2263.8186 -81263.703 1 
31 2457.58789 -80873 1 
32 2850.07983 -80300.164 1 
33 2191.68188 -81000.773 1 
34 2158.7561 -80540.07 1 
35 2218.05664 -80795.469 1 
36 2208.14014 -80151.023 1 
37 2196.95093 -81002.586 1 
38 2351.42041 -80557.898 1 
39 2264.92407 -80626.875 1 
40 2088.90649 -81059.133 1 
41 2321.43286 -80958.469 1 
42 2305.40112 -80800.563 1 
43 2258.46582 -81222.836 1 
44 2287.58594 -80977.406 1 
45 2840.82178 -80186.875 1 
46 2059.99951 -80844.906 1 
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47 2199.75562 -81180.797 1 
48 2261.15869 -80733.078 1 
49 2297.5564 -80903.969 1 
50 2178.57251 -80375.148 1 
51 2194.84961 -80670.898 1 
52 2217.43994 -80835.859 1 
53 2373.91528 -81056.742 1 
54 2492.0022 -80714.625 1 
55 2353.00537 -80898.742 1 
56 2115.56787 -80553.297 1 
57 2140.40454 -81125.68 1 
58 2240.88623 -80981.133 1 
59 2538.65967 -80843.594 1 
60 2097.5022 -80590.531 1 
61 2278.38379 -80965.398 1 
62 2315.10254 -80464.977 1 
63 2276.68726 -80240.555 1 
64 2335.35132 -80978.047 1 
65 2237.10986 -80735.789 1 
66 2357.88745 -81298.203 1 
67 2719.89062 -80617.375 1 
68 2160.12109 -80786.305 1 
69 2263.10913 -80971.703 1 
70 2470.77026 -80265.836 1 
71 2497.51489 -80293.984 1 
72 2267.38086 -80721.344 1 
73 2288.39795 -80812.063 1 
74 2744.96997 -80152.367 1 
75 2319.60376 -80594.078 1 
76 2532.76953 -80920.414 1 
77 2246.51392 -80802.156 1 
78 2486.87012 -80580.813 1 
79 2124.20068 -80516.82 1 
80 2309.64868 -80761.984 1 
81 2427.55835 -80430.789 1 
82 2249.85938 -80793.789 1 
83 2205.91138 -80527.406 1 
84 2403.64966 -80706.984 1 
85 2308.40161 -80717.531 1 
86 2163.9563 -80779.164 1 
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87 2306.92822 -80651.492 1 
88 2136.55273 -80786.703 1 
89 2386.12451 -80416.367 1 
90 2209.34473 -80970.094 1 
91 2294.87183 -80202.742 1 
92 2180.16797 -81048.109 1 
93 2429.8584 -80373.031 1 
94 2398.53198 -80368.875 1 
95 2369.08984 -80816.422 1 
96 2149.12427 -80747.383 1 
97 2156.55591 -80753.289 1 
98 2252.84424 -80353.633 1 
99 2148.31299 -80806.344 1 
100 2565.34888 -80920.672 1 
 
PyMOL was used to visualize evaluate homology model #66 (Figure 37A), and 
PROCHECK was used to evaluate model #66 on the basis of allowed phi and psi angles.205 A 
Ramachandran plot was generated showing that 95.6% of residues were in the most favored 
regions, 4.2% were in additional allowed regions, 0.2% were in generously allowed regions, and 
0.0% were in disallowed regions (Figure 37B). A model is considered high-quality if it has 90% 
or greater residues in the favored regions. Model 66, therefore, appears to be a very strong model. 
The one residue in the generously allowed region (Asp493) was inspected visually using PyMOL 
(Figure 37C). It was far from the putative binding site, and should not interfere with induced-fit 
docking studies. 
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 In addition to evaluating the best model, the population of 100 models was maintained 
for future studies as a way to account for the plasticity of the substrate binding pocket and 
account for protein flexibility during docking studies. The consistent score of one using the 
objective GA341 scoring function supports the use of the entire population of models. 
 
(A) (B) 
(C) 
Figure 37. Model evaluation using PyMOL and PROCHECK. (A) Homology model #66 of 
hNET, generated in PyMOL; (B) Ramachandran plot of homology model #66, generated in 
PROCHECK; (C) Visualization of Asp493 and surrounding residues, generated in PyMOL. 
D493 
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3. Docking endogenous substrates 
Both to validate the models, and to gain insight into substrate binding at hNET, the 
endogenous substrates DA and NE were docked to the population of hNET models. With the 
common Asp residue (Asp75 for hNET) used to define a 12-Angstrom binding pocket, the 
substrates were docked to each of the 100 models 10 times using GOLD, thus accounting for 
both ligand and protein flexibility. 
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The docking solutions were sorted into clusters by similarity. The top-ranking cluster by 
GOLD score and population was labeled DA-1. Cluster DA-1 consisted of 62 out of 100 of the 
top docking solutions, outranking the next cluster in terms of population by 44 solutions, thereby 
indicating its superiority. This cluster also contained the  highest scoring pose, with a GOLD 
score of 59.4. In this pose, a pi-pi interaction was predicted between the DA aryl ring and Tyr152. 
Notably, the protonated nitrogen of DA was shifted away from Asp75 (3.9 Å), favoring 
hydrogen-bonding interactions between the catechol hydroxyl groups and Ala145 and Ser420 
(Figure 38A). This served as validation for the model, as the crystal structure of dDAT bound to 
DA (PDB ID: 4XP1) revealed a similar shift in binding of dopamine relative to the binding of  
amphetamine or methamphetamine, which favored closeness with the aspartate. This shift was 
observed in these hNET models, despite having used the methamphetamine-bound (PDB ID: 
4XP6) rather than DA-bound (PDB ID: 4XP1) structure as the template (Figure 38B). DA-hNET 
binding pose and model were aligned with the co-crystal structure dDAT-DA (4XP1) using 
PyMOL (Figure 39B), resulting in an RMSD value of 0.496 Å. 
     
Figure 38. Induced-fit docking pose for DA at hNET. (A) DA-1 with predicted distances from 
potential residues of interaction emphasized. (B) DA-1 (red), DA as co-crystallized with dDAT 
(salmon, PDB ID: 4XP1), and methamphetamine as co-crystallized with dDAT (lavender, 4XP6). 
(A) (B) 
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For NE, there were two equally populated clusters of binding modes, each with a similar 
GOLD score. Cluster NE-1 consisted of 26 top poses, with a highest GOLD score of 57.59, and 
cluster NE-2 also consisted of 26 top poses, with a highest GOLD score of 57.52. In NE-1, the 
aryl ring of NE was sandwiched between two aromatic residue side-chains, forming pi-pi edge-
to-face interactions with Tyr152 on one side, and Phe323 on the other. The β-hydroxyl group 
was predicted to form a hydrogen bond with the side-chain carbonyl oxygen atom of Phe317, 
while the NE protonated nitrogen forms ion-dipole interactions and hydrogen bonds with Phe72 
and Ala73 (Figure 39A).  
In cluster NE-2, the aryl ring was shifted away from the Asp75. However, the amine 
nitrogen was simultaneously shifted closer to the Asp residue, allowing for ionic interactions and 
hydrogen bonding. The aromatic interaction with Tyr152 is retained as well (Figure 39B). 
Cluster NE-2 was similar to DA-1. The two were overlaid in PyMOL, revealing that they were 
roughly equivalent (RMSD = 0.445; Figure 39D). Interestingly, the fourth-ranking cluster of DA 
poses by population (DA-4) was visually similar to NE cluster NE-1 (Figure 39C). Cluster DA-4 
consisted of four top-scoring binding poses, and had a top GOLD score of 53.89. Cluster DA-4 
was rotated at the aryl ring as compared to NE-1, sacrificing edge-to-face aromatic interactions 
for the less favorable face-to-face interactions, but both occupied roughly the same area in the 
binding pocket. In DA-4, the distance between the basic nitrogen atom and the aspartate residue 
was shortened to 2.5 Å, allowing for highly favored ionic interactions and hydrogen bonding.  
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Overall, the docking of endogenous substrates DA and NE served to validate the hNET 
models further. They could be used to predict shifted binding that was observed in the crystal 
structure of hDAT, and to predict various modes of interaction, accounting for the dynamic 
nature of substrate transport. The predicted binding of DA and NE were roughly equivalent, 
though NE is considered the actual endogenous substrate of hNET. Though unintuitive, the lack 
of distinction between DA and NE binding is consistent with biological data. Binding studies 
using radiolabeled β-citalopram have found a negligible difference between DA and NE at hNET 
(KM = 0.24 µM and 0.58 µM, respectively).206 Furthermore, uptake studies have shown that 
Figure 39. Induced-fit docking poses for NE at hNET. (A) NE-1; (B) NE-2; (C) NE-1 and 
DA-4 overlaid; (D) NE-2 and DA-1 overlaid. Image generated in PyMOL and Microsoft 
PowerPoint. 
(A) (B) 
(C) (D) 
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hNET transports DA at a slightly faster rate (Vmax DA = 32 pmol/min/mg protein; Vmax NE = 17 
pmol/min/mg protein).206 On the other hand, hDAT is more selective.206 
 
4. Insights to MCAT selectivity 
Previous modeling studies in our laboratory identified a particular non-conserved residue 
as responsible for the difference in selectivity of 4-substituted MCAT analogs between DAT and 
SERT.25 That residue was a serine (Ser149) in hDAT and an alanine (Ala169) in hSERT. As the 
selectivity for hDAT over hSERT had been correlated with steric bulk (Es),68 volume, 69  and 
maximum width (B5) of the substituent,69 it was proposed that the larger serine residue in hDAT, 
which was near the 4-substituent in the models, could not accommodate the larger substituent, 
thus conferring selectivity to hSERT in the case of a large substituent.  
Later, the 4-substituted MCAT series was tested in rat brain synaptosomes at hNET. A 
high correlation between hDAT and hNET potency was observed.181 Therefore, DAT/SERT 
selectivity was roughly equivalent to NET/SERT selectivity for this series. In constructing the 
hNET models, it was expected that the same serine residue would be conserved between hDAT 
and hNET. However, the alignment of amino acid residues showed that hNET had an alanine 
residue at that position (Ala145), conserved with hSERT, suggesting that the residue cannot be 
responsible for the observed selectivity.  
 
 
Docking studies were conducted to determine whether another residue in the region of 
the 4-substituent, which was not conserved between hDAT and hSERT, could explain the 
selectivity between the MATs. All residues that were conserved between hDAT and hNET, but 
non-conserved between hDAT and hSERT (highlighted in green in Table 13), were visualized 
after docking the series of 4-substituted MCAT analogs compounds at all three MAT models and 
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identifying common binding modes. All non-conserved residues were sterically more bulky in 
hSERT than in hDAT and hNET, ruling them out, with one exception: an alanine residue (Ala81 
and Ala77 in hDAT and hNET, respectively) is a glycine residue in hSERT (Gly100). On the 
basis of these docking studies, these non-conserved residues appeared to be too far from the 
ligand to account for the discrepancy. In Figure 40, they are the top-most residue in the image of 
each MAT, showing its distance from the MCAT 4-substituent. On the basis of these docking 
studies, it seems unlikely that a non-conserved residue in the binding pocket can explain the 
selectivity of 4-substituted MCATs between hDAT and hSERT.  
 
Table 13. Alignment of binding site residues between hDAT, hNET, and hSERT. Conserved 
alanine residue between hNET and hSERT highlighted in red. All those residues that are not 
conserved between hNET and hSERT are highlighted in green. 
hDAT F76 A77 V78 D79 L80 A81 N82 I148 S149 L150 V152  
hNET F72 A73 V74 D76 L76 A77 N78 I144 A145 L146 V148  
hSERT Y95 A96 V97 D98 L99 G100 N101 I168 A169 F170 I172  
hDAT G153 F155 Y156 N157 C319 F320 S321 L322 G323 F326 V328 S422 A423 
hNET G149 Y151 Y152 N153 F316 F317 S318 L319 G320 F323 V325 S419 S420 
hSERT A173 Y175 Y176 N177 F334 F335 S336 L337 G338 F341 V343 S438 T439 
 
 
113 
 
 
 
Figure 40. Side-by-side comparison of the docked 4-substituted MCATs at hDAT, hNET, and 
hSERT, with the alignment of their binding-site residues displayed below. In the hNET model, 
magenta and blue have been used to indicate residues conserved with hDAT and hSERT, 
respectively. The only residues that were conserved between hDAT and hNET (A81 and A77, 
respectively), but smaller in hSERT (G100) are circled in white. 
Alternative means of evaluating the differences in the hDAT/hNET/hSERT binding 
pockets were considered. The volume of the binding pockets were calculated using Sybyl-X 2.1. 
the hSERT binding pocket was calculated to be substantially smaller (94 Å3) than the hDAT and 
hNET binding pockets, which were equal in size to one another (157 Å3) These values were in 
keeping with observations gleaned from the alignment of the binding site residues, which were 
mostly sterically larger in hSERT, but counterintuitive to the QSAR determined for the 4-MCAT 
series, in which a larger size molecule was favored at hSERT. Steric hindrance seemed unlikely 
to be the determining factor, and so it was hypothesized that the larger size of substituent might 
instead allow greater opportunity for hydrophobic interactions. 
 
 
114 
There was one exception to the conclusion that the alanine/serine non-conserved residue 
does not control selectivity. In the case of 4-methoxy-MCAT, unlike all the other compounds, 
the potencies at hNET and hSERT were similar, and dissimilar from hDAT (EC50 = 111 nM, 120 
nM, and 506 nM, respectively). This is also the only long substituent of the series, and length 
was notably not found as a correlate of DAT/SERT selectivity. It is possible that the 
alanine/serine non-conserved residue controls selectivity in the case of long substituents, as 
shown in Figure 41. 
 
 
Figure 41. Docked poses of 4-methoxyMCAT at hDAT, hNET, and hSERT. Highlighted is a 
residue conserved between hNET and hSERT, but not hDAT. Image generated in Sybyl-X 2.1. 
 
To further investigate and quantify hydrophobic interactions for substrates at MATs, 
Hydrophatic INTeraction (HINT) studies were conducted.207 Previous HINT studies had been 
conducted using the docked 4-MCATs at hSERT and hDAT. Here, HINT studies were 
conducted for the docked 4-MCATs at hNET, and compared to those from earlier investigations. 
The previous investigations had focused exclusively on the HINT scores for interactions with the 
4-position substituent, so these were calculated for hNET as well (Table 14). 
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Table 14. HINT Scores for 4-MCATs at MATs. 
 HINT Score 
Agent hDAT hNET hSERT 
MCAT    0       0     0 
4-Fluoro-MCAT 22     15   51 
4-MeO-MCAT -88 -136 125 
4-Methyl-MCAT -23 -7 136 
4-Cl-MCAT     2 -22 135 
4-Br-MCAT -13 -31   78 
4-CF3-MCAT   -5 16   97 
  
Pearson correlational analysis was conducted between potency and HINT score for each 
MAT to test whether relationships existed between the potencies at individual transporters and 
polar or nonpolar interactions. Supporting the hypothesis that larger substituents provide 
opportunity for more favorable interactions at hSERT, significant correlations were found for 
polar contributions and hydrophobic contributions to hSERT potency, but not for either of the 
other transporters (Table 15). 
 
Table 15. Pearson correlation between HINT scores and potency at individual transporters. 
 Pearson Correlation:  
HINT and LogEC50 
 hDAT hNET hSERT 
Total R = 0.044 R = 0.033 R = -0.864 
 P = 0.93 P = 0.94 P = 0.01 
Polar contribution R = 0.103 R = -0.036 R = 0.841 
 P = 0.84 P = 0.94 P = 0.02 
Hydrophobic contribution R = 0.057 R = 0.078 R = -0.910 
 P = 0.90 P = 0.87 P < 0.01 
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V. Conclusions 
These studies represent progress towards constructing comprehensive SAR for synthetic 
cathinones and related agents, with particular attention to the α-carbon atom. They represent the 
first studies of the MCAT isomers at MATs, and the first systematic SAR study of aryl 
substitution of α-pyrrolidinophenones. Additionally, synthetic strategies were developed and 
synthetic targets prepared to be used in further SAR studies, as well as drug development in the 
case of therapeutic ATS. Finally, a population of hNET models were produced, facilitating 
insights to substrate selectivity at MATs and completing the MAT docking picture.  
In the first known studies to evaluate MCAT isomers at MATs, we find only a small (1.3-
fold) difference in the potency between S(-)5, R(+)5, and (±)5 is less than 1.3-fold at hDAT. 
However, considerable differences were found for the isomers at hSERT, suggesting hSERT is 
less tolerant of R-isomers for synthetic cathinone substrates, as greater hDAT selectivity has also 
been observed for R-mephedrone in other studies.152 In future studies, it might be of interest to 
test whether R-isomers of synthetic cathinone substrates are reliably more selective for hDAT 
over hSERT by evaluating a series of 4-substituted MCATs. The MCAT isomers, racemate, and 
achiral analogs 26 and 27 are at the time of writing being evaluated in ICSS to determine their 
abuse-related effects. As hDAT/hSERT selectivity predicts abuse potential, the R isomer may 
show greater abuse-related effects in the ICSS study. Though the compounds are all more 
selective for hDAT by greater than 20-fold, the R(+)5 is completely hDAT selective, even when 
testing it at hSERT at concentrations over 3-fold higher than the EC50 of S(-)5. This, without 
paying much of a penalty in potency at hDAT. The gem-dimethyl analog is the least selective for 
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hDAT, suggesting diminished abuse potential. It is also slightly less potent at hDAT. The gem-
dimethyl modification should be more thoroughly investigated for therapeutic applications, as a 
moderate potency at hDAT and a diminished abuse potential could be clinically useful. 
Though the chiral center seems preferred, the study goal to remove it was realized in both 
achiral MCAT analogs. Both were active as substrates, suggesting that either achiral 
modification might be a viable pathway for future studies and drug development. Indeed, these 
scaffolds are found among phenylalkylamines available for clinical use (i.e., phentermine, 
phenylephrine, Figure 42), though they have not been observed in clinically used cathinones. The 
chiral center is preferable, but the gem-dimethyl compound was less potent by only 2-fold, 
suggesting the penalty is minor for this modification.  
Future SAR studies at the β-carbon atom might be able to utilize either achiral 
modification to the α-carbon atom to facilitate the investigation. The gem-dimethyl scaffold 
might be a superior choice, as it is only two-fold less potent than the racemate, and isomers, as 
opposed to the des-methyl modification, which is 10-fold less potent. Further studies are needed 
to fully validate this design concept. Parallel SAR studies utilizing the gem-dimethyl 
modification might be of interest. 
HO
HO
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Figure 42. Clinically available achiral phenylalkylamines phentermine (73) and phenylephrine 
(74), alongside structurally similar achiral MCAT analogs from these studies 26 and 27. 
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The use of K2CO3/MeOH in the introduction of the amine via bromine substitution was 
found to be necessary for the gem-dimethyl product. This step theoretically allows the 
substitution to proceed via an epoxide intermediate that prevents the formation of the Michael 
addition product observed in the course of these studies. A mechanism was proposed herein for 
the Michael product.  Forgoing this step might result in Michael addition products for other 
target compounds, resulting in synthetic difficulties and inefficiency of SAR investigations. 
Literature support exists for the utility of these reagents to produce amines through an epoxide 
intermediate. Stevens and Chang208 first wrote about the utility of “epoxy ethers” in the 
formation of “alpha-amino ketones” (i.e., cathinones) in 1962. De Kimpe et al.209 proposed a 
mechanism for the epoxide intermediate in the synthesis of similar compounds in 1983. Further 
synthetic studies might compare the routes with and without K2CO3/MeOH for other target gem-
dimethyl cathinones, to further establish the necessity of these reagents and the relationship to 
the gem-dimethyl chemical environment. 
 These studies demonstrate that there are multiple viable routes to alpha-
pyrrrolidinophenone analogs. The one-pot method described by Guha et al.195 was a particularly 
useful method, as it utilized less toxic, more environmentally friendly reagents, simplified 
several steps into one and, unlike the Friedel-Craft’s-based approach, allows for access to 
analogs with a wide variety of para-substituents, including strongly electron-withdrawing groups 
(e.g. 4-CF3). 
These SAR studies were enriched by the addition of molecular modeling, in which a 
population of hNET models were produced. The inclusion of these models allowed for insight 
into the nature of substrate discrimination at the MATs. On the basis of endogenous substrate 
docking, it was concluded that substrate selectivity between hNET and hDAT is unlikely to 
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occur in the predicted hNET binding pocket. This pocket is non-discriminatory between DA and 
NE, in keeping with biological data. On the other hand, hDAT is more selective, transporting its 
endogenous substrate DA at a significantly higher rate, and binding DA with greater 
selectivity.206 Further studies might benefit from docking the endogenous substrates NE and DA 
at hDAT and comparing the binding modes to those obtained here at hNET.  
A population of hNET models was included for the first time in the examination of 
synthetic cathinone interactions with MATs. This allowed for an update to a previously 
published model of the structural basis for hDAT/hSERT selectivity among synthetic cathinone 
substrates. An alanine residue, which was proposed to be responsible for hDAT/hSERT 
selectivity in a series of aryl-substituted MCAT analogs,69 was in fact conserved between hSERT 
and hNET, despite the high correlation between hDAT and hNET substrate activity.181 On the 
basis of these studies, it was concluded that the previous explanation could no longer be accepted 
as the primary deciding factor in hDAT/hSERT selectivity. As no other non-conserved residues 
between hDAT and hSERT in the region of the varied substituent could be identified, it can be 
concluded that other aspects of substrate transport are more important to substrate selectivity. 
Such features are important to understand, as the hDAT/hSERT ratio is clearly important to 
abuse potential.68,152 Future studies might include blind docking to the MAT models used in 
these studies, or docking to potential allosteric sites. 
There was one caveat to the dismissal of the alanine/serine residue model for explaining 
substrate selectivity. In the 4-substituted MCAT series, one compound (4-methoxy-MCAT) was 
similar in potency between hNET and hSERT, and not hDAT. For all the other compounds 
tested, the hNET and hDAT values were very similar (Table 8). Methoxy was the only long 
substituent tested, and this could be more important when it comes to steric hindrance with the 
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hDAT serine residue. Further studies might investigate other 2-atom-length substituents or 
longer at this position, testing the hypothesis that one could develop a substrate selective for 
hNET and hSERT over hDAT. Such compounds would be predicted to be of reduced abuse 
potential, and potentially high in therapeutic potential. 
 In future studies, the 4-ethyl-MCAT might be a valuable target compound, as it would be 
isosteric to the 4-methoxy-MCAT, but without the hydrogen-bonding potential of the oxygen 
atom. If a similar correlation between hSERT and hNET was found for this compound, it would 
support the hypothesis that length at this position can bias the compounds in favor of hSERT. 
This would be valuable information for discriminating between compounds of high abuse and 
therapeutic potential in future drug development efforts. The 4-ethyl-MCAT compound would 
also be valuable to test in order to further test the parallel SAR concept that is tenuously 
proposed based on these investigations of α-pyrrolidinophenones.  
Overall, there are many long-term translational applications to this project, particularly in 
informing development of agents for the treatment of StUD and other mental health disorders. In 
terms of regulatory issues, the applications are more direct. Over the past century, the prohibition 
of psychoactive and addictive substances has driven the development of more potent compounds 
on the basis of the iron law (i.e., it is more efficient to illicitly transport pure ethanol or 
“moonshine” than diluted formulations like beer, so that is what was manufactured during 
alcohol prohibition). Over the past decade, with the emergence of internet drug markets and the 
development of clandestine chemistry infrastructure in India, China, and Mexico, the problem of 
high-potency NPS has accelerated, and the “khat and mouse game” between clandestine 
chemists and regulators got out of control. The synthetic cathinones are a case in point, as the 
scheduling of the original “bath salts” constituents directly led to the development and marketing 
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of novel pyrrolidinophenone analogs, such as α-PHP, that were dramatically increased in 
potency and hDAT-selectivity.  
The natural next step for regulatory authorities is to schedule α-PHP, along with other 
emerging synthetic cathinones. Our studies suggest that this effort would be futile and counter-
productive. The chemical space of synthetic cathinones is wide open with compounds that are 
potent hDAT releasers or blockers, including the achiral MCAT analogs and the aryl-substituted 
PHPs of these investigations. It is entirely possible that an even more dangerous synthetic 
cathinone is around the corner from the next scheduling motion. 
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VI. Experimentals 
A. Synthesis 
 Compound identity was determined by proton nuclear magnetic resonance spectrometry 
([1H]NMR),  infrared (IR) spectroscopy, melting point (mp), and mass spectrometry (MS). Purity 
was determined by carbon, hydrogen, and nitrogen elemental analysis (CHN), which was 
conducted by Atlantic Microlab Inc. (Norcross, GA). The compounds were considered pure if 
the experimental values were within 0.4% of those calculated on the basis of theory. Melting 
points were obtained using a Thomas-Hoover melting point apparatus and are uncorrected. 
[1H]NMR spectra were obtained using a Bruker ARX 400 MHz spectrometer with 
tetramethylsilane as an internal standard. IR was conducted on a Thermo Nicolet instrument. 
Where flash chromatography was used, this was performed on a CombiFlash Companion/TS 
(Telodyne Isco Inc., Lincoln, NE) with RediSep Rf normal-phase silica flash columns as 
stationary phases, and silica gel (230-400 mesh) as adsorbent. Reaction monitoring was 
accomplished by thin-layer chromatography with silica gel plates (250 µ, 2.5 × 10 cm; Analtech 
Inc., Newark, DE). MS was obtained using electrospray ionization in positive ion mode. Optical 
rotation, where necessary, was obtained using a Jasco P-2000 polarimeter with a sodium lamp. 
Water-soluble salts of final target compounds were prepared (hydrochloride or oxalate) for the 
purposes of biological studies.  
 
α-Methylaminoisobutyrophenone Hydrochloride (26) 
Compound 26 is known,210 but was synthesized according to a patent procedure for a similar 
compound.193 In a sealed tube at room temperature, 40 (3.00 g, 13.2 mmol) was added to a 
stirred solution of potassium carbonate (5.53 g, 39.6 mmol) in MeOH (75 mL).  The reaction 
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mixture was allowed to stir for 5 h, at which time methylamine gas was bubbled in.  The 
temperature was increased to 57 °C, and the mixture stirred overnight.  Upon cooling to room 
temperature, Et2O (50 mL) was added to dilute the mixture, which was then filtered.  Solvent 
was evaporated under reduced pressure, and the resulting crude mixture was dissolved in EtOAc, 
then acidified and extracted with HCl (1 M, 5 mL, 6x).  The aqueous portion was basified with 
NaOH (1 M, 50 mL), and extracted with EtOAc (30 mL).  The combined organic portion was 
dried (Na2SO4), and solvent was removed under reduced pressure, to yield 1.40 g of the free base 
as a yellow oil. 
 
The free base was dissolved in EtOAc (30 mL), a saturated solution of gaseous HCl in Et2O (10 
mL) was added, and the reaction mixture was allowed to stir at room temperature for 2 h.  The 
solvent was removed by filtration to yield a white powder that was recrystallized from 
EtOH/Et2O to yield 0.60 g (21%) of 26 as a white solid: mp 218-220 °C (lit.210 mp 212-214 °C); 
1H NMR (DMSO-d6) δ 1.75 (s, 6H, 2 x CH3), 2.53 (s, 3H, CH3), 7.57 (dd, J = 7.6, 7.9 Hz, 2H, 
ArH), 7.70 (t, J = 7.4, 1H, ArH), 7.95 (dd, J = 8.5, 1.2, 1H, ArH), 9.49 (br s, 2H, NH2+). 
 
2-Methylamino-1-phenylethan-1-one Hydrochloride (27) 
Compound 27 was prepared in a three-step reaction sequence in which the intermediates were 
used directly without further purification, as described by Sakloth, but their transformations are 
described here individually (47, 48). Compound 27 is known in the literature,72 but synthesis by 
this method was reported to result in low yields by Sakloth, so the compound was made by a 
literature procedure for similar compounds.211 AlCl3 (9.20 g, 69 mmol) was added in a 
portionwise manner to a stirred solution of 48 (61 mmol) in anhydrous benzene (40 mL) under 
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an N2 atmosphere.  The stirred reaction mixture was heated at reflux for 4 h, allowed to cool to 
room temperature, quenched by addition of conc. HCl (12 mL) and ice (10 g). The organic layer 
was separated, washed with saturated NaHCO3 (3 x 15 mL) and brine (2 x 10 mL), dried 
(Na2SO4), and evaporated under reduced pressure. The resulting brown oil was then dissolved in 
conc. HCl (50 mL) and i-PrOH (75 mL) and stirred at 40 °C for 48 h. The solvent was 
evaporated to yield 0.50 g of residue, which was recrystallized twice from i-PrOH to yield 0.56 g 
of 27 (5%) as off-white crystals: mp 205-208 °C (lit.72 mp 219 °C). Though the observed mp is 
lower than the reported lit. mp, it was exactly consistent with the mp obtained by Sakloth 
(unpublished data). 1H NMR (DMSO-d6) δ 2.63 (s, 3H, CH3), 4.77 (s, 2H, CH2), 7.60 (t, J = 7.7 
Hz, 2H, ArH), 7.74 (t, J = 7.8 Hz, 1H, ArH), 8.00 (d, J = 7.4 Hz, 2H, ArH), 9.48 (br s, 2H, NH+). 
 
α-gem-Dimethyl-α-pyrrolidinopropiophenone Hydrochloride (28) 
The compound is known in the patent literature without physical data, and was synthesized 
according to its literature procedure.193 In a 2-neck flask under nitrogen, 40 (0.57 g, 2.5 mmol) 
was added to a stirred solution of potassium carbonate (1.00 g, 7.2 mmol) in MeOH (5.0 mL).  
After three hours of stirring at room temperature, pyrrolidine (0.53 g, 7.5 mmol) was added, and 
the mixture was stirred at reflux overnight (14 h).  Upon cooling the reaction mixture to room 
temperature, EtOAc (75 mL) was added to dilute the mixture, which was then filtered.  Solvent 
was removed from the filtrate under reduced pressure, and the resulting crude mixture was 
dissolved in EtOAc (75 mL) and washed with H2O (20 mL).  The mixture was acidified and 
extracted with HCl (1 N, 2 mL, 3x), the resulting aqueous portion of which was basified with 
NaOH (3 M, 2 mL) and extracted with EtOAc (10 mL).  The organic portion was dried (Na2SO4) 
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and solvent was removed under reduced pressure, resulting in a yellow liquid (0.10 g), which 
solidified upon cooling.  
 
The free base was dissolved in Et2O (30 mL), a saturated solution of gaseous HCl in Et2O (5 mL) 
was added, and the reaction mixture was allowed to stir at room temperature for 2 h.  The solvent 
was removed by filtration to yield a white powder that recrystallized from EtOH/Et2O to afford 
0.08 g (13%) of 28 as a white solid: mp 134-137 °C (EtOH/Et2O); 1H NMR (DMSO-d6) δ 1.80 (s, 
6H, 2 x CH3), 1.92-2.00 (m, 4H, 2 x CH2),  3.17-3.40 (m, 4H, 2 x CH2), 7.36 (m, 2H, ArH), 
6.67-7.77 (m, 1H, ArH), 7.92 (d, J = 7.4, 2H, ArH), 11.0 (br s, 1H, NH+); Anal. Calcd. For 
(C14H19NO•HCl•0.2H2O) C, 65.33; H, 7.99; N, 5.44.  Found: C, 65.29; H, 7.71; N, 5.36. 
 
α-Pyrrolidinohexanophenone Oxalate (29) 
The compound is known,25 and was synthesized according to the literature procedure. Compound 
50 (11.3 g, 44 mmol) was stirred in pyrrolidine (6.0 mL) overnight (24 h).  Et2O (50 mL) was 
added to dilute the mixture, followed by acidification and extraction with HCl (3 N, 20 mL, 3x). 
The combined aqueous portion of was basified with NaHCO3 (200 mL) and extracted with Et2O 
(3 x 15 mL).  The combined organic portion was washed with brine, dried (Na2SO4), and solvent 
was removed under reduced pressure, resulting in a brown liquid (4.48 g), which was dissolved 
in Et2O and added dropwise to a saturated solution of oxalic acid (1.8 g) in Et2O (129 mL). The 
mixture was allowed to stir at room temperature overnight.  The solvent was removed by 
filtration to yield a white powder that recrystallized from i-PrOH to afford 4.37 g (29%) of 29 as 
a white solid: mp 128-130 °C (i-PrOH; lit.25 mp 129-131 °C);  1H NMR (DMSO-d6) δ 0.76 (t, J 
= 7.1, 3H, CH3), 0.98-1.08 (m, 4H, 2 x CH2), 1.89-1.96 (m, 6H, 3 x CH2), 2.07-2.09 (m, 4H, 2 x 
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CH2), 3.15 (br s, 1H, OH), 4.8-5.0 (m, 1H, CH), 7.56-7.63 (m, 2H, ArH), 7.75 (t, J = 7.4, 1H, 
ArH), 8.06-8.08 (m, 2H, ArH). 
 
4-Methyl-α-pyrrolidinohexanophenone Hydrochloride (30)  
The compound is known in a patent with no physical data,212 but was synthesized according to a 
different procedure for similar compounds.195 Under open atmosphere and constant stirring, N-
bromosuccinimide (1.21 g, 6.8 mmol) was added directly to 65 (1.01 g, 5.26 mmol) at room 
temperature.  The mixture turned yellow, then orange, and released a burst of brown gas over the 
course of 2 min, at which time 1,4-dioxane (4 mL) was added.  After 10 min of stirring, 
pyrrolidine (1.3 mL, 1.12 g, 16 mmol) was added dropwise to the mixture, which became cloudy 
and colorless, then returned to clear yellow.  The mixture was allowed to stir, loosely covered, at 
room temperature for 36 h.  The mixture was washed with NaHCO3 (20 mL), then acidified with 
HCl (1N, 50 mL, to pH 1).  The aqueous portion was separated, basified with NaOH (3M, 50 mL, 
to pH 13), and extracted with EtOAc (3 x 20 mL).  The combined organic portion was dried 
(Na2SO4) and evaporated under reduced pressure, resulting in a yellow-colored oil.   
 
The yellow oil was dissolved in anhydrous Et2O (5 mL) at room temperature.  Under constant 
stirring, a saturated solution of gaseous HCl in Et2O (10 mL) was added) and the reaction 
mixture was allowed to stir at room temperature overnight. The solvent was evaporated to yield a 
brown solid that was recrystallized from acetonitrile to yield 0.23 g (15%) of 30 as a beige solid: 
mp 179-182 ºC (acetonitrile); 1H NMR (DMSO-d6) δ 0.77 (t, J = 7.1 Hz, 3H, CH3), 0.99-1.29 (m, 
4H, 2 x CH2), 1.94-2.09 (m, 6H, 3 x CH2), 2.45 (s, 3H, CH3), 3.05-3.07 (m, 1H, CH2), 3.20-3.29 
(m, 1H, CH2), 3.49-3.51 (m, 1H, CH2), 3.63-3.64 (m, 1H, CH2), 5.47-5.50 (m, 1H, CH), 7.47 (d, 
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J = 8.1 Hz, 2H, ArH), 8.02 (d, J = 8.3 Hz, 2H, ArH), 10.47 (br s, 1H, NH+); Anal. Calcd for 
(C17H25NO•1.0 HCl•0.6 H2O) C, 66.58; H, 8.94; N, 4.57.  Found: C, 66.56; H, 8.83; N, 4.47; 
HRMS-ESI+ (m/z) calcd for C17H26NO+ (M+H+) 260.2014, found 260.2017, calcd for 
C17H25NONa+ (M+Na+) 282.1834, found 282.1831. 
 
4-Methoxy-a-pyrrolidinohexanophenone Hydrochloride (31) 
The compound is previously unknown. It was prepared according to a general procedure for 
substitution of a halogen by an amine. Compound 62 (460 mg, 1.8 mmol) was stirred in in 
pyrrolidine (2.0 mL, 24.0 mmol) for 1 h at room temperature. The stirred reaction mixture was 
quenched by careful addition of ice-cold H2O (10 mL), acidified with HCl (6 N, 3 x 5 mL, to pH 
1), and extracted with EtOAc (3 x 10 mL). The combined acidic portion was basified with NaOH 
(3 M, 3 x 5 mL, to pH 13), and re-extracted with Et2O (3 x 15 mL). The combined organic 
portion was washed with brine (15 mL), dried (Na2SO4), and evaporated under reduced pressure. 
The crude free base was dissolved in anhydrous Et2O (2 mL), to which saturated ethereal HCl 
solution was added dropwise at -78 °C (dry ice/acetone) under constant stirring. The mixture was 
allowed to stir at room temperature for 24 h, after which the solvent was evaporated to yield a 
white solid that was recrystallized from acetonitrile to yield 97 mg (19%) of 31 as white needles: 
mp 195-198 °C; 1H NMR (DMSO-d6) δ 0.76 (t, J = 7.1 Hz, 3H, CH3), 1.01-1.26 (m, 4H, 2 x 
CH2), 1.93-2.09 (m, 6H, 3 x CH2), 3.00-3.01 (m, 1H, CH2), 3.17-3.25 (m, 1H, CH2), 3.36-3.48 
(m, 1H, CH2), 3.60-3.61 (m, 1H, CH2), 3.90 (s, 3H, CH3), 5.43-5.51 (m, 1H, CH), 7.16 (d, J = 
8.8 Hz, 2H, ArH), 8.08 (d, J = 8.9 Hz, 2H, ArH), 10.28 (br s, 1H, NH+); Anal. Calcd for 
(C17H25NO2·HCl) C, 65.48; H, 8.40; N, 4.49.  Found: C, 65.76; H, 8.54; N, 4.46. 
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4-Ethyl-a-pyrrolidinohexanophenone Hydrochloride (32) 
The compound is previously unknown. It was prepared according to a general procedure for 
substitution of a halogen by an amine. Compound 63 (520 mg, 1.8 mmol) was stirred in 
pyrrolidine (2.0 mL, 24.0 mmol) for 1 h at room temperature. The stirred reaction mixture was 
quenched by careful addition of ice-cold H2O (10 mL), acidified with HCl (1 N, 3 x 15 mL, to 
pH 1), and extracted with Et2O (3 x 5 mL). The combined acidic portion was basified with 
NaOH (3 M, to pH 13), and re-extracted with Et2O (3 x 15 mL). The combined organic portion 
was washed with brine (15 mL), dried (Na2SO4), and evaporated under reduced pressure. The 
crude free base was dissolved in anhydrous Et2O (2 mL), to which saturated ethereal HCl 
solution was added dropwise at -78 °C (dry ice/acetone) under constant stirring. The mixture was 
allowed to stir at room temperature for 24 h, solids were collected by filtration and recrystallized 
from acetonitrile to yield 152 mg (27%) of 32 as yellow crystals: mp 182-184 °C; 1H NMR 
(DMSO-d6) δ 0.75 (t, J = 7.0 Hz, 3H, CH3), 0.92-1.27 (m, 7H, 2 x CH2, CH3), 1.87-2.09 (m, 6H, 
3 x CH2), 2.73 (q, J = 7.6 Hz, 2H, CH2), 2.97-3.10 (m, 1H, CH2), 3.21-3.28 (m, 1H, CH2), 3.45-
3.49 (m, 1H, CH2), 3.60-3.61 (m, 1H, CH2), 5.42-5.47 (m, 1H, CH), 7.49 (d, J = 8.2 Hz, 2H, 
ArH), 8.01 (d, J = 8.3 Hz, 2H, ArH), 10.24 (br s, 1H, NH+); Anal. Calcd for (C18H27NO·HCl) C, 
69.77; H, 9.11; N, 4.52. Found: C, 69.81; H, 9.21; N, 4.57. 
 
4-Chloro-α-pyrrolidinohexanophenone Hydrochloride (33)  
The compound is unknown, and was synthesized according to a procedure for similar 
compounds.195 Under open atmosphere and constant stirring, N-bromosuccinimide (5.49 g, 31 
mmol) was added directly to 66 (5.08 g, 24 mmol) at room temperature.  The temperature was 
increased to 30 ºC, and the mixture was stirred for 1 h. Upon the release of brown gas, 1,4-
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dioxane (10 mL) was added. The mixture turned clear yellow after 10 min of stirring at room 
temperature, and pyrrolidine (5.90 mL, 5.09 g, 72 mmol) was added dropwise. The mixture was 
allowed to stir, loosely covered, at room temperature overnight.  The mixture was washed with 
NaHCO3 (20 mL) and extracted with EtOAc (3 x 20 mL). To the organic portion was added HCl 
(3N, 15 mL, to pH 1), and the aqueous portion was separated, basified with NaHCO3 (3M, 50 
mL, to pH 13), and extracted with EtOAc (3 x 20 mL).  The combined organic portion was dried 
(Na2SO4) and evaporated under reduced pressure, resulting in 3.5 g of a crude brown oil.    
 
The residual oil was dissolved in anhydrous Et2O (5 mL) at room temperature.  Under constant 
stirring, a saturated solution of gaseous HCl in Et2O (10 mL) was added and the reaction mixture 
was allowed to stir at room temperature overnight. The precipitate was filtered to yield a brown 
solid that was recrystallized from i-PrOH/Et2O resulting in 0.15 g (2%) of 33 as an off-white 
powder: mp 198-200 ºC; 1H NMR (DMSO-d6) δ 0.74 (t, J = 7.2 Hz, 3H, CH3), 0.89-1.27 (m, 4H, 
2 x CH2), 1.93-2.05 (m, 6H, 3 x CH2), 3.07-3.29 (m, 2H, CH2), 3.41-3.61 (m, 2H, CH2), 5.54-
5.55 (m, 1H, CH), 7.72 (d, J = 8.6 Hz, 2H, ArH), 8.10 (d, J = 8.6 Hz, 2H, ArH), 10.59 (br s, 1H, 
NH+); Anal. Calcd for (C16H22ClNO•HCl) C, 60.76; H, 7.33; N, 4.43. Found: C, 60.66; H, 7.21; 
N, 4.53. 
 
4-Bromo-a-pyrrolidinohexanophenone Hydrochloride (34) 
The compound is previously unknown. It was prepared according to a general procedure for 
substitution of a halogen by an amine. Compound 64 (860 mg, 2.6 mmol) was stirred in 
pyrrolidine (3.0 mL, 36.0 mmol) for 30 min at room temperature. The stirred reaction mixture 
was quenched by careful addition of ice-cold H2O (10 mL), acidified with HCl (2 N, to pH 1), 
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and extracted with Et2O (3 x 10 mL). The combined acidic portion was basified with NaOH 
(15%, 20 mL, to pH 13), and re-extracted with Et2O (3 x 20 mL). The combined organic portion 
was washed with brine (15 mL), dried (Na2SO4), and evaporated under reduced pressure. The 
residual oil was purified by flash chromatography (silica gel; hexanes/EtOAc; 95/5 to 80/20) to 
afford the free base as a yellow oil. The free base was dissolved in anhydrous Et2O (2 mL) under 
N2 atmosphere, and HCl gas was bubbled in. The precipitate was recrystallized from acetonitrile 
to yield 152 mg (27%) of 34 as an off-white powder: mp 199-201 °C; 1H NMR (DMSO-d6) δ 
0.75 (t, J = 6.7 Hz, 3H, CH3), 1.19 (m, 1H, CH2), 1.78-1.94 (m, 3H, 2 x CH2), 1.78-2.05 (m, 6H, 
3 x CH2), 2.99-3.07 (m, 1H, CH2), 3.21 (m, 1H, CH2), 3.49 (m, 1H, CH2), 3.61 (m, 1H, CH2), 
5.39-5.58 (m, 1H, CH), 7.88 (d, J = 7.6 Hz, 2H, ArH), 8.01 (d, J = 8.5 Hz, 2H, ArH), 10.38 (br s, 
1H, NH+); Anal. Calcd for (C16H22BrNO·HCl·0.4 H2O) C, 52.23; H, 6.52; N, 3.81.  Found: C, 
52.01; H, 6.30; N, 3.96. 
 
4-Trifluoromethyl-α-pyrrolidinohexanophenone Hydrochloride (35)  
The compound is unknown, and was synthesized according to a procedure for similar 
compounds.195 Under open atmosphere and constant stirring, N-bromosuccinimide (2.08 g, 11.7 
mmol) was added directly to 67 (2.21g, 9.0 mmol) at room temperature.  The temperature was 
increased to 30 ºC, and the mixture was stirred for 40 min. Upon the release of  brown gas, 1,4-
dioxane (10 mL) was added. After stirring the reaction mixture for 10 min, pyrrolidine (2.21 mL, 
1.92 g, 26.9 mmol) was added to the mixture, dropwise. The mixture was allowed to stir, loosely 
covered, at room temperature overnight.  The mixture was quenched carefully with NaHCO3 (20 
mL) at 0 ºC and extracted with Et2O (3 x 20 mL). To the organic portion was added HCl (3N, 15 
mL, to pH 1), and the aqueous portion was separated, basified with NaHCO3 (3M, 50 mL, to pH 
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13), and extracted with Et2O (3 x 20 mL).  The combined organic portion was dried (Na2SO4) 
and evaporated under reduced pressure. The resulting crude oil was dissolved in anhydrous Et2O 
(5 mL) at room temperature.  Under constant stirring, gaseous HCl was bubbled in and the 
reaction mixture was allowed to stir at room temperature overnight. The precipitate was filtered 
to yield a brown solid that was recrystallized from EtOH/Et2O resulting in 0.17 g (5%) of 35 as a 
white powder: mp 219-222 ºC; 1H NMR (DMSO-d6) δ 0.74 (t, J = 7.2 Hz, 3H, CH3), 0.99-1.25 
(m, 4H, 2 x CH2), 1.96-2.07 (m, 6H, 3 x CH2), 3.13-3.26 (m, 2H, CH2), 3.52-3.62 (m, 2H, CH2), 
5.61 (m, 1H, CH), 8.03 (d, J = 8.1 Hz, 2H, ArH), 8.28 (d, J = 8.2 Hz, 2H, ArH), 10.59 (br s, 1H, 
NH+); Anal. Calcd for (C17H22F3NO•HCl) C, 58.37; H, 6.63; N, 4.00. Found: C, 58.18; H, 6.45; 
N, 3.99. 
 
α-Ethyl-4-methylmethamphetamine Hydrochloride (36) 
The compound is known,213 but was synthesized by two different methods for comparison. The 
first (Method A) was a procedure for a similar compound, as this procedure had been used 
successfully by others in the lab.196 The second (Method B) followed a literature procedure for 
similar compounds.197  
 
Method A 
Methylamine (21.5 mL, 40% in H2O, 248 mmol) was diluted with MeOH (34 mL) and adjusted 
to pH 6 with HOAc (15 mL) at 0 °C. Compound 53 (0.44 g, 2.7 mmol) was added to the stirred 
solution along with additional MeOH (20 mL), and followed by NaB(CN)H3 (0.53 g, 8.5 mmol).  
The ice bath was removed and gas evolution was observed.  The contents were allowed to stir at 
room temperature for 40 min, then were quenched by the careful addition of NaOH (3M, 5 mL), 
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extracted with EtOAc (10 mL), and dried (Na2SO4).  Solvent was removed under reduced 
pressure, and the resulting gummy solid was dissolved in EtOH (5 mL). A saturated hydrochloric 
acid solution in anhydrous Et2O (5 mL) was added and the mixture was allowed to warm to room 
temperature and stirred overnight. The precipitate was collected by filtration to yield a white-
colored solid which upon recrystallization from EtOH/Et2O afforded 0.030 g (5%) of 36 as a 
white solid: mp 159-160 °C (lit.213 mp 159°C); IR (solid, cm-1) 1447, 2463, 2709, 2745, 3187; 1H 
NMR (DMSO-d6) δ 0.89 (t, J = 7.5 Hz, 3H, CH3), 1.46-1.63 (m, 2H, CH2), 2.29 (s, 3H, CH3), 
2.54 (s, 3H, CH3), 2.74 (dd, J = 9.3, 13.7 Hz, 1H, CH2), 3.07 (dd, J = 4.7, 13.7 Hz, 1H, CH2), 
7.13-7.22 (m, 4H, ArH), 8.99 (br s, 2H, NH2+). 
 
Method B 
Methylamine (16 mL, 33% in EtOH, 130 mmol), 53 (0.23 g, 1.4 mmol) and platinum (II) oxide 
(5.0 mg, 0.020 mmol) in EtOH (25 mL) were shaken with hydrogen gas (>50 psi) at room 
temperature.  The reaction never went to completion, but was stopped after 72 hours and filtered 
to remove the catalyst.  The mixture was evaporated to dryness under reduced pressure, resulting 
in a yellow mixture of oil and solid, which was diluted with Et2O (10 mL) and filtered.  The 
mixture was acidified with HCl (1N, to pH 1) and extracted with deionized water (35 mL). The 
aqueous portion was basified with NaOH (3M, to pH 13), and extracted with Et2O (10 mL). The 
combined organic portion was dried (Na2SO4), and solvent was removed under reduced pressure 
to yield 160 mg of yellow oil.  A saturated HCl solution in anhydrous EtOAc (3 mL) was added, 
and the mixture was stirred at room temperature for 30 hours.  The precipitate was collected by 
filtration to yield a white solid which, upon recrystallization from EtOH, afforded 23 mg (8%) of 
36 as a white solid: mp 158-159 °C (lit.213 mp 159°C); IR (solid, cm-1) 2463; 1H NMR (DMSO-
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d6) δ 0.89 (t, J = 7.5 Hz, 3H, CH3), 1.46-1.63 (m, 2H, CH2), 2.29 (s, 3H, CH3), 2.54 (s, 3H, CH3), 
2.74 (dd, J = 9.3, 13.7 Hz, 1H, CH2), 3.07 (dd, J = 4.7, J = 13.7, 1H, CH2), 7.13-7.22 (m, 4H, 
ArH), 8.99 (br s, 2H, NH2+). 
 
N-Methyl-1-(p-tolyl)pentan-2-amine Hydrochloride (37) 
To a solution of 68 (150 mg, 0.63 mmol) in TFA (5.0 mL) at room temperature was added 
palladium on carbon (10%, 0.085).  The mixture was shaken at 55 psi until the pressure was 
reduced to 50 psi (1 h), at which time pressure was restored to 55 psi, and the mixture allowed to 
shake for 60 h. The reaction was stopped by the addition of NaHCO3 and filtered to remove the 
catalyst.  The mixture was extracted with Et2O (3 x 10 mL). The combined organic portion was 
dried (Na2SO4), and solvent was removed under reduced pressure to yield 160 mg of yellow oil.  
A saturated HCl solution in anhydrous Et2O (3 mL) was added, and the mixture was stirred at 
room temperature for 30 hours.  The precipitate was collected by filtration to yield a white-
colored solid which, upon recrystallization from EtOH, afforded 37 as a white solid: mp 162-
167 °C; 1H NMR (DMSO-d6) δ 0.80 (t,  J = 7.2 Hz, 3H, CH3), 1.17-1.40 (m, 4H, 2 x CH2), 2.29 
(s, 3H, CH3), 2.72 (dd, J = 9.1, 13.7 Hz, 1H, CH2), 3.01-3.08 (m, 2H, CH + CH2), 7.14-7.20 (m, 
4H, ArH), 8.64 (br s, 2H, NH2+); Anal. Calcd. for (C13H21N·HCl·0.7 H2O) C, 64.95; H, 9.81; N, 
5.83.  Found: C, 65.13; H, 9.74; N, 6.15. 
 
 
R(-)N-Ethylamphetamine Hydrochloride (R(-)38) 
The compound is known,214 but it was synthesized according to a new procedure.  The Kondekar 
procedure was used as a guideline.215 Aqueous ethylamine (70%, 19 mL, 230 mmol) was added 
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to a solution of S(+)58 (2.5 g, 12 mmol) in DMF (70 mL) at room temperature. After the mixture 
was stirred at 50 °C for 36 h, another portion of aqueous ethylamine solution (70%, 5.0 mL, 63 
mmol) was added.  The resulting mixture was stirred for 12 h at 50 °C, and another portion of 
ethylamine (70%, 7.0 mL, 88 mmol) was added. After stirring for another 12 h at 50 °C, the 
mixture was diluted with Et2O (100 mL) and water (30 mL). The aqueous phase was extracted 
with Et2O (3 x 50 mL) and washed with brine (3 x 20 mL).  The combined extracts were dried 
(Na2S04), and the solvent was evaporated under reduced pressure to yield 1.4 g of oil.  The oil 
was dissolved in anhydrous Et2O (5 mL), and a saturated HCl solution in anhydrous Et2O (5 mL) 
was added.  The mixture was allowed to stir overnight. The precipitate was collected by filtration 
to yield a white solid, which upon recrystallization from EtOH/Et2O afforded 0.38 g (16%) of 
R(-)38 as a white solid: mp 152-154 °C (lit.214 mp 155 °C); 1H NMR (DMSO-d6) δ: 1.09 (d, J = 
6.5 Hz, 3H, CH3), 1.25 (t, J = 7.2 Hz, 3H, CH3), 2.63 (dd, J = 2.4 Hz, 10.5 Hz, 1H, CH2), 2.92-
3.06 (m, 2H, CH2), 3.27 (dd, J = 3.6, 9.4 Hz, 1H, CH2), 3.35-3.39 (m, 1H, CH), 7.25 (d, J = 3.0 
Hz, 1H, ArH), 7.27 (s, 2H, ArH), 7.34 (dd, J = 7.1, 7.6 Hz, 2H, ArH), 9.12 (br s, 2H, NH2+); αD20 
= -17.7 º (c = 0.99 H2O); Anal. Calcd for (C11H17N•HCl) C, 66.15; H, 9.08; N, 7.01.  Found: C, 
65.96; H, 9.13; N, 6.92. 
 
S(+)N-Ethylamphetamine Hydrochloride (S(+)38) 
The compound is known,214 but it was synthesized according to a new procedure. The Kondekar 
procedure for similar compounds was used as a guideline.215 Aqueous ethylamine (70%, 20 mL, 
240 mmol) was added to a solution of R(-)58 (3.5 g, 16 mmol) in DMF (70 mL) at room 
temperature. After the mixture was stirred at 50 °C for 32 h, another portion of aqueous 
ethylamine solution (9.0 mL, 110 mmol) was added.  The resulting mixture was stirred overnight 
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(12 h) at 50 °C, and another portion of ethylamine (9.0 mL, 110 mmol) was added. After stirring 
for another 24 h at 50 °C, the mixture was diluted with Et2O (100 mL) and water (30 mL). The 
aqueous phase was extracted with Et2O (3 x 40 mL) and washed with brine (3 x 20 mL).  The 
combined extracts were dried (Na2S04), and solvent was evaporated under reduced pressure to 
yield 1.60 g of yellow liquid. A saturated HCl solution in anhydrous Et2O (20 mL) was added to 
a solution of this liquid dissolved in anhydrous Et2O (10 mL); this mixture was allowed to warm 
to room temperature and stirred overnight. The precipitate was collected by filtration to yield a 
white solid, which upon recrystallization from EtOH/Et2O afforded 0.41 g (13%) of S(+)38 as a 
white solid: mp 152-154 °C (lit.214 mp 154.2 °C); 1H NMR (DMSO-d6) δ: 1.09 (d, J = 6.5 Hz, 
3H, CH3), 1.25 (t, J = 7.2 Hz, 3H, CH3), 2.63 (dd, J = 2.4 Hz, 10.5 Hz, 1H, CH2), 2.92-3.06 (m, 
2H, CH2), 3.27 (dd, J = 3.6, 9.4 Hz, 1H, CH2), 3.35-3.39 (m, 1H, CH), 7.25 (d, J = 3.1 Hz, 1H, 
ArH), 7.27 (s, 2H, ArH), 7.34 (dd, J = 7.1, 7.6 Hz, 2H, ArH), 9.12 (br s, 2H, NH2+); αD20 = +15.9 
º (c = 1.0 H2O). 
 
α-Bromoisobutyrophenone (40) 
Compound 40 was synthesized according to a modified literature procedure for the same 
compound.191 Bromine (3.2 g, 20 mmol) diluted 10-fold with CHCl3 (8.9 mL) was added in a 
dropwise manner to a stirred solution of isobutyrophenone (3.0 g, 20 mmol) in CHCl3 (15 mL).  
The reaction mixture was allowed to stir at room temperature overnight (24 h), at which time it 
was extracted with CHCl3 (40 mL), washed with NaHCO3 (50% aq., 50 mL) and brine (15 mL), 
and dried (Na2SO4).  Solvent was removed under reduced pressure to yield 4.9 g (>99%) of 40 as 
a yellow liquid (>99%) that was used without further purification. 1H NMR (CDCl3) δ 2.04 (s, 
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6H, 2 x CH3), 7.45 (t, J = 7.4 Hz, 2H, ArH), 7.53 (t, J = 7.4 Hz, 1H, ArH), 8.12 (d, J = 7.4 Hz, 
2H, ArH). 
 
3-(Benzyl(methyl)amino)-2-methyl-1-phenylpropan-1-one Oxalate (41) 
The compound is known in the literature as a free base,216 but was prepared according to the 
general method of Blough et al.192 for substitution of a halogen by N-benzylmethylamine. In a 2-
neck flask, N-benzylmethylamine (3.0 g, 12 mmol) was added to a stirred solution of 40 (1.5 g, 6 
mmol) in THF (10 mL).  The mixture was stirred at reflux overnight (24 h).  Upon cooling to 
room temperature, THF was removed under reduced pressure, and the mixture was dissolved in 
EtOAc (50 mL). The mixture was washed with saturated NaHCO3 (50 mL) and DIH2O (100 mL). 
The organic portion was washed with brine, dried (Na2SO4), and solvent was removed under 
reduced pressure. The crude base was purified by flash chromatography (silica gel; 
hexanes/EtOAc; 75/25), resulting in 1.5 g (91%) of the free base as an oil. After difficulty 
making the HCl salt, the oxalate salt was prepared by stirring a portion of the free base (0.2 g) in 
a saturated solution of oxalic acid (74 mg) in Et2O (20 mL) for 72 h at room temperature. The 
solids were filtered and dried in an abderhalden, resulting in 0.2 g (64%) of 41 as a white 
powder: mp 165-180 °C (Et2O); 1H NMR (DMSO-d6) δ 1.13 (d, J = 6.9 Hz, 3H, CH3), 2.12 (s, 
3H, CH3), 2.42 (dd,  J = 7.2 Hz, 5.3 Hz, 1H, CH2), 2.81 (dd, J = 7.2 Hz, 5.3 Hz, 1H, CH2), 3.44 
(d, J = 2.9 Hz, 2H, CH2), 3.62-3.71 (m, 1H, CH), 7.12-7.17 (m, 5H, ArH), 7.37-7.41 (m, 2H, 
ArH), 7.47-7.51 (m, 1H, ArH), 7.87-7.90 (m, 2H, ArH); Anal. Calcd. For C18H21NO•(COOH)2: 
C, 67.21; H, 6.49; N, 3.92.  Found: C, 67.11; H, 6.44; N, 3.93. 
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N-Trifluoroacetyl Sarcosine (47) 
Compound 47 was prepared by a literature procedure for the same compound.217 Trifluoroacetic 
anhydride (8.60 mL, 61.78 mmol) was added in a dropwise manner at 0 °C to a stirred 
suspension of sarcosine (5.00 g, 56.16 mmol) in anhydrous CH2Cl2 (14 mL) under an N2 
atmosphere.  The reaction mixture was allowed to stir at room temperature for 2 h. The solvent 
was evaporated under reduced pressure to give 11.3 g (>99%) of 47 as a yellow solid that was 
used without further purification.  
 
N-Trifluoroacetyl Sarcosinyl Chloride (48) 
Compound 48 was known in the literature without any physical data,217 but was prepared 
according to a literature procedure for the same compound.211 Oxalyl chloride (5.7 mL, 8.57 g, 
68 mmol) was added in a dropwise manner over 5 min to a stirred solution of 47 (11.3 g, 185 
mmol) and pyridine (3 drops) in anhydrous benzene (22 mL) under an N2 atmosphere.  The 
stirred reaction mixture was heated at reflux for 1 h, allowed to cool to room temperature and 
solvents were removed under reduced pressure to give a brown-colored liquid that was brought 
under N2 atmosphere and used directly without further purification, to avoid degradation. 
 
a-Bromohexanophenone (50) 
The compound is known, and was prepared according to the method described previously,25 but 
using Et2O as a solvent. Bromine (9.06 g, 57 mmol) was added at 0 ºC (ice-bath) to a stirred 
solution of hexanophenone (10 g, 57 mmol) in anhydrous Et2O (20 mL). The reaction mixture 
was stirred at room temperature for 2 h. The reaction was quenched by the careful addition of 
H2O (100 mL) and extracted with Et2O (3 x 25 mL). The combined organic portion was washed 
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with brine (40 mL), dried (Na2SO4), and evaporated under reduced pressure to afford 11.3 g 
(78%) of 50 as a clear yellow oil: 1H NMR (CDCl3) δ 0.93 (t, J = 7.1 Hz, 3H, CH3), 1.33-1.56 
(m, 4H, 2 x CH2), 2.08-2.26 (m, 2H, CH2), 5.12 (t, J = 7.1 Hz, 1H, CH), 7.49 (t, J = 7.6 Hz, 2H, 
ArH), 7.57-7.61 (m, 1H, ArH), 8.01 (dd, J = 8.2, 1.0 Hz, 2H, ArH). 
 
1-(p-Tolyl)-2-nitrobut-1-ene (52) 
The compound is known, and was synthesized generally following a modified version of the 
published procedure.198 Different quantities were used because they were working on a much 
larger scale, different times were used to allow the reaction to reach completion, and flash 
chromatography was used instead of distillation because previous attempted purification by 
Kugelrohr was unsuccessful. In a 3-neck flask, p-tolualdehyde (1.00 g, 8.3 mmol) and 1-
nitropropane (0.74 g, 8.3 mmol) were added to a stirred solution of NH4OAc (0.33 g, 4.3 mmol) 
in HOAc (4.2 mL).  The stirred reaction mixture was heated at reflux overnight (19.5 h), cooled 
to room temperature, and solvent was evaporated under reduced pressure.  The resulting orange-
colored oil was purified by flash chromatography (silica gel; 100% hexanes) to afford 0.72 g 
(45%) of 52 as a yellow oil: H1 NMR (CDCl3) δ 1.41 (t, J = 7.4 Hz, 3H, CH3), 2.53 (s, 3H, CH3), 
3.01 (q, J = 7.4 Hz, 2H, CH2), 7.39 (d, J = 3.9, 2H, ArH), 7.46 (d, J = 8.18, 2H, ArH). 
 
1-(p-Tolyl)butan-2-one (53) 
The compound is known,218 but was synthesized by a procedure for a similar compound because 
the one for similar compounds was used with success by others in the lab.196 Iron powder (2.70 g, 
44.9 mmol) was added to a stirred solution of aqueous HOAc (90%) at room temperature.  
Temperature was increased to 60 °C followed by dropwise addition of 52 (0.75 g) to the mixture.  
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After stirring for 20 min, during which time gas evolution and a reddening of color was observed, 
the mixture was quenched carefully with H2O (20 mL), extracted with EtOAc (20 mL), dried 
(Na2SO4) and evaporated to dryness under reduced pressure.  The mixture was purified by flash 
chromatography (silica gel; 100% hexanes) and solvent removed under reduced pressure, 
resulting in 0.43 g (68%) of 53 as a yellow oil: H1 NMR (CDCl3) δ 1.18 (t, J = 7.1 Hz, 3H, CH3), 
2.26 (s, 3H, CH3), 2.35-2.41 (m, 2H, CH2), 2.34 (s, 2H, CH2), 7.01-7.07 (m, 4H, ArH). 
 
1-(p-Tolyl)hexan-1-ol (54) 
The compound is known, but was synthesized according to a literature procedure for a similar 
compound.194 To a stirred solution of p-tolualdehyde (1.2 g, 10 mmol) in THF (10 mL), under N2 
at 5 ºC, was added butylmagnesium chloride in THF (2 M, 10 mL).  The reaction mixture was 
allowed to stir at room temperature overnight (17 h), at which time it was cooled below 5 ºC and 
quenched carefully with H2O (5 mL) and HCl (2 N, 10 mL).  A white precipitate was observed.  
Extraction with THF (3 x 10 mL) resulted in a pale-yellow liquid which was dried (Na2SO4), and 
evaporated under reduced pressure to yield a clear purple liquid.  This was further purified by 
Kugelrohr and flash chromatography (silica gel; hexanes/EtOAc, 70:30) to afford 54 as a clear, 
colorless oil (0.75 g, 42%).  1H NMR (CDCl3) δ 0.886 (t, J = 7.0 Hz, 3H, CH3), 1.20-1.29 (m, 2H, 
CH2), 1.31-1.44 (m, 2H, CH2), 1.65-1.85 (m, 2H, CH2), 2.35 (s, 3H, CH3), 4.61-4.65 (m, 2H, 
CH2), 7.16 (d, J = 7.9 Hz, 2H, ArH), 7.24 (d, J = 8.0 Hz, 2H, ArH). 
 
2-(Benzyl(methyl)amino)-1-(p-tolyl)pentan-1-one (55)  
The compound is unknown, but was synthesized according to a procedure for similar 
compounds.195 Under open atmosphere and constant stirring, N-bromosuccinimide (0.97 g, 5.4 
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mmol) was added directly to 54 (0.75 g, 4.2 mmol) at room temperature.  The mixture turned 
yellow, then orange, and released a burst of brown gas over the course of 2 min, at which time 
1,4-dioxane (4.0 mL) was added, resulting in a clear yellow solution.  After 10 min of stirring, N-
benzylmethylamine (1.3 mL, 12 mmol) was added dropwise, and the mixture became cloudy and 
colorless, then returned shortly to yellow.  It was allowed to stir, loosely covered, at room 
temperature for 36 h.  The reaction was quenched carefully with NaHCO3 (20 mL), extracted 
with EtOAc (3 x 20 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure, 
resulting in a yellow liquid that was further purified by flash chromatography (silica gel; 
hexanes/EtOAc, 95:5).  This afforded 0.68 g (55%) of 55 as a yellow oil: 1H NMR (CDCl3) δ 
0.94 (t, J = 7.4 Hz, 3H, CH3), 1.26-1.37 (m, 2H, CH2), 1.66-1.75 (m, 1H, CH2), 1.88-1.97 (m, 1H, 
CH2), 2.26 (s, 3H, CH3), 2.41 (s, 3H, CH3), 3.69 (dd, J = 10.6, 13.6 Hz, 2H, CH2), 4.16 (dd, J = 
3.5, 5.2 Hz, 1H, CH), 7.22-7.30 (m, 7H, ArH), 7.83 (d, J = 8.2 Hz, 2H, ArH). 
 
R(-)1-Phenylpropan-2-ol (R(-)57) 
The compound is not known, but it was synthesized according to a procedure for similar 
compounds.219 In a 2-neck flask, under N2 atmosphere, at -60 °C, CuI (1.14 g, 6.0 mmol) was 
added to solution of phenylmagnesium bromide (1 M, 30.0 mmol) in anhydrous THF (15 mL). 
The reaction mixture was allowed to stir for about 30 min, when a solution of R-(-)-propylene 
oxide (1.8 g, 30.0 mmol) in 15 mL of anhydrous THF was added slowly with a syringe. Stirring 
was continued for 2 h at -60 °C and for 24 h at room temperature. The reaction mixture was 
quenched (NH4Cl), and the aqueous phase was extracted with EtOAc (3 x 50 mL). The 
combined organic portions were washed with brine, dried (MgSO4), and evaporated under 
reduced pressure to give an oil. The crude compound was purified using flash chromatography 
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(silica gel; hexanes/EtOAc; 88/12) to afford 3.60 g of R(-)57 (89%) as a clear, colorless oil. 1H 
NMR (CDCl3) δ: 1.17 (d, J = 6.1 Hz, 3H, CH3), 1.44 (d,  J = 3.4 Hz, OH), 2.61 (dd, J = 7.9, 13.6 
Hz, 1H, CH), 2.72 (dd, J = 4.8, 13.6 Hz, 1H, CH), 3.89-4.00 (m, 1H, CH), 7.10- 7.18 (m, 3H, 
ArH), 7.24 (dd, J = 6.9, 7.5 Hz, 2H, ArH); αD20 = - 32.7 (c = 2.2 CHCl3). 
 
S(+)1-Phenylpropan-2-ol (S(+)57) 
This compound was prepared by U. Battisti. The compound is not known, but it was synthesized 
according to a procedure for similar compounds.219 This procedure was used because it allows 
for stereospecific phenylpropan-2-ol synthesis. In a 2-neck flask under N2 atmosphere at -35 °C, 
CuI (1.14 g, 6.0 mmol) was added to solution of phenylmagnesium bromide (1 M, 30.0 mmol) in 
anhydrous THF (30 mL). The reaction mixture was allowed to stir for about 30 min, when a 
solution of S-(+)-propylene oxide (1.75 g, 30.0 mmol) in 15 mL of anhydrous THF was added 
slowly with a syringe. Stirring was continued for 2 h at -35 °C and for 2 h at room temperature. 
The reaction mixture was quenched with aqueous ammonium chloride solution, and the aqueous 
phase was extracted with EtOAc (3 x 40 mL). The combined organic portions were washed with 
brine, dried (MgSO4), and evaporated under reduced pressure to give a black oil. The crude 
compound was purified using flash chromatography (silica gel; hexanes/EtOAc; 80/20) to afford 
4.08 g of S(+)57 (99%) as a colorless oil. 1H NMR (CDCl3) δ: 1.17 (d, J = 6.1 Hz, 3H, CH3), 
1.44 (d,  J = 3.4 Hz, OH), 2.61 (dd, J = 7.9, 13.6 Hz, 1H, CH), 2.72 (dd, J = 4.8, 13.6 Hz, 1H, 
CH), 3.89-4.00 (m, 1H, CH), 7.10- 7.18 (m, 3H, ArH), 7.24 (dd, J = 6.9, 7.5 Hz, 2H, ArH); αD20 
= + 37.1 (c = 1.0 CHCl3). 
 
 
 
142 
R(-)1-Phenylpropan-2-yl Methanesulfonate (R(-)58) 
The compound is not known but it was synthesized according to a procedure for similar 
compounds.215 Methanesulfonyl chloride (4.40 g, 39 mmol) was added dropwise over 15 min to 
an ice-cold stirred solution of R(-)57 (3.50 g, 26 mmol) and Et3N (7.9 g, 78 mmol) in anhydrous 
CH2Cl2 (30 mL). The resulting mixture was allowed to warm to room temperature and stirred for 
12 h. After the addition of CH2Cl2 (100 mL), the solution was washed with water (3 x 40 mL) 
and brine, dried (Na2SO4), and evaporated under reduced pressure. The crude product was 
further purified by flash chromatography (silica gel; hexanes/EtOAc; 80/20) to afford 4.50 g 
(81%) of R(-)58 as yellow crystals. 1H NMR (CDCl3) δ: 1.40 (d, J = 6.2 Hz, 3H, CH3), 2.43 (s, 
3H, SO2CH3), 2.83 (dd, J = 5.3, 13.9 Hz, 1H, CH), 2.91 (dd, J = 8.1, 13.9 Hz, 1H, CH), 4.73-
4.89 (m, 1H, CH), 7.11-7.21(m, 3H, ArH), 7.22-7.29 (m, 2H, ArH); αD20 = -35.2 (c = 1.2 CHCl3). 
 
S(+)1-Phenylpropan-2-yl Methanesulfonate (S(+)58) 
The compound was synthesized by U. Battisti. The compound is not known but it was 
synthesized according to procedure for similar compounds.215 Methanesulfonyl chloride (6.5 g, 
45.0 mmol) was added dropwise over 15 min to an ice-cold stirred solution of S(+)57 (4.08 g, 30 
mmol) and Et3N (9.1 g, 90 mmol) in anhydrous CH2Cl2 (50 mL). The resulting mixture was 
allowed to warm to room temperature and stirred for 12 h. After the addition of CH2Cl2 (25 mL), 
the solution was washed with water (3 x 30 mL) and brine, dried (Na2SO4), and evaporated under 
reduced pressure. The crude product was purified by flash chromatography (silica gel; 
hexanes/EtOAc; 80/20) to afford 5.6 g (87%) of S(+)58 as yellow crystals: mp 60-62 °C; 1H 
NMR (CDCl3) δ: 1.40 (d, J = 6.2 Hz, 3H, CH3), 2.43 (s, 3H, SO2CH3), 2.83 (dd, J = 5.3, 13.9 Hz, 
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1H, CH), 2.91 (dd, J = 8.1, 13.9 Hz, 1H, CH), 4.73-4.89 (m, 1H, CH), 7.11-7.21(m, 3H, ArH), 
7.22-7.29 (m, 2H, ArH); αD20 = +35.0 (c = 1.1 g CHCl3). 
 
4-Methoxyhexanophenone (59) 
Compound 59 is known, and was synthesized according to a literature procedure for the same 
compound.220 In a 2-neck flask, hexanoyl chloride (1.4 g, 10.2 mmol) was added to a solution of 
AlCl3 (1.36 g, 10.2 mmol) in anhydrous DCM (10 mL) under a N2 atmosphere and cooled to -
10 °C (salt/ice-bath). The contents were allowed to stir at -10 to -5 °C for 10 min. A solution of 
anisole (1.00 g, 9.3 mmol) in anhydrous DCM (10 mL) was added in a dropwise manner over 30 
min at -10 to -3 °C. The ice bath was removed and the contents were allowed to stir at room 
temperature for 1 h, quenched by the careful addition of ice-cold HCl (1N, 50 mL), and extracted 
with DCM (3x 20 mL). The combined organic portion was washed with brine (20 mL), dried 
(Na2SO4), and evaporated under reduced pressure to yield 1.71 g (90%) of 59 as a yellow-
colored waxy solid: mp 34-36 °C (lit.220 mp 38 °C); 1H NMR (CDCl3) δ 0.91 (t, J = 5.5 Hz, 3H, 
CH3), 1.32-1.41 (m, 4H, 2 x CH2), 1.67-1.76 (m, 2H, CH2), 2.90 (t, J = 7.3, 2H, CH2), 3.86 (s, 
3H, CH3),  7.93 (d, J = 7.0, 2H, ArH), 7.94 (d, J = 8.9, 2H, ArH). 
 
4-Ethylhexanophenone (60) 
Compound 60 is known, and was synthesized according to a literature procedure for the same 
compound.220 In a 2-neck flask, hexanoyl chloride (1.4 g, 10.2 mmol) was added to a solution of 
AlCl3 (1.36 g, 10.2 mmol) in anhydrous DCM (10 mL) under a N2 atmosphere and cooled to -
10 °C (salt/ice-bath). The contents were allowed to stir at -10 to -5 °C for 10 min. A solution of 
ethylbenzene (1.1 g, 9.3 mmol) in anhydrous DCM (10 mL) was added in a dropwise manner 
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over 30 min at -10 to -3 °C. The ice bath was removed and the contents were allowed to stir at 
room temperature for 1 h, quenched by the careful addition of ice-cold HCl (1N, 50 mL), and 
extracted with DCM (3x 20 mL). The combined organic portion was washed with brine (20 mL), 
dried (Na2SO4), evaporated under reduced pressure, and used without further purification, 
yielding 1.88 g (>99%) of 60 as a yellow-colored oil: 1H NMR (CDCl3) δ 0.93 (t, J = 3.0 Hz, 3H, 
CH3), 1.28 (t, J = 7.6 Hz, 3H, CH3), 1.33-1.45 (m, 4H, 2 x CH2), 1.72-1.79 (m, 2H, CH2), 2.73 (q, 
J = 7.6, 2H, CH2), 2.96 (t, J = 7.4, 2H, CH2), 7.30 (d, J = 8.1, 2H, ArH), 7.91 (d, J = 8.2, 2H, 
ArH). 
 
4-Bromohexanophenone (61) 
Compound 61 is known,221 but was synthesized according to a literature procedure for a similar 
compound220 because it had been used successfully for the 4-methoxy analog 59. In a 2-neck 
flask, hexanoyl chloride (1.9 g, 14.0 mmol) was added to a solution of AlCl3 (1.9 g, 14.0 mmol) 
in anhydrous DCM (10 mL) under a N2 atmosphere and cooled to -10 °C (salt/ice-bath). The 
contents were allowed to stir at -10 to -5 °C for 10 min. A solution of bromobenzene (2.0 g, 12.7 
mmol) in anhydrous DCM (10 mL) was added in a dropwise manner over 30 min at -10 to -3 °C. 
The ice bath was removed and the contents were allowed to stir at room temperature for 1 h, 
quenched by the careful addition of ice-cold HCl (1N, 50 mL), and extracted with DCM (3x 20 
mL). The combined organic portion was washed with brine (20 mL), dried (Na2SO4), and 
evaporated under reduced pressure. The residual semi-solid was crystallized from hexanes, 
yielding 0.9 g (27%) of 61 as a yellow-colored solid: mp 61-65 °C (lit.221 mp 59-60 °C); 1H 
NMR (CDCl3) δ 0.91 (t, J = 4.1 Hz, 3H, CH3), 1.25-1.41 (m, 4H, 2 x CH2), 1.68-1.76 (m, 2H, 
CH2), 2.91 (t, J = 7.4, 2H, CH2), 7.59 (d, J = 7.9, 2H, ArH), 7.81 (d, J = 7.9, 2H, ArH). 
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4-Methoxy-a-bromohexanophenone (62) 
The compound is known,222 but was prepared according to a literature procedure for a similar 
compound.223 AlCl3 (5 mg) was added at room temperature to a stirred solution of 59 (1.7 g, 8.3 
mmol) in anhydrous Et2O (10 mL). After cooling the reaction mixture to 0 °C (ice-bath), a 
solution of bromine (1.3 g, 8.3 mmol) in anhydrous Et2O (10 mL) was added in a dropwise 
manner over 20 min, and the reaction mixture was stirred at room temperature for 1 h. The 
reaction was quenched by the careful addition of H2O (30 mL), washed with brine (10 mL), dried 
(Na2SO4), and evaporated under reduced pressure resulting in 1.45 g of a yellow-colored oil, 
which upon crystallization from hexane afforded  1.2 g (50%) of 62 as a yellow-colored solid: 
mp 51-53 °C (lit.222 mp 51-52 °C); IR (solid, cm-1) 1667 (s, C=O); 1H NMR (CDCl3) δ 0.92 (t, J 
= 6.9 Hz, 3H, CH3), 1.52-1.59 (m, 4H, 2 x CH2), 2.05-2.25 (m, 2H, CH2), 3.89 (s, 3H, CH3), 5.10 
(t, J = 7.2 Hz, 1H, CH), 6.96 (d, J = 8.9 Hz, 2H, ArH), 8.00 (d, J = 8.9, 2H, ArH). 
 
4-Ethyl-a-bromohexanophenone (63) 
The compound is unknown, and was prepared according to a procedure for bromination of a 
similar compound.223 AlCl3 (5 mg) was added at room temperature to a stirred solution of 60 
(1.05 g, 5.14 mmol) in anhydrous Et2O (10 mL). After cooling the reaction mixture to 0 °C (ice-
bath), a solution of bromine (0.81 g, 5.14 mmol) in anhydrous Et2O (10 mL) was added in a 
dropwise manner over 20 min, and the reaction mixture was stirred at room temperature for 1 h. 
The reaction was quenched by the careful addition of H2O (30 mL), washed with brine (10 mL), 
dried (Na2SO4), and evaporated under reduced pressure. The residual oil was purified by flash 
chromatography (silica gel; hexanes/EtOAc; 80/20) to afford 0.52 g (36%) of 63 as a clear 
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yellow oil: 1H NMR (CDCl3) δ 0.85 (t, J = 7.1 Hz, 3H, CH3), 1.18-1.21 (m, 3H, CH3), 1.25-1.47 
(m, 4H, 2 x CH2), 1.97-2.19 (m, 2H, CH2), 2.65 (q, J = 7.6 Hz, 2H, CH2), 5.05 (t, J = 6.9, 1H, 
CH), 7.25 (d, J = 8.3, 2H, ArH), 7.87 (d, J = 8.3, 2H, ArH). 
 
4-Bromo-a-bromohexanophenone (64) 
The compound is unknown, and was prepared according to a procedure for bromination of a 
similar compound.223 AlCl3 (5 mg) was added at room temperature to a stirred solution of 61 
(890 mg, 3.5 mmol) in anhydrous Et2O (10 mL). After cooling the reaction mixture to 0 °C (ice-
bath), a solution of bromine (550 mg, 3.5 mmol) in anhydrous Et2O (10 mL) was added in a 
dropwise manner over 30 min, and the reaction mixture was stirred at room temperature for 6 h. 
Additional bromine was added (270 mg, 1.7 mmol) at 0 °C (ice-bath), and the reaction was 
allowed to stir for 30 min. The reaction was quenched by the careful addition of NaHCO3 (60 
mL), extracted with Et2O, washed with brine (10 mL), dried (Na2SO4), and evaporated under 
reduced pressure. The resulting 860 mg (74%) white solid, 64, was used without further 
purification: mp 37-38 °C; 1H NMR (CDCl3) δ 0.92 (t, J = 7.1 Hz, 3H, CH3), 1.32-1.57 (m, 6H, 
3 x CH2), 2.06-2.26 (m, 2H, CH2), 5.04 (dd, J = 7.7, 6.6 Hz, 1H, CH), 7.63 (d, 8.7 Hz, 2H, ArH), 
7.87 (d, 8.7 Hz, 2H, ArH).  
 
1-(p-Tolyl)hexan-1-ol (65) 
The compound is known, but was synthesized according to a literature procedure for a similar 
compound.194 In a three-neck flask under N2 at room temperature, 1-bromopentane (2.5 mL, 20 
mmol) and 1,2-dibromoethane (several drops) diluted by THF (12 mL) were added dropwise to a 
stirred solution of magnesium (0.48 g, 20 mmol) in THF (8.0 mL).  After stirring at room 
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temperature for two hours, the mixture was cooled to 0 ºC and p-tolualdehyde (2.4 mL, 20 
mmol) was added dropwise over the course of 20 min.  The mixture was allowed to come to 
room temperature while stirring overnight (24 h).  The reaction was quenched carefully with 
NH4Cl (50 mL) and extracted with EtOAc (3 x 20 mL).  The combined organic portions were 
washed with brine (30 mL), dried (Na2SO4), and evaporated under reduced pressure, resulting in 
an orange liquid.  This was further purified by flash chromatography (silica gel; hexanes/EtOAc; 
80/20) to afford 65 as a clear, yellow oil: (1.01 g, 26%) 1H NMR (CDCl3) δ 0.89 (t, J = 6.2 Hz, 
3H, CH3), 1.11-1.31 (m, 6H, 3 x CH2), 1.42-1.53 (m, 1H, OH), 1.55-1.77 (m, 2H, CH2), 2.37 (s, 
3H, CH3), 4.61-4.65 (m, 1H, CH), 7.16 (d, J = 7.9 Hz, 2H, ArH), 7.24 (d, J = 8.0 Hz, 2H, ArH). 
 
1-(4-Chlorophenyl)hexan-1-ol (66) 
The compound is known, but was synthesized according to a literature procedure for a similar 
compound.224 Magnesium turnings (2.4 g, 100 mmol), ground with a mortar and pestle, were 
added to a three-neck flask, brought under N2 at room temperature, and THF was added (12 mL). 
The suspension was stirred for 5 min, after which 1,2-dibromoethane (several drops) was added. 
The mixture was stirred for 10 min, when it turned opaque gray, and 1-bromopentane (11.0 mL, 
89 mmol) was added, followed by additional THF (6 mL). The mixture was stirred at room 
temperature for 2 h, and heated at reflux for 1 h. Upon cooling to 0 ºC (ice-bath), 4-
chlorobenzaldehyde (10.0, 71 mmol) was added dropwise over the course of 20 min.  The 
mixture was allowed to come to room temperature while stirring for 1 h.  The reaction was 
quenched carefully with H2O, followed by the addition of NH4Cl (50 mL). The organic portion 
was washed with brine (30 mL), dried (Na2SO4), and evaporated under reduced pressure to 
afford 66 as a clear, yellow oil: (5.45 g, 36%). 1H NMR (CDCl3) δ 0.89 (t, J = 5.8 Hz, 3H, CH3), 
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1.22-1.45 (m, 6H, 3 x CH2), 1.64-1.83 (m, 2H, CH2), 1.88 (d, J = 3.0, 1H, OH), 4.65-4.70 (m, 1H, 
CH), 7.28-7.35 (m, 4H, ArH). 
 
1-(4-(Trifluoromethyl)phenyl)hexan-1-ol (67) 
The compound is known, and was synthesized according to a slightly modified literature 
procedure. The modification was to the time, as the reaction was stopped when all starting 
material was gone as determined by TLC.225 Magnesium turnings (0.72 g, 30 mmol), ground in a 
mortar and pestle, were added to anhydrous THF (6 mL) at room temperature, under constant 
stirring and N2 atmosphere. A solution of 1-bromopentane (3.6 mL, 29 mmol) and 1,2-
dibromoethane (several drops) in anhydrous THF (5 mL) was added dropwise to the stirred 
solution.  After stirring at room temperature for two hours, the mixture was cooled to 0 ºC (ice-
bath) and 4-(trifluoromethyl)benzaldehyde (1.3 mL, 29 mmol) was added dropwise over the 
course of 20 min. The mixture was allowed to come to room temperature and stirred for 5 h. The 
reaction was quenched carefully with saturated aqueous NH4Cl (50 mL). The mixture was 
adjusted to pH 4 with HCl (2N) and extracted with EtOAc (3 x 15 mL). The combined organic 
portions were washed with brine (30 mL), dried (MgSO4), evaporated under reduced pressure, 
and purified by flash chromatography (silica gel; hexanes/EtOAc; 80/20) to afford 67 as a clear, 
yellow oil: (2.36 g, 33%) 1H NMR (CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H, CH3), 1.25-1.46 (m, 6H, 3 
x CH2), 1.64-1.82 (m, 2H, CH2), 1.95 (d, J = 2.9, 1H, OH), 4.72-4.76 (m, 1H, CH), 7.46 (d, J = 
8.1 Hz, 2H, ArH), 7.60 (d, J = 8.1 Hz, 2H, ArH). 
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2-(Methylamino)-1-(p-tolyl)-pentan-1-one Hydrochloride (68) 
The compound is unknown, but was synthesized according to a procedure for similar 
compounds.192 To a stirred solution of 55 (0.68 g, 2.3 mmol) in dichloroethane (10 mL) was 
added 1-chloroethyl chloroformate (0.66 g, 4.6 mmol).  The mixture was heated at reflux for 2 h, 
after which it was evaporated to dryness under reduced pressure.  The residue was dissolved in 
MeOH (10 mL), stirred at reflux for 1 h, and evaporated to dryness again. This residue was 
dissolved in Et2O (10 mL) and stirred overnight (18 h).  The resulting precipitate was filtered, 
washed with Et2O (10 mL), and recrystallized from EtOH/Et2O to afford 0.30 g (54%) of 68 as a 
white solid: mp 216-219 °C; 1H NMR (DMSO-d6) δ 0.79 (t,  J = 7.3 Hz, 3H, CH3), 1.02-1.15 (m, 
1H, CH2), 1.24-1.37 (m, 1H, CH2), 1.78-1.95 (m, 2H, CH2), 2.42 (s, 3H, CH3), 2.56 (s, 3H, CH3), 
5.20 (t, J = 5.3 Hz, 1H, CH), 7.43 (d, J = 8.3 Hz, 2H, ArH), 7.97 (d, J = 8.2 Hz, 2H, ArH), 9.37 
(br s, 2H, NH2+); Anal. Calcd. for (C13H19NO·HCl) C, 64.59; H, 8.34; N, 5.79.  Found: C, 64.31; 
H, 8.32; N, 5.76. 
 
B. Computational Modeling 
1. Homology Modeling.  
a. hDAT and hSERT 
The hDAT and hSERT models used were generated by former Glennon laboratory 
student F. Sakloth, as described in the literature.69  
 
b. hNET 
The sequences of dDAT and hNET were obtained as FASTA files from the NCBI using 
the protein search tool, and aligned using Clustal Omega. Artifacts of the crystallization process 
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and co-crystallized ligands were removed from dDAT (PDB ID:4XP6) leaving only the dDAT 
protein for the template structure. To generate a population of 100 three-dimensional models of 
hNET based on its alignment with the template dDAT, Modeller v9.14 (University of California 
San Francisco, San Francisco, CA) was used,201 resulting in a population of 100 models of 
various conformations. These were evaluated using molpdf, DOPE, and GA341 scoring 
functions. Ramachandran plots were generated for the best-scoring models using PROCHECK 
v.3.5.4.205  
 
2. Docking 
Compounds were sketched in Sybyl-X 2.1. Docking was performed using GOLD.226 
Each agent was docked 10 times to each of the population of 100 models of either hNET, hSERT, 
or hDAT. The common Asp residue between them was used to define a 12 Angstrom binding 
pocket (Asp73 in hNET). Using in-house scripts, docking solutions were clustered by similarity 
(within 2.0 angstroms RMSD) and the clusters were ranked by population and GOLD score. 
Clustered solutions were then sorted visually in Sybyl-X 2.1 to identify plausible binding modes. 
Clusters were additionally created between compounds to help identify common binding modes 
for a group of related structures. Selected binding modes were energy minimized in Sybyl-X 2.1 
and further visualized in PyMOL.227 
 
C. Cell Culture and expression of MATs 
 Ca2+ imaging for the purpose of measuring substrate or blocker activity at MATs was 
performed according to procedures developed in J. Eltit’s laboratory.190,228–230 hDAT or hSERT 
was expressed in HEK-293 cells using the FlpIn-TREx system (Invitrogen). The culture media 
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was Dulbecco’s modified eagle medium (DMEM), which was supplemented with fetal bovine 
serum (FBS). Cells were plated in 96-well flat-bottom plates. 
 
D. Ca2+ Imaging for evaluation of test compounds 
Plated cells were transfected with the cardiac isoform of voltage-gated Ca2+ channel 
Cav1.2, its auxiliary subunits, and transfection marker EGFP. Plasmids α1, β3, α2δ1, and EGFP 
in a ratio of 0.9:0.5:0.75:0.25, in µg, along with Fugene 6 (Promega) in OptiMEM media. The 
media was later supplemented with doxycycline (1 µg/mL) in DMEM to induce expression of 
transporters. Ca2+ determinations were made with Fura2, a ratiometric Ca2+ sensor. 
Experiments performed in imaging solution (IS; 130 mM NaCl, 4 mM KCl, 2 mM CaCl2, 
1 mM MgCl2, 10 mM Hepes, 10 mM glucose, pH = 7.3). Test compounds or controls were 
exposed to the cells under constant perfusion at 35 °C (ThermoClamp-1, Automate Scientific). 
Fluorescence was observed using an Olympus IX70 microscope using a 20× 0.75 numerical 
aperture (NA) objective with a fluorescence imaging attachment (Till Photonics). Ratio images 
were obtained at 340 nm and 380 nm excitation, then recoded for off-line analysis. Each well 
was used for a single concentration of test agent. 2 to 5 wells were collected per concentration 
per compound per experiment, and 2 to 5 experiments were conducted for each compound at 
multiple concentrations. Each well contained multiple cells, which were individually evaluated 
for either substrate or blocker activity using the following protocols. Concentration-response 
curves were generated using GraphPad Prism 6.0.  
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1. Substrate activity using Ca2+ imaging 
 Substrate activity was measured using the  following protocol. Cells were perfused with 
IS for 10 s, followed by perfusion of a positive control (DA for hDAT or hNET, 5-HT for 
hSERT; 10 µM) for 5 s. Following a 30 s washout with IS, the test compound was perfused for 
5s, followed by an additional 5 s washout with IS. 
 
2. Blocker activity using Ca2+ imaging 
Blocker activity was measured using the following protocol. Cells were perfused with IS 
for 10 s, followed by perfusion of a positive control (DA for hDAT or hNET, 5-HT for hSERT; 
10 µM) for 5 s. Following a 30 s washout with IS, the test compound was perfused for 30 s, 
followed by the test compound at a given concentration with the positive control for 5 s, and a 
final washout of 30 s with IS. 
 
E. APP+ Imaging for assessing blocker activity 
Plated cells were transfected with dsRed as a transfection marker, along with Fugene 6 
(Promega) in OptiMEM media. The media was later supplemented with doxycycline in DMEM 
to induce expression of transporters. Experiments performed in IS (130 mM NaCl, 4 mM KCl, 2 
mM CaCl2, 1 mM MgCl2, 10 mM Hepes, 10 mM glucose, pH = 7.3). Test compounds or 
controls were exposed to the cells under constant perfusion. Fluorescence was observed using an 
Olympus IX70 microscope using a 20× 0.75NA objective with a fluorescence imaging 
attachment (Till Photonics). Images were obtained at 460 nm excitation, then recoded for off-line 
analysis. Each well was used for a single concentration of test agent. 2 to 5 wells were collected 
per concentration per compound per experiment, and 2 experiments were conducted for each 
compound at multiple concentrations. Each well contained at least 40 cells, which were 
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evaluated by measuring the amplitude of fluorescence and taking an average value per well, then 
comparing test compounds to positive controls. Dose-response curves were generated using 
GraphPad Prism 6.0.  
Blocker activity was assessed by the following protocol. Cells were perfused with IS for 
10 s, followed by perfusion of the test compound or control (IS) for 40 s. Then, a mixture of 
APP+ (3 µM) and the test compound or control (IS) were perfused for 30 s. 
Inhibition potency (IC50) was calculated by fitting data to the Hill equation (equation 1). 
 
 
 
Equation 1. The Hill equation, used for calculating IC50 potency values.  
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